10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended March 31, 2025

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File No. 001-35210

INNOVATE CORP.

(Exact name of registrant as specified in its charter)

Delaware	54-1708481
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
295 Madison Ave., 12th Floor, New York, NY	10017
(Address of principal executive offices)	(Zip Code)

(212) 235-2691

(Registrant’s telephone number, including area code)

____________________________________________________________________________________________________________________

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value $0.001 per share	VATE	New York Stock Exchange
Preferred Stock Purchase Rights	N/A	New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: None.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer", "accelerated filer", "smaller reporting company", and "emerging growth company" in Rule 12b-2 of the Exchange Act.:

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes   ☐    No  ý

As of May 2, 2025, 13,283,218 shares of common stock, par value $0.001, were outstanding.

1

INNOVATE CORP.

INDEX TO FORM 10-Q

	PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited)	2
	Condensed Consolidated Statements of Operations	2
	Condensed Consolidated Statements of Comprehensive Loss	3
	Condensed Consolidated Balance Sheets	4
	Condensed Consolidated Statements of Stockholders’ Deficit	5
	Condensed Consolidated Statements of Cash Flows	6
	Notes to Condensed Consolidated Financial Statements (Unaudited)	7
	(1) Organization and Business	7
	(2) Summary of Significant Accounting Policies	7
	(3) Revenue and Contracts in Process	9
	(4) Accounts Receivable, Net	11
	(5) Inventory	11
	(6) Investments	12
	(7) Property, Plant and Equipment, Net	13
	(8) Goodwill and Intangibles, Net	13
	(9) Leases	14
	(10) Other Assets, Accrued Liabilities and Other Liabilities	15
	(11) Debt Obligations	17
	(12) Income Taxes	20
	(13) Commitments and Contingencies	21
	(14) Share-Based Compensation	22
	(15) Equity and Temporary Equity	22
	(16) Related Parties	26
	(17) Operating Segments and Related Information	27
	(18) Basic and Diluted Loss Per Common Share	28
	(19) Fair Value of Financial Instruments	29
	(20) Supplementary Financial Information	30
	(21) Subsequent Events	31
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	32
Item 4.	Controls and Procedures	48
	PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	48
Item 1A.	Risk Factors	48
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	49
Item 5.	Other Information	49
Item 6.	Exhibits	49
SIGNATURES

1

PART I. FINANCIAL INFORMATION

Item 1. Unaudited Financial Statements

INNOVATE CORP.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, in millions, except shares and per share amounts)

	Three Months Ended March 31,
	2025		2024
Revenue	$	274.2	$	315.2
Cost of revenue	228.7		266.6
Gross profit	45.5		48.6
Operating expenses:
Selling, general and administrative	37.8		39.5
Depreciation and amortization	4.4		4.4
Other operating (income) loss	(0.1)		1.9
Income from operations	3.4		2.8
Other (expense) income:
Interest expense	(20.2)		(17.2)
Loss from equity investees	(5.9)		(1.2)
Other income (expense), net	4.0		(1.2)
Loss from operations before income taxes	(18.7)		(16.8)
Income tax expense	(7.1)		(3.3)
Net loss	(25.8)		(20.1)
Net loss attributable to non-controlling interests and redeemable non-controlling interests	1.3		2.7
Net loss attributable to INNOVATE Corp.	(24.5)		(17.4)
Less: Preferred dividends	0.3		0.3
Net loss attributable to common stockholders and participating preferred stockholders	$	(24.8)	$	(17.7)
Loss per common share - basic and diluted (1)	$	(1.89)	$	(2.21)
Weighted-average common shares outstanding - basic and diluted (1)	13,114,804		7,865,361

(1) Basic and diluted loss per common share and weighted-average common shares outstanding for the three months ended March 31, 2024, have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on August 8, 2024.

The accompanying notes are an integral part of these condensed consolidated financial statements.

2

INNOVATE CORP.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Unaudited, in millions)

	Three Months Ended March 31,
	2025		2024
Net loss	$	(25.8)	$	(20.1)
Other comprehensive income (loss)
Foreign currency translation adjustment, net of tax	0.2		(1.1)
Other comprehensive income (loss)	$	0.2	$	(1.1)
Comprehensive loss	(25.6)		(21.2)
Comprehensive loss attributable to non-controlling interests and redeemable non-controlling interests	1.3		2.8
Comprehensive loss attributable to INNOVATE Corp.	$	(24.3)	$	(18.4)

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

INNOVATE CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited, in millions, except share amounts)

	March 31, 2025		December 31, 2024
Assets
Current assets
Cash and cash equivalents	$	33.3	$	48.8
Accounts receivable, net	164.5		194.0
Contract assets	135.3		106.3
Inventory	19.7		20.8
Other current assets	18.7		21.0
Total current assets	371.5		390.9
Investments	4.1		3.6
Deferred tax asset	1.6		1.6
Property, plant and equipment, net	132.6		133.6
Goodwill	126.7		126.7
Intangibles, net	170.4		172.4
Other assets	61.1		62.3
Total assets	$	868.0	$	891.1
Liabilities, temporary equity and stockholders’ deficit
Current liabilities
Accounts payable	$	104.7	$	84.8
Accrued liabilities	106.8		109.7
Current portion of debt obligations	523.5		162.2
Contract liabilities	95.3		109.1
Other current liabilities	17.3		17.2
Total current liabilities	847.6		483.0
Deferred tax liability	4.5		4.4
Debt obligations	139.9		500.6
Other liabilities	44.9		46.8
Total liabilities	1,036.9		1,034.8
Commitments and contingencies (Note 13)
Temporary equity
Preferred Stock Series A-3 and Preferred Stock Series A-4, $0.001 par value	16.1		16.1
Shares authorized: 20,000,000; Shares issued and outstanding: 6,125 of Series A-3 and 10,000 of Series A-4
Redeemable non-controlling interest	(0.7)		(0.5)
Total temporary equity	15.4		15.6
Stockholders’ deficit
Common stock, $0.001 par value	—		—
Shares authorized: 250,000,000
Shares issued: 13,447,060 and 13,410,179, respectively
Shares outstanding: 13,283,218 and 13,261,379, respectively
Additional paid-in capital	350.7		350.1
Treasury stock, at cost: 163,842 and 148,800 shares, respectively	(5.5)		(5.4)
Accumulated deficit	(546.4)		(521.9)
Accumulated other comprehensive loss	(3.0)		(3.2)
Total INNOVATE Corp. stockholders’ deficit	(204.2)		(180.4)
Non-controlling interest	19.9		21.1
Total stockholders’ deficit	(184.3)		(159.3)
Total liabilities, temporary equity and stockholders’ deficit	$	868.0	$	891.1

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

INNOVATE CORP.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

(Unaudited, in millions, except share amounts)

	Temporary Equity		Stockholders' (Deficit) Equity
	Preferred Stock and Redeemable Non-Controlling Interest		Common Stock			Additional Paid-In Capital		Treasury Stock		Accumulated Deficit		Accumulated Comprehensive Income (Loss) (b)		Total INNOVATE Stockholders' (Deficit) Equity		Non-Controlling Interest		Total Stockholders' (Deficit) Equity
			Shares (a) (thousands)	Amount
Balance as of December 31, 2024	$	15.6	13,261.4	$	—	$	350.1	$	(5.4)	$	(521.9)	$	(3.2)	$	(180.4)	$	21.1	$	(159.3)
Share-based compensation	—		—	—		0.8		—		—		—		0.8		—		0.8
Shares received for taxes paid for share-based compensation	—		(15.1)	—		—		(0.1)		—		—		(0.1)		—		(0.1)
Preferred stock dividends	—		—	—		(0.3)		—		—		—		(0.3)		—		(0.3)
Issuance of common stock	—		36.9	—		—		—		—		—		—		—		—
Transactions with non-controlling interests	—		—	—		0.1		—		—		—		0.1		(0.1)		—
Net loss	(0.2)		—	—		—		—		(24.5)		—		(24.5)		(1.1)		(25.6)
Other comprehensive income	—		—	—		—		—		—		0.2		0.2		—		0.2
Balance as of March 31, 2025	$	15.4	13,283.2	$	—	$	350.7	$	(5.5)	$	(546.4)	$	(3.0)	$	(204.2)	$	19.9	$	(184.3)

	Temporary Equity		Stockholders' (Deficit) Equity
	Preferred Stock and Redeemable Non-Controlling Interest		Common Stock			Additional Paid-In Capital (a)		Treasury Stock		Accumulated Deficit		Accumulated Comprehensive Income (Loss) (b)		Total INNOVATE Stockholders' (Deficit) Equity		Non-Controlling Interest		Total Stockholders' (Deficit) Equity
			Shares (a) (thousands)	Amount (a)
Balance as of December 31, 2023	$	15.4	7,923.5	$	—	$	328.3	$	(5.4)	$	(487.3)	$	(1.1)	$	(165.5)	$	13.8	$	(151.7)
Share-based compensation	—		—	—		0.4		—		—		—		0.4		—		0.4
Preferred stock dividends	(0.3)		—	—		(0.3)		—		—		—		(0.3)		—		(0.3)
Issuance of common stock	—		65.1	—		—		—		—		—		—		—		—
Issuance of preferred stock in private placement	25.0		—	—		—		—		—		—		—		—		—
Rights offering and private placement transaction costs	(1.3)		—	—		(0.5)		—		—		—		(0.5)		—		(0.5)
Other	—		—	—		(0.1)		—		—		—		(0.1)		—		(0.1)
Net loss	(0.2)		—	—		—		—		(17.4)		—		(17.4)		(2.5)		(19.9)
Other comprehensive loss	—		—	—		—		—		—		(1.0)		(1.0)		(0.1)		(1.1)
Balance as of March 31, 2024	$	38.6	7,988.6	$	—	$	327.8	$	(5.4)	$	(504.7)	$	(2.1)	$	(184.4)	$	11.2	$	(173.2)

(a) The number and amount of shares and Additional Paid-in Capital as of December 31, 2023, and as of and for three month period ended March 31, 2024, have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on August 8, 2024. Refer to Note 15. Equity and Temporary Equity.

(b) Inclusive of other comprehensive loss, foreign currency cumulative translation adjustments totaled a loss of $4.2 million and $4.5 million as of March 31, 2025 and December 31, 2024, respectively.

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

INNOVATE CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, in millions)

	Three Months Ended March 31,
	2025		2024
Cash flows from operating activities
Net loss	$	(25.8)	$	(20.1)
Adjustments to reconcile net loss to cash used in operating activities
Share-based compensation expense	0.8		0.4
Depreciation and amortization (including amounts in cost of revenue)	7.9		8.4
Amortization of deferred financing costs and debt discount	5.6		1.7
Net loss on extinguishment of debt	—		2.2
Loss from equity investees	5.9		1.2
Step-up of equity method investments and unrealized gains on marketable securities	(4.6)		—
Deferred income tax expense	0.1		0.1
Other operating activities, net	0.3		1.2
Changes in assets and liabilities:
Accounts receivable	29.2		9.0
Contract assets	(29.0)		36.4
Other current assets	1.4		0.6
Inventory	1.1		0.6
Other assets	2.4		2.8
Accounts payable	19.3		(20.0)
Accrued liabilities	(10.9)		(20.6)
Contract liabilities	(13.8)		(28.1)
Other current liabilities	—		0.3
Other liabilities	(4.0)		(1.5)
Cash used in operating activities	(14.1)		(25.4)
Cash flows from investing activities
Purchase of property, plant and equipment	(4.7)		(5.6)
Proceeds from disposal of property, plant and equipment	1.1		3.1
Loans to equity method investee	—		(1.2)
Purchase of investments	(0.3)		—
Other investing activities	—		0.4
Cash used in investing activities	(3.9)		(3.3)
Cash flows from financing activities
Proceeds from issuance of preferred stock	—		25.0
Proceeds from lines of credit	20.0		—
Payments on lines of credit	(15.0)		(30.0)
Principal payments for other debt obligations	(2.2)		(7.6)
Dividend payments	(0.3)		(0.3)
Other financing activities	(0.1)		—
Cash provided by (used in) financing activities	2.4		(12.9)
Effects of exchange rate changes on cash, cash equivalents and restricted cash	0.2		(0.8)
Net decrease in cash and cash equivalents, including restricted cash	(15.4)		(42.4)
Cash, cash equivalents and restricted cash, beginning of period	49.3		82.3
Cash, cash equivalents and restricted cash, end of period	$	33.9	$	39.9

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Organization and Business

INNOVATE Corp. ("INNOVATE" and, together with its consolidated subsidiaries, the "Company", "we" and "our") is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments. The Company seeks to grow these businesses so that they can generate long-term sustainable free cash flow and attractive returns in order to maximize value for all stakeholders. While the Company generally intends to acquire controlling equity interests in its operating subsidiaries, the Company may invest to a limited extent in a variety of non-controlling equity interest positions or debt instruments. The Company’s shares of common stock trade on the New York Stock Exchange ("NYSE") under the symbol "VATE".

The Company currently has three reportable segments, plus our Other segment, based on management’s organization of the enterprise: Infrastructure, Life Sciences, Spectrum, and Other which includes businesses that do not meet the separately reportable segment thresholds.

1.The Company's Infrastructure segment is comprised of DBM Global Inc. ("DBMG") and its wholly-owned subsidiaries. DBMG is a fully integrated industrial construction, structural steel and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services and also fabricates trusses and girders and specializes in the fabrication and erection of large-diameter water pipe and water storage tanks, as well as 3-D Building Information Modeling (“BIM”) and detailing. DBMG provides these services on commercial, industrial, and infrastructure construction projects such as high- and low-rise buildings and office complexes, hotels and casinos, convention centers, sports arenas and stadiums, shopping malls, hospitals, dams, bridges, mines, metal processing, refineries, pulp and paper mills and power plants. Through GrayWolf Industrial Inc. ("GrayWolf"), DBMG provides integrated solutions for digital engineering, modeling and detailing, construction, heavy equipment installation and facility services including maintenance, repair, and installation to a diverse range of end markets. Through Aitken Manufacturing, Inc., DBMG manufactures pollution control scrubbers, tunnel liners, pressure vessels, strainers, filters, separators and a variety of customized products. Through Banker Steel, a division of Schuff Steel Company, DBMG provides full-service fabricated structural steel and erection services primarily for the U.S. East Coast and Southeast commercial and industrial construction markets, in addition to full design-assist services. The Company maintains a 91.2% controlling interest in DBMG.

2.The Company's Life Sciences segment is comprised of Pansend Life Sciences, LLC ("Pansend"), its subsidiaries and its equity investments. Pansend maintains a controlling interest of 80.0% in Genovel Orthopedics, Inc. ("Genovel"), which seeks to develop products to treat early osteoarthritis of the knee, and also has a controlling interest of 81.0% (81.4% as of December 31, 2024) in R2 Technologies, Inc. ("R2 Technologies"), which develops aesthetic and medical technologies for the skin. Pansend also invests in other early stage or developmental stage healthcare companies and, as of March 31, 2025, had a 44.7% interest (45.9% as of December 31, 2024) in MediBeacon Inc. ("MediBeacon"), a medical technology company specializing in the advances of fluorescent tracer agents and transdermal measurement, potentially enabling real-time, direct monitoring of kidney function, and maintained a 1.6% fully diluted interest in Triple Ring Technologies, Inc. ("Triple Ring"), a science and technology co-development company, and a 20.1% interest in Scaled Cell Solutions, Inc. ("Scaled Cell"), an immunotherapy company developing a novel autologous cell therapy system to potentially improve current CAR-T treatments.

3.The Company's Spectrum segment is comprised of HC2 Broadcasting Holdings Inc. ("Broadcasting") and its subsidiaries. Broadcasting strategically acquires and operates over-the-air broadcasting stations across the United States. The Company maintains a 98.0% controlling interest in Broadcasting and maintains a controlling interest of approximately 69.2%, inclusive of 2.8% proxy rights from minority holders of DTV America Corporation ("DTV"). On a fully diluted basis, the Company would have an 85.8% controlling interest in Broadcasting.

4.The Company's Other segment represents all other businesses or investments that do not meet the definition of a segment individually or in the aggregate. The Other segment primarily includes legacy businesses or holding companies such as the holding company of the Company's former Marine Services segment, Global Marine Holdings, LLC ("GMH") in which the Company had a 72.8% controlling interest until its dissolution on December 13, 2024, and TIC Holdco, Inc. ("TIC"), which was dissolved on May 23, 2024.

2. Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of the Company, its wholly owned subsidiaries and all other subsidiaries over which the Company exerts control. All intercompany profits, transactions and balances have been eliminated in consolidation. The remaining interests not owned by the Company are presented as a non-controlling interest component of total equity.

Basis of Presentation

The accompanying interim unaudited Condensed Consolidated Financial Statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). The financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair statement of such information. All such adjustments are of a normal recurring nature. Certain information and note disclosures, including a description of significant accounting policies normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"), have been condensed or omitted in these interim unaudited Condensed Consolidated Financial Statements pursuant to such rules and regulations.

7

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

(Unaudited)

These interim unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Company’s annual audited Consolidated Financial Statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025. The results of operations for the three months ended March 31, 2025, are not necessarily indicative of the results for any subsequent periods or the entire fiscal year ending December 31, 2025. Certain prior amounts have been reclassified or combined to conform to the current year presentation.

Where applicable, information presented within these Condensed Consolidated Financial Statements has been retroactively adjusted to reflect the 1-for-10 reverse stock split of the Company's issued and outstanding common stock that occurred in August 2024 (the “Reverse Stock Split”). Refer to Note 15. Equity and Temporary Equity for additional information.

Going Concern

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared assuming that the Company will continue as a going concern. However, as of the date of these financial statements, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.

The principal conditions leading to this conclusion are the upcoming maturities and covenants of the Company's Non-Operating Corporate segment's Senior Secured Notes, other current debt at the Non-Operating Corporate segment and the Company's subsidiaries, as well as from certain cross-default provisions in the Company's Senior Secured Notes. Based on these conditions, the Company may not be able to meet its obligations at maturity and comply with certain cross-default provisions under the Senior Secured Notes over the next twelve months.

Management has evaluated the significance of these conditions in relation to the Company's ability to meet its obligations. The potential inability to refinance or extend the maturity of the aforementioned current debt, or to obtain additional financing, raises substantial doubt about the Company's ability to continue as a going concern.

The Company plans to alleviate these conditions through various initiatives it is currently exploring, including refinancing the debt at the Non-Operating Corporate segment and its subsidiaries, pursuing asset sales, and raising additional capital. However, there can be no assurance that the Company will have the ability to raise additional capital when needed, be successful in any asset sales, or refinance its existing debt, on attractive terms, or at all nor any assurances that lenders will provide additional extensions, waivers or amendments in the event of future non-compliance with the Company’s debt covenants or other possible events of default. Further, there can be no assurance that the Company will be able to execute a reduction, extension, or refinancing of the debt, or that the terms of any replacement financing would be as favorable as the terms of the debt prior to the maturity date. There can be no assurance that these plans will be successfully implemented or that they will mitigate the conditions that raise substantial doubt about the Company's ability to continue as a going concern.

These unaudited Condensed Consolidated Financial Statements do not include any adjustments to the carrying amounts and classification of assets, liabilities, or expenses that may result if the Company is unable to continue as a going concern.

Use of Estimates and Assumptions

The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and various disclosures within these Condensed Consolidated Financial Statements as of the date of the Condensed Consolidated Financial Statements and the reported amounts of net revenue and expenses during the reporting period. These estimates are based on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Actual results may differ from these estimates.

Recent Accounting Pronouncements

Accounting Pronouncements Issued But Pending Adoption

On November 26, 2024, the FASB issued ASU 2024-04, Debt - Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments ("ASU 2024-04"). The amendments in this update affect entities that settle convertible debt instruments for which the conversion privileges were changed to induce conversion. The amendments clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. ASU 2024-04 is effective for fiscal years beginning after December 15, 2025, and interim periods within those annual reporting periods. Entities may apply the amendments retrospectively for all prior periods presented in the financial statements or prospectively. The Company expects that it will apply the new guidance prospectively and is currently evaluating the potential effect of this ASU on future transactions and the Company’s Condensed Consolidated Financial Statements.

8

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

(Unaudited)

On November 4, 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03"). The amendments in this ASU require disclosure, in the notes to financial statements, of specified information about certain costs and expenses, including the total amount of selling expenses incurred in the period and an entity's definition of selling expenses. ASU 2024-03, with effective dates as clarified by ASU 2025-01 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating this ASU, which will only have an effect on the disclosures within the Company’s Condensed Consolidated Financial Statements.

On January 1, 2025, ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), became effective and requires, among other things, greater disaggregation of information in the rate reconciliation and for paid income taxes to be disaggregated by jurisdiction. ASU 2023-09 affects financial statement disclosure only, which is not required until year end 2025 and, as a result, does not affect our results of operations or financial condition.

Subsequent Events

ASC 855, Subsequent Events requires the Company to evaluate events that occur after the balance sheet date as of which the financial statements are issued, and to determine whether adjustments to or additional disclosures in the financial statements are necessary. Refer to Note 21. Subsequent Events.

3. Revenue and Contracts in Process

Revenue from contracts with customers consisted of the following (in millions):

	Three Months Ended March 31,
	2025		2024
Infrastructure	$	264.9	$	307.9
Life Sciences	3.1		1.0
Spectrum	6.2		6.3
Total revenue	$	274.2	$	315.2

Accounts receivables, net, from contracts with customers consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Infrastructure	$	156.3	$	184.8
Life Sciences	2.1		1.5
Spectrum	2.0		1.9
Total accounts receivables with customers	$	160.4	$	188.2

As of January 1, 2024, accounts receivable, net, from contracts with customers totaled $273.2 million.

Infrastructure Segment

The following table disaggregates DBMG's revenue by market (in millions):

	Three Months Ended March 31,
	2025		2024
Industrial	$	74.6	$	84.1
Commercial	53.8		77.3
Healthcare	52.0		34.3
Transportation	44.7		100.4
Government	24.8		2.7
Leisure	6.6		1.0
Convention	5.9		5.5
Energy	1.9		2.2
Total revenue from contracts with customers	$	264.3	$	307.5
Other revenue	0.6		0.4
Total Infrastructure segment revenue	$	264.9	$	307.9

9

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

(Unaudited)

Contract assets and contract liabilities consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Costs incurred on contracts in progress	$	1,245.9	$	1,435.2
Estimated earnings	97.5		75.8
Contract revenue earned on uncompleted contracts	1,343.4		1,511.0
Less: progress billings	1,303.4		1,513.8
	$	40.0	$	(2.8)
The above is included in the accompanying Condensed Consolidated Balance Sheets under the following line items:
Contract assets	$	135.3	$	106.3
Contract liabilities	(95.3)		(109.1)
	$	40.0	$	(2.8)

	March 31, 2025		December 31, 2024
Cost in excess of billings and estimated earnings	$	71.2	$	50.8
Conditional retainage	64.1		55.5
Contract assets	$	135.3	$	106.3
Billings in excess of costs and estimated earnings	$	(127.4)	$	(147.7)
Conditional retainage	32.1		38.6
Contract liabilities	$	(95.3)	$	(109.1)

As of January 1, 2024, contract assets were $118.6 million and contract liabilities were $153.5 million.

The change in contract assets during the three months ended March 31, 2025 and 2024, is a result of the recording of $74.6 million and $15.7 million, respectively, of contract assets driven by new commercial projects, partially offset by $45.6 million and $52.1 million, respectively, of contract assets transferred to receivables from contract assets recognized at the beginning of the year, including from certain large projects completed or nearing completion and the corresponding billing of amounts previously recorded as contract assets.

The change in contract liabilities during the three months ended March 31, 2025 and 2024, is a result of the recording of periodic contract liabilities of $54.0 million and $62.9 million, respectively, driven largely by new commercial projects, partially offset by revenue recognized that was included in the contract liability balance at the beginning of the year in the amount of $67.8 million and $91.0 million, respectively, including from certain large projects completed or nearing completion.

Transaction Price Allocated to Remaining Unsatisfied Performance Obligations

As of March 31, 2025, the transaction price allocated to remaining unsatisfied performance obligations consisted of the following (in millions):

	Within One Year		Within Five Years		Total
Commercial	$	333.8	$	107.6	$	441.4
Industrial	250.8		34.7		285.5
Healthcare	176.2		70.9		247.1
Transportation	114.6		78.8		193.4
Government	162.0		5.3		167.3
Leisure	17.0		1.9		18.9
Convention	2.6		—		2.6
Energy	1.6		—		1.6
Remaining unsatisfied performance obligations	$	1,058.6	$	299.2	$	1,357.8

DBMG's remaining unsatisfied performance obligations increase with awards of new contracts and decrease as it performs work and recognizes revenue on existing contracts. DBMG includes a project within its remaining unsatisfied performance obligations at such time the project is awarded and agreement on contract terms has been reached. DBMG's remaining unsatisfied performance obligations include amounts related to contracts for which a fixed price contract value is not assigned when a reasonable estimate of total transaction price can be made. DBMG expects to recognize this revenue approximately within the next 2.0 years.

10

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

(Unaudited)

Remaining unsatisfied performance obligations include unrecognized revenues to be realized from uncompleted construction contracts. Although many of DBMG's contracts are subject to cancellation at the election of its customers, in accordance with industry practice, DBMG does not limit the amount of unrecognized revenue included within its remaining unsatisfied performance obligations due to the inherent substantial economic penalty that would be incurred by its customers upon cancellation.

Life Sciences Segment

The following table disaggregates the Life Sciences segment's revenue by type (in millions):

	Three Months Ended March 31,
	2025		2024
Systems and consumables revenue	$	3.1	$	1.0
Total Life Sciences segment revenue	$	3.1	$	1.0

Spectrum Segment

The following table disaggregates the Spectrum segment's revenue by type (in millions):

	Three Months Ended March 31,
	2025		2024
Broadcast station	$	6.2	$	6.3
Total Spectrum segment revenue	$	6.2	$	6.3

Transaction Price Allocated to Remaining Unsatisfied Performance Obligations

As of March 31, 2025, the transaction price allocated to remaining unsatisfied performance obligations consisted of $14.6 million of broadcast station revenues of which $8.8 million is expected to be recognized within one year and $5.8 million is expected to be recognized within the next 3 years.

4. Accounts Receivable, Net

Accounts receivable, net, consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Contracts in progress	$	156.3	$	184.9
Unbilled retentions	0.1		0.1
Trade receivables	4.1		3.3
Other receivables	4.1		5.8
Allowance for expected credit losses	(0.1)		(0.1)
Total	$	164.5	$	194.0

As of January 1, 2024, accounts receivable, net totaled $278.4 million.

5. Inventory

Inventory consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Raw materials and consumables	$	18.5	$	19.6
Work in process	0.4		0.4
Finished goods	0.8		0.8
Total inventory	$	19.7	$	20.8

11

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

(Unaudited)

6. Investments

The carrying values of the Company's investments, by category, were as follows (in millions):

Date	Equity Method (1)		Fair Value (2)		Measurement Alternative (3)		Total
March 31, 2025	$	0.9	$	2.3	$	0.9	$	4.1
December 31, 2024	$	0.9	$	1.8	$	0.9	$	3.6

(1) The Company's equity method investments were comprised of MediBeacon and Scaled Cell as of both March 31, 2025 and December 31, 2024.

(2) The Company's fair value investments in common stock are comprised of marketable equity securities in two publicly traded companies that were purchased in October 2024 and March 2025.

(3) The Company's measurement alternative method investment was comprised of Triple Ring as of both March 31, 2025 and December 31, 2024.

The Company's share of net losses from its equity method investments was $5.9 million and $1.2 million for the three months ended March 31, 2025 and 2024, respectively.

MediBeacon

Pansend accounts for its preferred stock investment in MediBeacon under the equity method of accounting, inclusive of any fixed maturity securities (notes) issued by MediBeacon to Pansend.

On January 17, 2025, MediBeacon received approval from the U.S. Food and Drug Administration ("FDA") for its Transdermal GFR Measurement System ("TGFR"). Pursuant to the terms of MediBeacon's convertible notes, upon the FDA approval, Pansend's convertible notes of $11.4 million and the related accrued interest of $1.5 million, together totaling $12.9 million, were converted into Series 3 Preferred Stock. In addition, pursuant to its amended commercial partnership with Huadong and, as a result of FDA approval, a $7.5 million milestone payment from Huadong Medicine Co. Ltd ("Huadong"), a publicly traded company on the Shenzhen Stock Exchange, to MediBeacon for MediBeacon preferred stock was received in the first quarter of 2025. As a result of these transactions, Pansend's ownership in MediBeacon decreased from 45.9% prior to the transactions to 44.7% subsequent to the transactions. On a fully diluted basis, Pansend's ownership in MediBeacon decreased from 40.1% to 39.7%. As a result of these transactions, Pansend recognized a step-up gain of $4.4 million in Other (expense) income, net in the Condensed Consolidated Statements of Operations for the three months ended March 31, 2025, which increased Pansend's carrying amount of its investment in MediBeacon. Concurrently, Pansend recognized equity method losses of $5.9 million, driven by the $4.4 million step-up gain and $1.5 million of interest from the conversion of the convertible notes, which were previously unrecognized because Pansend's carrying amount of its investment in MediBeacon had been previously reduced to zero.

MediBeacon's total outstanding principal amount of notes due to Pansend was $0.5 million and $12.0 million, as of March 31, 2025, and December 31, 2024, respectively. Interest income earned by Pansend from the MediBeacon notes totaled $0.1 million and $0.3 million for the three months ended March 31, 2025 and 2024, respectively, and the related accrued interest receivable was $0.3 million and $1.7 million, as of March 31, 2025 and December 31, 2024, respectively.

As of March 31, 2025, Pansend's carrying amount of its investment in MediBeacon remained at zero, inclusive of the $0.5 million in secured promissory notes which were offset against recognized equity method losses, and Pansend has cumulative unrecognized equity method losses relating to MediBeacon of $15.4 million.

Marketable Securities

In October 2024, the Company purchased common shares in the open market of a publicly traded company for approximately $2.0 million, which represents less than 1% of the total outstanding common stock of the issuer. In March 2025, the Company purchased common shares in the open market of another publicly traded company for $0.3 million, which represents less than 1% of the total outstanding equity of the issuer. These securities are remeasured at fair value each reporting period using the externally quoted market prices, Fair Value Level 1 inputs. For the three months ended March 31, 2025, unrealized fair value gains of $0.2 million related to these securities were included in Other income (expense), net in the Condensed Consolidated Financial Statements.

12

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

(Unaudited)

7. Property, Plant and Equipment, Net

Property, plant and equipment, net, ("PP&E") consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Equipment, furniture and fixtures, and software	$	212.6	$	211.0
Building and leasehold improvements	36.9		36.8
Land	18.6		18.6
Construction in progress	10.9		8.0
Plant and transportation equipment	7.4		7.4
	$	286.4	$	281.8
Less: Accumulated depreciation	153.8		148.2
Total	$	132.6	$	133.6

Depreciation expense was $5.9 million and $6.5 million for the three months ended March 31, 2025 and 2024, respectively. These amounts included $3.5 million and $4.0 million of depreciation expense recognized within cost of revenue for the three months ended March 31, 2025 and 2024, respectively.

As of March 31, 2025 and December 31, 2024, the net book value of equipment held under finance leases included in PP&E was $0.1 million and $0.5 million, respectively. As of both March 31, 2025 and December 31, 2024, the gross value of capitalized internal-use software included in PP&E was $20.7 million, and the net book value as of March 31, 2025 and December 31, 2024, was $9.0 million and $9.8 million, respectively.

Assets held-for-sale are included within Other current assets in the Condensed Consolidated Balance Sheets. As of March 31, 2025, there were $6.0 million in assets held-for-sale, which primarily consisted of one building, equipment and land and the associated improvements at the Company's Infrastructure segment. As of December 31, 2024, there were $7.0 million in assets held-for-sale, which primarily consisted of one building, equipment and land and the associated building improvements at the Company's Infrastructure segment.

8. Goodwill and Intangibles, Net

Goodwill

The carrying amounts of goodwill by segment were as follows (in millions):

	Infrastructure		Spectrum		Total
Balance as of December 31, 2024	$	105.3	$	21.4	$	126.7
Balance as of March 31, 2025	$	105.3	$	21.4	$	126.7

Indefinite-lived Intangible Assets

The carrying amounts of indefinite-lived intangible assets were as follows (in millions):

	March 31, 2025		December 31, 2024
FCC licenses	$	107.7	$	107.7
Total	$	107.7	$	107.7

Definite Lived Intangible Assets

The gross carrying amounts and accumulated amortization of definite lived intangible assets by major intangible asset class were as follows (in millions):

	Weighted-Average Original Useful Life	March 31, 2025
		Gross Carrying Amount		Accumulated Amortization			Net
Trade names	15 years	$	25.1		$	(11.4)	$	13.7
Customer relationships and contracts	11 years	87.4			(50.4)		37.0
Channel sharing arrangements	35 years	12.6			(2.3)		10.3
Other	10 years	3.7			(2.0)		1.7
Total		$	128.8		$	(66.1)	$	62.7

13

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

(Unaudited)

	Weighted-Average Original Useful Life	December 31, 2024
		Gross Carrying Amount		Accumulated Amortization			Net
Trade names	15 years	$	25.1		$	(11.0)	$	14.1
Customer relationships and contracts	11 years	87.4			(49.1)		38.3
Channel sharing arrangements	35 years	12.6			(2.2)		10.4
Other	10 years	3.9			(2.0)		1.9
Total		$	129.0		$	(64.3)	$	64.7

Amortization expense for definite lived intangible assets was $2.0 million and $1.9 million for the three months ended March 31, 2025 and 2024, respectively. Amortization expense is included in Depreciation and amortization in the Condensed Consolidated Statements of Operations.

9. Leases

The Company has entered into operating leases for land, office space, and certain Company vehicles and equipment and has entered into finance leases for certain Company vehicles and equipment. The leases will expire between 2025 and 2045. Right-of-use lease assets and lease liabilities consisted of the following (in millions):

	Balance Sheet Location	March 31, 2025		December 31, 2024
Right-of-use assets:
Operating lease	Other assets (non-current)	$	53.0	$	53.7
Finance lease	Property, plant and equipment, net	0.1		0.5
Total right-of-use assets		$	53.1	$	54.2
Lease liabilities:
Current portion of operating lease	Other current liabilities	$	12.9	$	12.9
Non-current portion of operating lease	Other liabilities	41.9		43.5
Finance lease	Debt obligations	0.2		0.6
Total lease liabilities		$	55.0	$	57.0

The following table summarizes the components of lease expense (in millions):

	Three Months Ended March 31,
	2025		2024
Finance lease cost:
Amortization of right-of-use assets	$	0.1	$	0.1
Net finance lease cost	0.1		0.1
Operating lease cost	4.2		4.5
Variable lease cost	0.2		0.1
Sublease income	—		(0.2)
Total non-current lease cost	4.5		4.5
Short-term lease costs	8.0		7.2
Total lease cost	$	12.5	$	11.7

Cash flow information related to leases is as follows (in millions):

	Three Months Ended March 31,
	2025		2024
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	5.2	$	5.0
Financing cash flows for finance leases	$	0.1	$	0.1
Right-of-use assets obtained in exchange for new lease liabilities:
Operating leases	$	2.5	$	2.6

14

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

(Unaudited)

The weighted-average remaining lease term and the weighted-average discount rate for the Company's leases were as follows:

	March 31, 2025		December 31, 2024
Weighted-average remaining lease term (years) - operating leases	7.3		7.4
Weighted-average remaining lease term (years) - finance leases	2.6		2.7
Weighted-average discount rate - operating leases	6.2	%	6.1	%
Weighted-average discount rate - finance leases	5.0	%	5.3	%

Future minimum lease commitments (undiscounted) as of March 31, 2025, were as follows (in millions):

	Operating Leases		Finance Leases
2025 (remaining period)	$	11.4	$	0.1
2026	12.7		0.1
2027	10.0		—
2028	7.4		—
2029	4.7		—
Thereafter	21.4		—
Total future minimum lease payments	67.6		0.2
Less: amounts representing interest	(12.8)		—
Total lease liability	$	54.8	$	0.2

On May 1, 2024, a subsidiary of DBMG amended the termination date of three property leases that had an original expiry date of March 31, 2031. In exchange, and as an inducement for DBMG to early terminate, the landlord agreed to pay DBMG $12.0 million in surrender fees in three equal installments, contingent on timely vacate and inspection milestones, of which DBMG received $4.0 million in surrender fees in 2024, with the remaining two $4.0 million payments due to DBMG due within five business days of the vacate dates in 2025 and 2027, respectively. After final surrender of the properties, DBMG will have no further obligations under these leases.

10. Other Assets, Accrued Liabilities and Other Liabilities

Other Current Assets

Other current assets consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Prepaid assets	$	9.8	$	10.9
Assets held-for-sale	6.0		7.0
Income tax receivable	0.5		0.6
Other	2.4		2.5
Total other current assets	$	18.7	$	21.0

Other Assets

Other assets, which are reflected within non-current assets in the Condensed Consolidated Balance Sheets, consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Right-of-use assets	$	53.0	$	53.7
Restricted cash - non-current	0.6		0.5
Other	7.5		8.1
Total other assets	$	61.1	$	62.3

15

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

(Unaudited)

Accrued Liabilities

Accrued liabilities consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Accrued expenses	$	12.3	$	13.4
Accrued payroll and employee benefits	22.9		34.1
Accrued interest and exit fees (current portion)	64.3		61.0
Accrued sales and use taxes	0.3		0.4
Accrued income taxes	7.0		0.8
Total accrued liabilities	$	106.8	$	109.7

Other Current Liabilities

Other current liabilities consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Operating lease liability, current portion	$	12.9	$	12.9
Other	4.4		4.3
Total other current liabilities	$	17.3	$	17.2

Other Liabilities

Other liabilities, which are reflected within non-current liabilities in the Condensed Consolidated Balance Sheets, consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Operating lease liability, net of current portion	$	41.9	$	43.5
Accrued interest (non-current portion)	—		0.7
Other	3.0		2.6
Total other liabilities	$	44.9	$	46.8

16

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

(Unaudited)

11. Debt Obligations

Debt obligations, including finance lease obligations, consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Infrastructure
PRIME minus 1.00% Line of Credit due 2025	$	50.0	$	45.0
3.25% Term Loan due 2026	72.8		74.6
PRIME minus 1.00% Term Loan due 2026	24.2		24.5
Obligations under finance leases	0.2		0.6
Total Infrastructure	$	147.2	$	144.7
Spectrum
8.50% Note due 2025	$	19.3	$	19.3
11.45% Notes due 2025	50.4		50.4
Total Spectrum	$	69.7	$	69.7
Life Sciences
20.00% Notes due 2025	$	25.2	24.0
Total Life Sciences	$	25.2	$	24.0
Non-Operating Corporate
8.50% Senior Secured Notes due 2026	$	330.0	$	330.0
7.50% Convertible Senior Notes due 2026	48.9		48.9
SOFR plus 5.75% Line of Credit due 2025	20.0		20.0
CGIC Unsecured Note due 2026	31.0		31.0
Total Non-Operating Corporate	$	429.9	$	429.9
Total outstanding principal	$	672.0	$	668.3
Unamortized issuance discount, issuance premium, and deferred financing costs	(8.6)		(5.5)
Less: current portion of debt obligations	(523.5)		(162.2)
Debt obligations, net of current portion	$	139.9	$	500.6

As of March 31, 2025, estimated future aggregate finance lease and debt payments, including interest, were as follows (in millions):

	Finance Leases		Debt		Total
2025 (remaining period) (1)	$	0.1	$	234.5	$	234.6
2026	0.1		507.6		507.7
Total minimum principal and interest payments	0.2		742.1		742.3
Less: Amount representing interest (1)	—		(70.3)		(70.3)
Total aggregate finance lease and debt payments	$	0.2	$	671.8	$	672.0

(1) Excludes exit fees for Spectrum and R2 Technologies.

The interest rates on finance leases ranged from approximately 3.0% to 6.8%.

Infrastructure

DBMG has a $135.0 million Revolving Line with UMB that bears interest at a prime rate minus a spread with an interest rate floor of 4.25%. The Revolving Line with UMB matures on August 15, 2025. The outstanding balance was $50.0 million and $45.0 million, as of March 31, 2025 and December 31, 2024, respectively, and availability for revolving loans was $84.9 million and $89.9 million as of March 31, 2025 and December 31, 2024, respectively. Interest is paid monthly, and the effective interest rate on the Revolving Line with UMB was 6.72% and 6.98% as of March 31, 2025 and December 31, 2024, respectively. The Revolving Line with UMB also includes a commitment fee equal to 0.25% per annum times the average daily unused availability under the line.

DBMG also has a $72.8 million 3.25% term loan due 2026 (the "3.25% UMB Term Loan"), which matures May 31, 2026, and bears interest, which is paid monthly, at an annual rate of 3.25% with an effective interest rate of 3.3%.

On June 28, 2024, DBM and UMB entered into the Third Amendment to the UMB Credit Agreement, which added an incremental separate term loan of $25.0 million to the existing credit facility ("PRIME minus 1.00% Term Loan due 2026"), with the same interest rate as the Revolving Line with UMB and the same maturity date as the initial 3.25% UMB Term Loan. Principal payments and interest are paid monthly.

17

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

(Unaudited)

The UMB term loans and Revolving Line with UMB associated with the Infrastructure segment contain customary restrictive and financial covenants related to debt levels and performance, including a Fixed Charge Coverage Ratio covenant, as defined in their agreements.

DBMG is in compliance with its debt covenants as of March 31, 2025.

Spectrum

The maturity date of Spectrum's 8.50% and 11.45% Notes is August 15, 2025, as amended in November 2023. As a result of amendments to extend the maturity date during the year ended December 31, 2023, additional exit fees of $8.3 million were incurred. The exit fees associated with the notes, which are payable on the earlier of maturity or repayment of the principal, were recorded as original issue discount and are being amortized over the remaining life of the notes, which is assumed to be the maturity date. A corresponding liability for the total exit fees of $15.9 million is reflected within Accrued Liabilities in the Condensed Consolidated Balance Sheets as of both March 31, 2025 and December 31, 2024. Interest is capitalized and payable upon maturity of the notes, of which there was $22.4 million and $20.5 million of accrued but unpaid interest as of March 31, 2025 and December 31, 2024, respectively. As of March 31, 2025 and December 31, 2024, the weighted-average effective interest rate on the notes, as amended, was 22.9% and 22.8% per annum, respectively.

During November 2023, concurrently with Broadcasting's execution of the Ninth Amendment to Secured Notes, which among other things extended the maturity of the notes, INNOVATE entered into a related side letter with the lenders, whereby INNOVATE agreed to utilize proceeds from a sale of certain of its existing operations, as allowable under the Company's current agreements and indentures and after all other required payments have been made, for repayment of a portion of Broadcasting's Senior Secured Notes. Assuming there are sufficient proceeds remaining after such repayment, an additional $2.0 million fee is payable for payments made after November 9, 2024, and in exchange for the additional $2.0 million fee, the institutional investors will return their equity interests in HC2 Broadcasting Holdings, Inc. and their equity interests in DTV America. The lenders hold warrants to purchase 145,825 shares of common stock of HC2 Broadcasting Holdings, Inc which can be exercised at any time until August 2027 at an exercise price of $0.01 per share.

Life Sciences

Effective January 31, 2024, a 20% note was entered into with Lancer Capital, which replaced the prior 20% note. The new note had an aggregate original principal amount of $20.0 million, which was comprised of all prior outstanding principal amounts of $17.4 million and unpaid accrued interest of $2.6 million which was capitalized into the new principal balance. The 20% $20.0 million note also included an exit fee, which would be 10.5% of the principal amount being repaid as of April 30, 2024. As a result of the addition of the exit fee effective January 31, 2024, the transaction was determined to be an extinguishment of debt under ASC 470-50, Debt - Modifications and Extinguishments ("ASC 470-50"), and the $2.2 million exit fee payable to the existing lender was included as a loss on debt extinguishment within Other income (expense), net on the Condensed Consolidated Statement of Operations for the three months ended March 31, 2024. The original maturity date of the 20% $20.0 million note was April 30, 2024, or within five business days of the date on which R2 Technologies receives an aggregate $20.0 million from the consummation of a debt or equity financing or has a change in control, as defined in the agreement, with an optional prepayment of the entire then-outstanding and unpaid principal and accrued interest upon five-days written notice to Lancer Capital. Effective May 17, 2024, the maturity date of the note was extended to December 31, 2024, and the exit fees were amended. The May 17, 2024, amendment was determined to be a modification of debt under ASC 470-50 as the terms of the debt were not determined to be substantially different, including taking into consideration the ability to prepay the debt at anytime, and, therefore, the additional exit fees were amortized using the effective interest method.

During the first quarter of 2025, with an effective date of December 31, 2024, the maturity date of the note was extended to August 1, 2025, and another additional exit fee of $1.0 million was incurred under the amendment, which continues to increase by $1.0 million each month until maturity. The base exit fee, as amended, and as of March 31, 2025, was equal to 12.41% of the principal amount being repaid and continues to increase by 0.17% each month until maturity. The total new exit fees associated with the notes have been recorded as an original issue discount of $8.7 million and are being amortized over the remaining life of the note, which is assumed to be the maturity date. A corresponding liability for the new exit fees of $8.7 million was recorded for total accrued exit fees amount of $16.5 million which are included within Accrued liabilities in the Condensed Consolidated Balance Sheet as of March 31, 2025. The exit fees are payable on the earliest of the maturity date, the date of the acceleration of the principal amount of the note for any reason or, if any portion of the note is prepaid at any time, the date of such prepayment of the note. In addition, under the recent amendment, a new $5.0 million default fee will be payable on August 1, 2025, in the event all obligations under the note, including principal, any accrued and unpaid interest, and exit fees, are not repaid in full prior to the August 1, 2025, maturity date. The $5.0 million default fee will only be recognized in the event of a default on August 1, 2025.

The amendment, which is effective as of December 31, 2024, was determined to be a modification of debt under ASC 470-50, as the terms of the debt were not determined to be substantially different, including taking into consideration the ability to prepay the debt at anytime, and, therefore, the additional exit fees are being amortized over the term of the note using the effective interest rate method and are included in interest expense.

18

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

(Unaudited)

Interest on the note, as amended, is payable monthly in arrears, in cash or, if not paid in cash, accrued and unpaid interest is capitalized monthly into the principal balance. Interest expense, including amortization of all exit fees, related to the note with Lancer Capital was $4.5 million and $0.9 million for the three months ended March 31, 2025 and 2024, respectively. For the three months ended March 31, 2025 and 2024, in accordance with the 20% note agreement, $1.2 million and $0.7 million, respectively, of interest was capitalized into the principal balance.

As of March 31, 2025, the total carrying amount relating to the note was $36.4 million, inclusive of $25.2 million of principal and capitalized interest, partially offset by $5.3 million of unamortized original issue discount, which are included within the Current portion of debt obligations in the Condensed Consolidated Balance Sheet, and $16.5 million in total accrued exit fees which are included within Accrued liabilities in the Condensed Consolidated Balance Sheet. As of December 31, 2024, the total outstanding amount relating to the note was $31.9 million, inclusive of $24.0 million of principal and capitalized interest, which total was included within Current portion of debt obligations in the Condensed Consolidated Balance Sheet, and $7.9 million in total accrued exit fees which were included within Accrued liabilities in the Condensed Consolidated Balance Sheet. As of March 31, 2025 and December 31, 2024, the effective interest rate on the note, as amended, was 51.3% and 57.8%, respectively.

Non-Operating Corporate

2026 Senior Secured Notes

The Company has $330.0 million aggregate principal amount of 8.50% senior secured notes due February 1, 2026 (the "2026 Senior Secured Notes"), which were issued in 2021 at 100% of par. The 2026 Senior Secured Notes have a stated annual interest rate of 8.50% and have an effective interest rate of 9.3%, which reflects the initial $10.8 million of deferred financing fees, including underwriting fees. Interest is payable semi-annually in arrears on February 1st and August 1st of each year. Aggregate interest expense, including the contractual interest coupon and amortization of the deferred financing fees was $7.6 million for both the three months ended March 31, 2025 and 2024, respectively. There were $2.2 million and $2.8 million of unamortized deferred financing fees as of March 31, 2025 and December 31, 2024, respectively.

2026 Convertible Notes

The original $51.8 million aggregate principal amount of 7.50% convertible notes (the "2026 Convertible Notes") were issued under a separate indenture dated February 1, 2021, between the Company and U.S. Bank, as trustee (the "Convertible Indenture"). The 2026 Convertible Notes mature on August 1, 2026, unless earlier converted, redeemed or purchased. The 2026 Convertible Notes were issued at 100% of par with a stated annual interest rate of 7.50%. The fair value of the embedded conversion feature contained in the 2026 Convertible Notes had a fair value of $12.3 million, which was recorded as a premium on the 2026 Convertible Notes. The 2026 Convertible Notes have an effective interest rate of 3.21%, which reflects the initial $12.3 million premium and $1.1 million of deferred financing fees.

During July 2024, INNOVATE repurchased $2.9 million principal amount of its 2026 Convertible Notes at a market discount for $1.1 million, which was inclusive of accrued interest of $0.1 million. As of March 31, 2025, the 2026 Convertible Notes had a net carrying value of $51.8 million inclusive of the remaining unamortized premium of $3.2 million and unamortized deferred financing costs of $0.3 million. As of December 31, 2024, the 2026 Convertible Notes had a net carrying value of $52.3 million, inclusive of an unamortized premium of $3.8 million and unamortized deferred financing costs of $0.4 million.

Interest is payable semi-annually in arrears on February 1st and August 1st of each year. Aggregate interest expense recognized relating to both the contractual interest coupon and amortization of discount net of premium and deferred financing costs was $0.4 million and $0.5 million, for the three months ended March 31, 2025 and 2024, respectively.

Each $1,000 of principal of the 2026 Convertible Notes is convertible into 23.6327 shares of our common stock, which is equivalent to a conversion price of approximately $42.31 per share, both as adjusted for the 2024 Reverse Stock Split and subject to further adjustment upon the occurrence of specified events. Based on the closing price of our common stock of $7.83 on March 31, 2025, the if-converted value of the 2026 Convertible Notes did not exceed its principal value.

Revolving Line of Credit

The Company has a revolving credit agreement with MSD PCOF Partners IX, LLC ("MSD"), which has a maximum commitment of $20.0 million ("Revolving Line of Credit"). As of both March 31, 2025 and December 31, 2024, the outstanding balance was $20.0 million. The maturity date of the Revolving Line of Credit was amended on March 6, 2025, from May 16, 2025, to August 1, 2025. The Revolving Line of Credit has an interest rate margin applicable to loans borrowed under the Revolving Line of Credit of 5.75%, and the benchmark rates for the interest are SOFR-based rates. As of March 31, 2025 and December 31, 2024, the effective interest rate on the Revolving Line of Credit, as amended, was 10.3% and 10.6%, respectively. Interest is paid quarterly in arrears. The Revolving Line of Credit also includes a commitment fee at a per annum rate of 1.0% calculated based off the actual daily amount of unused availability under the Revolving Line of Credit with MSD, and also includes a requirement for a prepayment if net cash proceeds from certain asset sales in excess of $10.0 million are received. The affirmative and negative covenants governing the Revolving Line of Credit are substantially consistent with the affirmative and negative covenants contained in the indenture that governs the 2026 Senior Secured Notes.

19

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

(Unaudited)

CGIC Unsecured Note Due 2026

The Company has a subordinated unsecured promissory note with Continental General Insurance Company ("CGIC") in the original principal amount of $35.1 million (the "CGIC Unsecured Note"). The CGIC Note, which is due February 28, 2026, bore interest at 9.0% per annum through May 8, 2024, bears interest at 16.0% per annum from May 9, 2024, to May 8, 2025, and 32.0% per annum thereafter. As of both March 31, 2025 and December 31, 2024, the effective interest rate on the note, as adjusted, was 17.5%. The CGIC Unsecured Note also requires a mandatory prepayment from the proceeds from certain asset sales and the greater of $3.0 million or 12.5% of the net proceeds from certain equity sales. As a result of the closing of the rights offering and concurrent private placement in 2024 (refer to Note 15. Equity and Temporary Equity), INNOVATE redeemed $4.1 million of the CGIC Unsecured Note on April 26, 2024. Other covenants in the CGIC Unsecured Note are generally consistent with the Company's Indenture governing the 8.50% Senior Secured Notes due 2026, dated as of February 1, 2021, by and among the Company, the guarantors party thereto and U.S. Bank National Association.

For the three months ended March 31, 2025 and 2024, interest expense recognized relating to the CGIC Unsecured Note was $1.4 million and $1.6 million, respectively, and cash paid for interest to CGIC was $1.2 million and $0.8 million, respectively. Accrued interest related to the CGIC notes was $3.6 million and $3.4 million as of March 31, 2025, and December 31, 2024, respectively.

INNOVATE is in compliance with its debt covenants as of March 31, 2025.

12. Income Taxes

Income tax expense of $7.1 million and $3.3 million for the three months ended March 31, 2025 and 2024, primarily relates to tax expense as calculated for taxpaying entities, including the tax expense associated with the INNOVATE Corp. U.S. consolidated group due to the Tax Cut and Jobs Act's 80 percent limitation on net operating losses incurred after 2017. Additionally, the tax benefits associated with losses generated by certain other businesses have been reduced by a full valuation allowance as management does not believe it is more-likely-than-not that the losses will be utilized.

Net Operating Losses

At December 31, 2024, the Company had gross U.S. net operating loss ("NOL") carryforwards available to reduce future taxable income of the U.S. consolidated group in the amount of $174.3 million. The Company expects that approximately $117.7 million of the gross U.S. NOL carryforwards would be available to offset taxable income in 2025 and later periods. This estimate may change based on changes to actual results reported on the 2024 U.S. tax return. The amount of U.S. NOL carryforwards reflected in the financial statements differ from the amounts reported on the U.S. tax return due to uncertain tax positions related to tax laws and regulations that are subject to varied interpretation by the Internal Revenue Service ("IRS").

Additionally, as of December 31, 2024, the Company had $149.4 million of gross U.S. NOL carryforwards from its subsidiaries that do not qualify to be included in the INNOVATE U.S. consolidated income tax return, including $102.8 million from R2, $44.1 million from DTV America, and other entities of $2.5 million. Of the $149.4 million of gross U.S. NOL carryforwards, $113.3 million was generated after 2017 and will have an indefinite carryforward period; the remaining $36.1 million was generated prior to 2018 and will expire, if unused, by 2037.

Unrecognized Tax Benefits

The Company follows the provision of ASC 740 which prescribes a comprehensive model for how a company should recognize, measure, present, and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on a tax return. The Company is subject to challenge from various taxing authorities relative to certain tax planning strategies, including certain intercompany transactions as well as regulatory taxes.

The Company did not have any unrecognized tax benefits as of March 31, 2025 and 2024, related to uncertain tax positions that would impact the effective income tax rate if recognized. The Company has reduced the NOL carryforward by $58.7 million for uncertain tax positions based on our interpretation of tax laws and regulations that are subject to varied interpretation by the IRS.

Examinations

The Company conducts business globally, and as a result, INNOVATE or one or more of its subsidiaries files income tax returns in the United States federal jurisdiction and various state and foreign jurisdictions. In the normal course of business, the Company is subject to examination by taxing authorities throughout the world. Tax years 2002-2023 remain open for examination.

The Company is currently under examination in various domestic and foreign tax jurisdictions. The open tax years contain matters that could be subject to differing interpretations of applicable tax laws and regulations as they relate to the amount, character, timing or inclusion of revenue and expenses or the applicability of income tax credits for the relevant tax period. Given the nature of tax audits, there is a risk that disputes may arise.

20

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

(Unaudited)

13. Commitments and Contingencies

Litigation

The Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Company’s Condensed Consolidated Financial Statements. Such legal matters may include, but is not limited to, actions or claims relating to sensitive data, including proprietary business information and intellectual property, personally identifiable information of employees and contractors, cyber-attacks, data breaches and non-compliance with contractual or other legal obligations. Litigation and other legal matters are inherently unpredictable and subject to substantial uncertainties and adverse resolutions could occur. In addition, litigation and other legal matters, including class-action lawsuits, government investigations and regulatory proceedings can be costly to defend and, depending on the class size and claims, could be costly to settle. The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its Condensed Consolidated Financial Statements. The Company records a liability in its Condensed Consolidated Financial Statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated as well as any legal costs incurred related to the litigation. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary for its Condensed Consolidated Financial Statements not to be misleading. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in the Company's Condensed Consolidated Financial Statements. Any legal or other expenses associated with the litigation are accrued for as the expenses are incurred. The Company maintains liability insurance that insures it against workers’ compensation, personal and bodily injury, property damage, directors’ and officers’ liability, errors and omissions, cyber liability, employment practices liability. There can be no assurance that the liability insurance will cover all events or that the limits of coverage will be sufficient to fully cover all liabilities.

Based on a review of the current facts and circumstances with counsel in each of the matters disclosed, management has provided for what is believed to be a reasonable estimate of loss exposure. While acknowledging the uncertainties of litigation, management believes that the ultimate outcome of litigation will not have a material effect on its financial position and will defend itself vigorously.

Marin General Hospital Replacement Litigation

On October 20, 2022, McCarthy Building Companies, Inc. (“McCarthy”) filed suit against Schuff Steel Company (“Schuff”), a subsidiary of DBMG, and Quality Assurance Engineering, Inc. dba Consolidated Engineering Laboratories (“CEL”) in the Superior Court of the State of California for the County of Marin, styled McCarthy Building Companies, Inc. v. Schuff Steel Company; Quality Engineering, Inc. dba Consolidated Engineering Laboratories, et al., Case No. CIV2203963 (the “Action”). In the Action, McCarthy alleges damages and delays caused by alleged failures in fabrication, erection, welding, and quality control by Schuff and improper quality assurance responsibilities by CEL on the Marin General Hospital Replacement Building (the “Project”). McCarthy asserts claims against Schuff for breach of contract, express indemnity, breach of express warranties, negligence, equitable implied indemnity, breach of implied warranties, and declaratory relief. On February 13, 2023, Schuff filed its response denying liability to McCarthy and asserting a Cross-Complaint against McCarthy, and other companies involved in the design, construction, and quality assurance, who potentially are liable for damages and delays alleged by McCarthy on the Project. In the Cross-Complaint, Schuff asserts claims for breach of contract, violation of statute, equitable indemnity apportionment, and contribution and express indemnity (the “Cross-Complaint”). Schuff intends to vigorously defend this Action and aggressively pursue the Cross-Complaint and cannot reasonably estimate any range of potential loss at this time.

Other Commitments and Contingencies

Letters of Credit and Performance Bonds

As of March 31, 2025, DBMG had outstanding letters of credit of $0.1 million under credit and security agreements and performance bonds of $259.1 million. As of December 31, 2024, DBMG had outstanding letters of credit of $0.1 million under credit and security agreements and performance bonds of $183.9 million. DBMG’s contract arrangements with customers sometimes require DBMG to provide performance bonds to partially secure its obligations under its contracts. Bonding requirements typically arise in connection with private contracts and sometimes with respect to certain public work projects. DBMG’s performance bonds are obtained through surety companies and typically cover the entire project price. The ratings of the bonding companies utilized by DBMG are highly rated, ranging from A-, A, A+ and AA.

Concentrations of Credit Risk

The Company's revenue concentrations of 10% and greater were as follows:

		Three Months Ended March 31,
		2025	2024
	Segment	Revenue	Revenue
Customer A	Infrastructure	*	27.6%

*Less than 10% concentration

21

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

(Unaudited)

14. Share-based Compensation

Total share-based compensation expense recognized by the Company and its subsidiaries under all equity compensation arrangements was $0.8 million and $0.4 million for the three months ended March 31, 2025 and 2024, respectively, which is reflected as a component of Selling, general and administrative expenses in the Condensed Consolidated Statements of Operations.

All grants are time based and vest either immediately or over a period established at grant, typically with a requisite service period of one to three years for a member of the Board of Directors or an employee to vest in the share-based award, subject to discretion by Compensation Committee. There are no other substantive conditions for vesting. The Company recognizes compensation expense for equity awards, reduced by actual forfeitures as they are incurred, using the straight-line basis.

Restricted Stock and Restricted Stock Units

A summary of INNOVATE’s restricted stock and restricted stock unit activity is as follows:

	Number of Shares	Weighted-Average Grant Date Fair Value
Unvested - December 31, 2024	294,663	$	8.12
Granted	36,881	$	7.66
Vested	(38,835)	$	18.46
Unvested - March 31, 2025	292,709	$	6.70

The aggregate vesting date fair value of the restricted stock and restricted stock units which vested during the three months ended March 31, 2025 and 2024, was $0.3 million and $0.2 million, respectively. As of March 31, 2025, the total unrecognized share-based compensation expense related to unvested restricted stock and restricted stock units was $1.2 million and is expected to be recognized over the remaining weighted-average period of 1.4 years.

Stock Options

A summary of INNOVATE’s stock option activity is as follows:

	Number of Stock Options	Weighted-Average Exercise Price
Outstanding - December 31, 2024	217,733	$	16.94
Outstanding - March 31, 2025	217,733	$	16.94
Exercisable - March 31, 2025 and December 31, 2024	117,733	$	27.74

As of March 31, 2025, the intrinsic value and weighted-average remaining life of the Company's outstanding and exercisable stock options were zero and approximately 7.7 years, respectively. The maximum contractual term of the Company's exercisable stock options is approximately ten years. As of March 31, 2025, there were 100,000 unvested stock options and $0.2 million of unrecognized share-based compensation expense related to unvested stock options and is expected to be recognized over the remaining period of 0.5 years.

15. Equity and Temporary Equity

2024 Rights Offering and Concurrent Private Placement

On March 8, 2024, the Company commenced a rights offering ("Rights Offering"), in which each holder of the Company’s common stock, Series A-3 Convertible Participating Preferred Stock, Series A-4 Convertible Participating Preferred Stock and the 2026 Convertible Notes as of March 6, 2024 (the “rights offering record date”), were granted rights to purchase common stock. In connection with the Rights Offering, the Company entered into an Investment Agreement with Lancer Capital (the "Investment Agreement"), pursuant to which Lancer Capital agreed to purchase up to $19.0 million of Series C Preferred Stock as a backstop to the Rights Offering (the "Backstop Commitment") and to purchase $16.0 million of Series C Preferred Stock in a private placement transaction ("Concurrent Private Placement"). Lancer Capital is an investment fund led by Avram A. Glazer, the Chairman of the Board and the Company’s largest stockholder. As the Rights Offering had not yet settled by March 28, 2024, in accordance with the Investment Agreement, Lancer Capital purchased $25.0 million of Series C Preferred Stock, referred to as the "equity advance." On April 24, 2024, the Company completed and closed on the Rights Offering and issued a total of 530,611 shares of common stock (5,306,105 shares of common stock on a pre Reverse Stock Split (see below) basis) for $3.7 million. In addition, Lancer Capital purchased an additional approximately 6,286 Series C Preferred Stock for $6.3 million under the Backstop Commitment. In total, the Company received $35.0 million in aggregate gross proceeds related to the Rights Offering and Concurrent Private Placement and incurred $1.8 million in dealer manager fees and other related costs which were capitalized into Additional paid in capital ("APIC"). On June 18, 2024, the Company's shareholders approved the conversion of the Series C Preferred Stock into common stock, and approximately 31,286 shares of Series C Preferred Stock, which were held by Lancer Capital, were converted into 4,469,390 shares of common stock (44,693,895 shares of common stock on a pre Reverse Stock Split basis), and there were no shares of the Series C Preferred Stock outstanding subsequent to their conversion into the Company's common stock.

22

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

(Unaudited)

Reverse Stock Split

On August 8, 2024, the Company effected a 1-for-10 reverse stock split of its issued and outstanding common stock (the “Reverse Stock Split”) following stockholder approval. The Reverse Stock Split was implemented for the primary purpose of regaining compliance with the minimum bid price requirement for continued listing of the Company’s common stock on the NYSE. The Reverse Stock Split did not change the $0.001 par value per share of the common stock. As a result of the Reverse Stock Split, the number of outstanding common shares was reduced from 130,529,931 to 13,166,057, inclusive of an additional 113,064 incremental whole shares issued for fractional shares. Unless noted, all share and per share amounts of common stock, options and restricted stock and any associated debt or preferred stock conversion rates contained in the historical periods, prior to the date of the Reverse Stock Split, presented within these Condensed Consolidated Financial Statements have been retroactively adjusted to reflect the 1-for-10 Reverse Stock Split as if it had occurred at the beginning of the earliest period presented.

Preferred Shares

The Company’s preferred shares authorized, issued and outstanding consisted of the following:

	March 31, 2025	December 31, 2024
Preferred shares authorized, $0.001 par value	20,000,000	20,000,000
Series A-3 shares issued and outstanding	6,125	6,125
Series A-4 shares issued and outstanding	10,000	10,000

Series A-3 and Series A-4 Shares

Issuance and Conversion. On July 1, 2021, (the "Exchange Date") as a part of the sale of Continental Insurance Group ("CIG"), INNOVATE entered into an exchange agreement (the "Exchange Agreement") with CGIC, also a former subsidiary, which held the remaining shares of the Company's previous Series A and Series A-2 Preferred Stock and was eliminated in consolidation prior to the sale of the Company's former Insurance segment on July 1, 2021. Per the Exchange Agreement, INNOVATE exchanged 6,125 shares of the Series A and 10,000 shares of the Series A-2 shares that CGIC held for an equivalent number of Series A-3 Convertible Participating Preferred Stock ("Series A-3") and Series A-4 Convertible Participating Preferred Stock ("Series A-4"), respectively. The terms remained substantially the same, except that the Series A-3 and Series A-4 mature on July 1, 2026.

Since the time of issuance of the Series A-3 and Series A-4 Preferred Stock on July 1, 2021, the Series A-3 and Series A-4 Preferred Stock have been classified as temporary equity in the Company's Condensed Consolidated Balance Sheet, with a combined redemption value of $16.1 million and with a current fair value of $16.4 million as of March 31, 2025, which is inclusive of the $0.3 million accrued dividend payable on April 15, 2025.

Dividends. The Series A-3 and Series A-4 Preferred Stock accrue a cumulative quarterly cash dividend at an annualized rate of 7.50%. The accrued values of the Series A-3 and Series A-4 Preferred Stock accrete quarterly at an annualized rate of 4.00% that is reduced to 2.00% or 0.0% if the Company achieves specified rates of growth measured by increases in its net asset value; provided, that the accreting dividend rate will be 7.25% in the event that (A) the daily volume weighted-average price ("VWAP") of the Company's common stock is less than a certain threshold amount, (B) the Company's common stock is not registered under Section 12(b) of the Securities Exchange Act of 1934, as amended, (C) the Company's common stock is not listed on certain national securities exchanges or the Company is delinquent in the payment of any cash dividends. The Series A-3 and Series A-4 Preferred Stock is also entitled to participate in cash and in-kind distributions to holders of shares of Company's common stock on an as-converted basis.

Subsequent Measurement. The Company elected to account for the Series A-3 and Series A-4 Preferred Stock by immediately recognizing changes in the redemption value as they occur. The carrying values of the Series A-3 and Series A-4 Preferred Stock are adjusted to equal what the redemption amount would be as if the redemption were to occur at the end of the reporting period as if it were also the redemption date for the Series A-3 and Series A-4 Preferred Stock. Any cash dividends paid directly reduce the carrying value of the Series A-3 and Series A-4 Preferred Stock until the carrying value equals the redemption value. Once the carrying value is equal to the redemption value, the dividends declared are accrued by debiting retained earnings, or if retained earnings is a deficit, then by debiting additional paid in capital. The Company has a history of paying dividends on its Series A-3 and Series A-4 Preferred Stock and expects to continue to pay such dividends each quarter.

23

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

(Unaudited)

Optional Conversion. Each share of Series A-3 and Series A-4 may be converted by the holder into shares of the Company's common stock at any time based on the then-applicable conversion price. As of March 31, 2025, each share of the Series A-3 Preferred Stock was convertible at an accrued value of $1,000 per share, divided by the conversion price of $23.63 (as it may be adjusted from time to time, the "Series A-3 Conversion Price"), and each share of Series A-4 Preferred Stock was convertible at an accrued value of $1,000 per share divided by the conversion price of $34.40 (as it may be adjusted from time to time, the "Series A-4 Conversion Price") (collectively the “Conversion Prices”). The Conversion Prices have historically been adjusted from time to time and continue to be subject to potential adjustment for dividends, certain distributions, stock splits, combinations, reclassifications, reorganizations, mergers, recapitalizations and similar events, as well as in connection with issuances of equity or equity-linked or other comparable securities by the Company at a price per share (or with a conversion or exercise price or effective issue price) that is below the Conversion Prices’ (which adjustment shall be made on a weighted-average basis).

Redemption by the Holders / Automatic Conversion. On July 1, 2026, holders of the Series A-3 and Series A-4 shall be entitled to cause the Company to redeem the Series A-3 and Series A-4 at the accrued value per share plus accrued but unpaid dividends (to the extent not included in the accrued value of Series A-3 and Series A-4). Each share of Series A-3 and Series A-4 that is not so redeemed will be automatically converted into shares of the Company's common stock at the Conversion Price then in effect.

Upon a change of control (as defined in each Certificate of Designation) holders of the Series A-3 and Series A-4 shall be entitled to cause the Company to redeem their shares of Series A-3 and Series A-4 at a price per share of Series A-3 and Series A-4 equal to the greater of (i) the accrued value of the Series A-3 and Series A-4, plus any accrued and unpaid dividends (to the extent not included in the accrued value of Series A-3 and Series A-4 Preferred Stock), and (ii) the value that would be received if the share of Series A-3 and Series A-4 were converted into shares of the Company's common stock immediately prior to the change of control.

Redemption by the Company / "Company Call Option". At any time, the Company may redeem the Series A-3 and Series A-4, in whole but not in part, at a price per share generally equal to 150% of the accrued value per share, plus accrued but unpaid dividends (to the extent not included in the accrued value of the Series A-3 and Series A-4), subject to the holder's right to convert prior to such redemption.

Forced Conversion. The Company may force conversion of the Series A-3 and Series A-4 into shares of the Company's common stock if the common stock's thirty-day VWAP exceeds 150% of the then-applicable Conversion Price and the common stock’s daily VWAP exceeds 150% of the then-applicable Conversion Price for at least 20 trading days out of the thirty trading day period used to calculate the 30-day VWAP. In the event of a forced conversion, the holders of Series A-3 and Series A-4 will have the ability to elect cash settlement in lieu of conversion if certain market liquidity thresholds for the Company's common stock are not achieved.

Liquidation Preference. In the event of any liquidation, dissolution or winding up of the Company (any such event, a “Liquidation Event”), the holders of Series A-3 and Series A-4 will be entitled to receive per share the greater of (i) the accrued value of the Series A-3 and Series A-4, plus any accrued and unpaid dividends (to the extent not included in the accrued value of Series A-3 and Series A-4), and (ii) the value that would be received if the share of Series A-4 and Series A-4 were converted into shares of the Company's common stock immediately prior to such occurrence. The Series A-3 and Series A-4 will rank junior to any existing or future indebtedness but senior to the Company's common stock and any future equity securities other than any future senior or pari passu preferred stock issued in compliance with each Certificate of Designation. The Series A-3 Preferred Stock and the Series A-4 Preferred Stock rank at parity.

Voting Rights. Except as required by applicable law, the holders of the shares of the Series A-3 and Series A-4 will be entitled to vote on an as-converted basis with the holders of the Company’s common stock on all matters submitted to a vote of the holders of the Company's common stock with the holders of Series A-3 Preferred Stock and Series A-4 Preferred Stock on certain matters, and separately as a class on certain limited matters.

Consent Rights. For so long as any of the Series A-3 and Series A-4 is outstanding, consent of the holders of shares representing at least 75% of certain of the Series A-3 and Series A-4 then outstanding is required for certain material actions.

Participation Rights. Pursuant to the securities purchase agreements entered into with the initial purchasers of the Series A-3 Preferred Stock and the Series A-4 Preferred Stock, subject to meeting certain ownership thresholds, certain purchasers of the Series A-3 Preferred Stock and the Series A-4 Preferred Stock are entitled to participate, on a pro-rata basis in accordance with their ownership percentage, determined on an as-converted basis, in issuances of equity and equity linked securities by the Company. In addition, subject to meeting certain ownership thresholds, certain initial purchasers of the Series A-3 Preferred Stock and the Series A-4 Preferred Stock will be entitled to participate in issuances of preferred securities and in debt transactions of the Company.

As of both March 31, 2025 and December 31, 2024, the Series A-3 Preferred Stock and Series A-4 Preferred Stock were convertible into 259,212 and 290,672 shares, respectively of INNOVATE's common stock.

24

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

(Unaudited)

Series A-3 and Series A-4 Preferred Share Dividends

During the three months ended March 31, 2025 and 2024, INNOVATE's Board of Directors (the "Board") declared cash dividends with respect to INNOVATE’s issued and outstanding Series A-3 Preferred Stock and Series A-4 Preferred Stock, as presented in the following tables (in millions):

2025
Declaration Date and Holders of Record Date	March 31, 2025
Payment Date	April 15, 2025
Total Dividend	$	0.3

2024
Declaration Date and Holders of Record Date	March 31, 2024
Payment Date	April 15, 2024
Total Dividend	$	0.3

R2 Technologies Non-Controlling Interests

The Company has non-redeemable and redeemable non-controlling interests related to R2 Technologies in the form of common stock as well as convertible preferred stock that is redeemable upon the occurrence of a change in control, as defined in the respective agreements. If an event is not solely within the control of the Company, it is classified outside of permanent equity in the mezzanine section of the Company's Condensed Consolidated Balance Sheets. The Company adjusts the carrying value of the non-controlling interests based on an allocation of subsidiary earnings (losses) based on ownership interests. As of March 31, 2025 and December 31, 2024, it was not deemed probable that the amounts relating to convertible preferred stock in non-controlling interests will become redeemable as no change in control has occurred or is expected to occur; therefore, no additional adjustments or remeasurements were required under ASC 480-10, Distinguishing Liabilities from Equity.

On February 20, 2025, Pansend closed on a new $3.5 million convertible 13.0% note instrument with R2 Technologies. The principal amount of the note, together with any interest then accrued and unpaid, is convertible at the option Pansend, into shares of a new Series E Convertible Preferred Stock ("Series E") in R2 Technologies upon written notice to R2 Technologies and has a maturity date of the earlier of July 31, 2025, or a change in control of R2 Technologies, as defined in the note. The transaction is eliminated on consolidation.

As a result of the allocation of losses, the redeemable non-controlling interest related to R2 Technologies was negative $0.7 million and negative $0.5 million as of March 31, 2025 and December 31, 2024, respectively. As of March 31, 2025 and December 31, 2024, the Company had negative $6.2 million and negative $4.9 million, respectively, of R2 Technologies non-controlling interests reflected within Non-controlling interests within the Condensed Consolidated Balance Sheets.

Liquidation Preference

R2 Technologies has issued multiple A, B, C and D-series, and, in the future potentially E-series, participating convertible preferred stock (the "R2 Technologies Preferred Shares"), all of which contain a liquidation preference. In the event of a liquidation event, each Preferred Share has a liquidation preference to be paid out of the assets legally available for distribution, which entitles the holder of each series A, series C, series D and series E (upon conversion of the aforementioned $3.5 million note that is convertible into Series E) R2 Technologies Preferred Shares to receive, before any payments to holders of junior securities, the sum of the following: (i) the accrued value in cash; (ii) all accrued and unpaid dividends, including basic dividends and accreting dividends, if any, and (iii) an amount, in cash or otherwise, equivalent to what the holder would receive if they had converted the R2 Technologies Preferred Shares into R2 Technologies common stock or reference property just before the liquidation event. Series B R2 Technologies Preferred Shareholders would be entitled to receive, before any payments to holders of junior securities, the greater of (i) the sum of (A) the accrued value in cash, plus (B) all accrued and unpaid dividends, including basic dividends and accreting dividends, if any, or (ii) an amount, in cash or otherwise, equivalent to what the holder would receive if they had converted the R2 Technologies Preferred Shares into R2 Technologies common stock or reference property just before the liquidation event.

If the assets of R2 Technologies legally available for distribution are insufficient to pay these obligations in full, R2 Technologies Preferred Shareholders and holders of any parity securities share the remaining assets in proportion to the full respective amounts to which they are entitled. After receiving the full liquidation preference, R2 Technologies Preferred Shareholders have no further claim to R2 Technologies' assets, except for any new securities or instruments received as part of the liquidation preference. The value of non-cash assets distributed equals their fair market value on the distribution date. No holder of junior securities receives any payment unless the entire liquidation preference of R2 Technologies Preferred Shares is paid. If there is insufficient cash to pay the entire liquidation preference and any liquidation preference in respect of any parity securities in full in cash upon a liquidation event, R2 Technologies Preferred Shareholders and parity securities holders will share available cash proportionally.

25

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

(Unaudited)

R2 Technologies' total liquidation preference upon a hypothetical liquidation event, including the liquidation preference for Pansend Life Sciences, LLC, was $146.3 million and $143.5 million as of March 31, 2025 and December 31, 2024, respectively, of which $52.8 million and $51.8 million as of March 31, 2025 and December 31, 2024, respectively, was attributable to redeemable and non-redeemable non-controlling interests, inclusive of initial preferred stock and unpaid accreted dividends. However, as of both March 31, 2025 and December 31, 2024, R2 Technologies had negative net assets after consideration of intercompany and third party debt, as applicable, and, therefore, there would be no legally available funds to satisfy such liquidation preferences upon a hypothetical liquidation event.

16. Related Parties

Non-Operating Corporate

During the first quarter of 2024, in connection with the Rights Offering, the Company entered into an Investment Agreement with Lancer Capital, an entity controlled by Avram A. Glazer, pursuant to which Lancer Capital agreed to the Backstop Commitment to purchase up to $19.0 million of Series C Preferred Stock in connection with the Rights Offering and to purchase $16.0 million of Series C Preferred Stock in a private placement transaction ("Concurrent Private Placement"), of which $25.0 million would be purchased before the closing of the Rights Offering if the Rights Offering did not close by March 28, 2024. As a result of the extension of the Rights Offering, on March 28, 2024, Lancer Capital funded the equity advance of $25.0 million to the Company and received 25,000 shares of Series C Preferred Stock. As a result, Mr. Glazer's beneficial ownership increased from 29.1% as of March 5, 2024, immediately prior to the start of the Rights Offering, to 48.8% as of March 31, 2024. On April 24, 2024, as a result of the closing of the Rights Offering and Concurrent Private Placement, Lancer Capital purchased an additional approximately 6,286 shares of Series C Preferred Stock for $6.3 million, increasing Mr. Glazer's beneficial ownership to 52.1%. On June 18, 2024, the Company held its annual shareholder meeting where the Company's shareholders approved the conversion of the Series C Preferred Stock into common stock. As a result, approximately 31,286 Series C Preferred Stock held by Lancer Capital were converted into 4,469,390 shares of INNOVATE's common stock (44,693,895 on a pre Reverse Stock Split basis), and there were no shares of the Series C Preferred Stock outstanding subsequent to their conversion into the Company's common stock. Refer to Note 15. Equity and Temporary Equity for additional information. As of March 31, 2025, Mr. Glazer's beneficial ownership was 51.1%.

Lancer Capital held $2.0 million of principal amount of the Company's 7.50% 2026 Convertible Notes, as of both March 31, 2025 and December 31, 2024. As of both March 31, 2025 and December 31, 2024, the $2.0 million in 7.50% 2026 Convertible Notes are convertible into 47,265 shares of common stock of INNOVATE. Refer to Note 11. Debt Obligations for additional information on the 7.50% 2026 Convertible Notes. During both the three months ended March 31, 2025 and 2024, Lancer Capital earned $37.5 thousand in interest relating to these notes.

On May 9, 2023, the Company entered into a Stock Purchase Agreement and Subordinated Unsecured Promissory Note with CGIC in the principal amount of $35.1 million. CGIC is a former significant shareholder and is the shareholder of the Series A-3 Preferred Stock and Series A-4 Preferred Stock. As a result of the closing of the Rights Offering and Concurrent Private Placement in April 2024, a mandatory prepayment was required, and INNOVATE redeemed $4.1 million of the CGIC Unsecured Note on April 26, 2024. Refer to Note 11. Debt Obligations for additional information.

Infrastructure

DBMG and Banker Steel, jointly and severally, had a subordinated 4.0% note payable to Banker Steel's former owner, in which Donald Banker's family trust has a 25% interest. The 4.0% note and associated accrued interest matured on March 31, 2024, and was fully redeemed on April 2, 2024. During the three months ended March 31, 2024, DBMG made $2.5 million in scheduled principal payments on the 4.0% note.

Life Sciences

As of March 31, 2025 and December 31, 2024, R2 Technologies had $25.2 million and $24.0 million, respectively, in principal amount of a 20.0% senior secured promissory note due to Lancer Capital. Refer to Note 11. Debt Obligations for additional information on the 20.0% senior secured promissory note due to Lancer Capital.

For the three months ended March 31, 2025 and 2024, R2 Technologies recognized $0.4 million and $0.2 million, respectively, of revenue from sales and profit sharing agreements with a subsidiary of Huadong, a related party of R2 Technologies. There were $0.2 million and $0.1 million of related receivables from this subsidiary of Huadong as of March 31, 2025 and December 31, 2024, respectively.

Share-based compensation and royalty expenses related to Blossom Innovations, LLC, an investor of R2 Technologies since 2014, totaled $0.3 million and $0.1 million, for the three months ended March 31, 2025 and 2024, respectively.

Refer to Note 6. Investments for transactions with equity method investees of the Company.

26

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

(Unaudited)

17. Operating Segments and Related Information

The Company currently has one primary reportable geographic segment - United States, and primarily all revenue is derived in the United States, and primarily all PP&E and intangible assets reside in the United States. The reportable segments are identified based on the nature of the services and products provided, the organizational structure, and the internal reporting system used by the Chief Operating Decision Maker ("CODM") to assess performance and allocate resources. The Company has three reportable operating segments, plus the Other segment, based on management’s organization of the enterprise - Infrastructure, Life Sciences, Spectrum, and Other. The Company also has a Non-Operating Corporate segment. All inter-segment transactions are eliminated on consolidation. There are no inter-segment revenues. Refer to Note 1. Organization and Business for additional information on the organizational structure of the business and Note 3. Revenue and Contracts in Process for additional information on revenue by segment.

The Chief Operating Decision Maker ("CODM") for the Company is the Interim CEO, Paul Voigt. The CODM is primarily responsible for allocating resources at all levels that do not require board approval. The CODM monitors the performance of each segment and is responsible for making strategic decisions regarding capital and resource allocation. The CODM uses a combination of monthly reports, which detail revenue and income (loss) from operations, and quarterly summaries, which include detailed breakdowns of each segment's income (loss) from operations, to evaluate segment performance, allocate resources and make strategic decisions. These financial metrics are used to view operating trends, perform analytical comparisons and benchmark performance between periods and to monitor budget-to-actual variances on a monthly basis. The primary U.S. GAAP metric used by the CODM in assessing segment performance is income (loss) from operations.

Financial information, including revenue and expenses, with respect to the Company’s operating segments, is as follows (in millions):

	Three Months Ended March 31, 2025
	Infrastructure		Life Sciences		Spectrum		Non-Operating Corporate		Other and Eliminations		INNOVATE
Revenue	$	264.9	$	3.1	$	6.2	$	—			$	274.2
Cost of revenue	223.5		2.3		2.9		—		—		228.7
Selling, general and administrative expenses	29.3		3.7		1.9		2.9		—		37.8
Depreciation and amortization	3.1		0.1		1.2		—		—		4.4
Other operating income	(0.1)		—		—		—		—		(0.1)
Income (loss) from operations	$	9.1	$	(3.0)	$	0.2	$	(2.9)	$	—	$	3.4
Other data:
Capital expenditures (1)	$	4.1	$	0.1	$	0.5	$	—	$	—	$	4.7
Investments (2)	$	—	$	1.8	$	—	$	2.3	$	—	$	4.1
Total assets	$	671.9	$	11.7	$	178.3	$	6.1	$	—	$	868.0

(1) Capital expenditures reflect cash expenditures for the three months ended March 31, 2025.

(2) The Company's equity method investments in the Life Sciences segment totaled $0.9 million as of March 31, 2025.

	Three Months Ended March 31, 2024
	Infrastructure		Life Sciences		Spectrum		Non-Operating Corporate		Other and Eliminations		INNOVATE
Revenue	$	307.9	$	1.0	$	6.3	$	—	$	—	$	315.2
Cost of revenue	263.1		0.6		2.9		—		—		266.6
Selling, general and administrative expenses	30.9		3.5		1.9		3.2		—		39.5
Depreciation and amortization	3.0		0.1		1.3		—		—		4.4
Other operating loss (1)	1.6		—		—		0.3		—		1.9
Income (loss) from operations	$	9.3	$	(3.2)	$	0.2	$	(3.5)	$	—	$	2.8
Other data:
Capital expenditures (2)	$	5.2	$	0.1	$	0.3	$	—	$	—	$	5.6
	December 31, 2024
	Infrastructure		Life Sciences		Spectrum		Non-Operating Corporate		Other and Eliminations		INNOVATE
Investments (3)	$	—	$	1.8	$	—	$	1.8	$	—	$	3.6
Total assets	$	683.6	$	11.9	$	178.9	$	16.7	$	—	$	891.1

(1) Other operating loss for the three months ended March 31, 2024, primarily consisted of a loss on disposal related to a plant closure at our Infrastructure segment.

(2) Capital expenditures reflect cash expenditures for the three months ended March 31, 2024.

(3) The Company's equity method investments in the Life Sciences segment totaled $0.9 million as of December 31, 2024.

27

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

(Unaudited)

	Three Months Ended March 31,
	2025		2024
Reconciliation of the consolidated segment income from operations to consolidated loss from operations before income taxes:
Income from operations	$	3.4	$	2.8
Interest expense	(20.2)		(17.2)
Loss from equity investees	(5.9)		(1.2)
Other income (expense), net	4.0		(1.2)
Loss from operations before income taxes	$	(18.7)	$	(16.8)

18. Basic and Diluted Loss Per Common Share

Earnings (loss) per share ("EPS") is calculated using the two-class method, which allocates earnings among common stock and participating securities to calculate EPS when an entity's capital structure includes either two or more classes of common stock or common stock and participating securities. Unvested share-based payment awards, and, previously, the Series C Preferred Stock, that contain non-forfeitable rights to dividends or dividend equivalents (whether paid or unpaid) are participating securities. As such, shares of any unvested restricted stock, and, previously, the Series C Preferred Stock, of the Company are considered participating securities; however, unvested shares of restricted stock do not participate in losses and, as such, are excluded from the computation of basic earnings (loss) per share during periods of net losses. The dilutive effect, if applicable, of stock options and their equivalents (including non-vested stock issued under share-based compensation plans), is computed using the "if-converted method" if this measurement is determined to be more dilutive than the treasury stock method in a period.

The Company had no dilutive common stock equivalents during the three months ended March 31, 2025 and 2024, due to the results from continuing operations being a loss, net of tax. For the three months ended March 31, 2025 and 2024, 294,329 and 70,299, respectively, of common stock equivalents from unvested restricted stock awards and unvested restricted stock units were excluded from the weighted-average number of shares used to calculate diluted loss per share as their inclusion would have been anti-dilutive. Other instruments that may, in the future, if the average market price of the Company's stock exceeds the conversion prices, have a dilutive effect on EPS, but were excluded from the computations of diluted net loss per share, and may be excluded from computations of diluted EPS in the future, are: convertible preferred stock, convertible debt, and stock options. Refer to Note 14. Share-based Compensation and Note 15. Equity and Temporary Equity for additional information on INNOVATE's equity instruments.

28

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

(Unaudited)

The following table presents a reconciliation of net loss to net loss used in the basic and diluted EPS calculations (in millions, except shares and per share amounts):

	Three Months Ended March 31,
	2025			2024
Net loss	$	(25.8)		$	(20.1)
Net loss attributable to non-controlling interest and redeemable non-controlling interest	1.3			2.7
Net loss attributable to INNOVATE Corp.	(24.5)			(17.4)
Less: Preferred dividends	0.3			0.3
Net loss attributable to common stockholders and participating preferred stockholders	$	(24.8)		$	(17.7)
Participating shares
Weighted-average common shares outstanding (1)	13,114,804			7,865,361
Series C Preferred stock (1)	—			156,986
Total	13,114,804			8,022,347
Percentage of loss allocated to:
Common stock	100.0		%	98.0		%
Series C Preferred stock	—		%	2.0		%
Numerator for loss per share:
Net loss attributable to common stock holders, basic and diluted	$	(24.8)		$	(17.3)
Net loss attributable to Series C holder, basic and diluted	—			(0.4)
Denominator for loss per share:
Weighted-average common shares outstanding - basic and diluted (1)	13,114,804			7,865,361
Weighted-average Series C shares outstanding - basic and diluted (1)	—			156,986
Loss per share
Loss per common share - basic and diluted (1)	$	(1.89)		$	(2.21)
Loss per Series C share - basic and diluted (1)	$	(1.89)		$	(2.21)

(1) Basic and diluted loss per common share and weighted-average common shares outstanding for the three months ended March 31, 2024, in the table above have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on August 8, 2024.

19. Fair Value of Financial Instruments

Fair Value of Financial Instruments Not Measured at Fair Value

Our financial instruments primarily include cash and cash equivalents, restricted cash, accounts receivable and contract assets, marketable and non-marketable securities, including equity investments and certain other investments, notes receivable, accounts payable and other current and non-current liabilities, redeemable non-controlling interests and debt obligations. The following tables presents the carrying amounts and estimated fair values of the Company’s financial instruments, which were not measured at fair value on a recurring basis and not measured using the equity method of accounting, with fair values shown according to the fair value hierarchy. The tables exclude carrying amounts for cash and cash equivalents and restricted cash (Level 1 measurements), accounts receivable and contract assets, accounts payable, contract liabilities and other current liabilities, and other assets and liabilities (Level 2 measurements) that approximate fair value due to the relatively short periods to maturity (in millions):

29

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

(Unaudited)

March 31, 2025					Fair Value Measurement Using:
	Carrying Value		Estimated Fair Value		Quoted Prices (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets
Measurement alternative investment (1)	$	0.9	$	0.9	$	—	$	—	$	0.9
Total assets not accounted for at fair value	$	0.9	$	0.9	$	—	$	—	$	0.9
Liabilities
Debt obligations (2)	$	663.2	$	618.4	$	—	$	618.4	$	—
Total liabilities not accounted for at fair value	$	663.2	$	618.4	$	—	$	618.4	$	—

(1) Refer to Note 6. Investments for additional information.

(2) Excludes lease obligations accounted for under ASC 842, Leases.

December 31, 2024					Fair Value Measurement Using:
	Carrying Value		Estimated Fair Value		Quoted Prices (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets
Measurement alternative investment (1)	$	0.9	$	0.9	$	—	$	—	$	0.9
Total assets not accounted for at fair value	$	0.9	$	0.9	$	—	$	—	$	0.9
Liabilities
Debt obligations (2)	$	662.2	$	577.1	$	—	$	577.1	$	—
Total liabilities not accounted for at fair value	$	662.2	$	577.1	$	—	$	577.1	$	—

(1) Refer to Note 6. Investments for additional information.

(2) Excludes lease obligations accounted for under ASC 842, Leases.

Debt Obligations. The fair value of the Company’s long-term obligations was determined using reporting from externally quoted market prices for INNOVATE's 8.50% 2026 Senior Secured Notes and for INNOVATE's 7.50% Convertible Senior Notes due 2026, which are reflected as Level 2 fair value measurements due to limited recently available observable trading activity for these instruments. All other long-term obligations of the Company are also reflected as Level 2 fair value measurements, as this methodology combines direct recent transaction activity or, if available, market observations from contributed sources with quantitative pricing models or fair value reports from valuation providers to generate evaluated prices and are classified as Level 2 fair value measurements. Certain long-term obligations have a fair value estimate equal to their carrying value due to recent transaction activity. The fair value of the debt instruments is disclosed for informational purposes and does not necessarily represent the amount that would be realized upon settlement or transfer.

Fair Value of Financial Instruments Measured at Fair Value

The Company's investments in marketable securities are measured at fair value, using publicly available quoted market prices, a Level 1 input. Refer to Note 6. Investments.

20. Supplementary Financial Information

Other income (expense), net

The following table provides information relating to Other income (expense), net (in millions):

	Three Months Ended March 31,
	2025		2024
Gain on step-up of equity method investment	4.4		—
Net loss on extinguishment of debt	—		(2.2)
Interest income	0.4		0.5
Foreign currency translation (loss) gain	(0.4)		0.5
Other	(0.4)		—
Total other income (expense), net	$	4.0	$	(1.2)

30

INNOVATE CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

(Unaudited)

Supplemental Cash Flow Information

The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts reported within the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Cash Flows (in millions):

	Three Months Ended March 31,
	2025		2024
Cash and cash equivalents, beginning of the period	$	48.8	$	80.8
Restricted cash included in other current assets	—		0.9
Restricted cash included in other assets (non-current)	0.5		0.6
Total cash, cash equivalents and restricted cash, beginning of the period	$	49.3	$	82.3
Cash and cash equivalents, end of the period	$	33.3	$	38.4
Restricted cash included in other current assets	—		0.9
Restricted cash included in other assets (non-current)	0.6		0.6
Total cash and cash equivalents and restricted cash, end of the period	$	33.9	$	39.9
Supplemental cash flow information:
Cash paid for interest	$	19.5	$	19.6
Cash paid for income taxes (proceeds from tax refunds), net	$	0.8	$	(0.8)
Non-cash investing and financing activities:
Accrued interest capitalized into principal debt	$	1.2	$	3.3
Property, plant and equipment included in accounts payable or accrued expenses	$	1.1	$	0.9

21. Subsequent Events

None.

31

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations together with the consolidated annual audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 31, 2025 (the "2024 Annual Report"), and the unaudited condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q. Some of the information contained in this discussion and analysis includes forward-looking statements that involve risks and uncertainties. You should review the "Risk Factors" section in our 2024 Annual Report as well as the section below entitled "Special Note Regarding Forward-Looking Statements" for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Unless the context otherwise requires, in this Quarterly Report on Form 10-Q, "INNOVATE" means INNOVATE Corp. and the "Company," "we" and "our" mean INNOVATE together with its consolidated subsidiaries. "U.S. GAAP" means accounting principles accepted in the United States of America.

Our Business and Our Operations

We are a diversified holding company with principal operations conducted through three operating platforms or reportable segments: Infrastructure ("DBMG"), Life Sciences ("Pansend"), and Spectrum, plus our Other segment, which includes businesses that do not meet the separately reportable segment thresholds.

For additional information on our business, refer to Note 1. Organization and Business included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

Cyclical Patterns

Our segments' operations can be highly cyclical. Our volume of business in our Infrastructure segment may be adversely affected by declines or delays in projects, which may vary by geographic region. Project schedules, particularly in connection with large, complex, and longer-term projects can also create fluctuations in the services provided, which may adversely affect us in any given period.

For example, in connection with larger, more complicated projects, the timing of obtaining permits and other approvals may be delayed, and we may need to maintain a portion of our workforce and equipment in an underutilized capacity to ensure we are strategically positioned to deliver on such projects when they move forward.

Examples of other items that may cause our results or demand for our services to fluctuate materially from quarter to quarter include: weather or project site conditions; the spending patterns, including seasonal trends, and financial condition of our customers and their access to capital; our profit margins on projects performed during any particular period; rising interest rates and inflation; and regulatory, economic, political and market conditions on a regional, national or global scale.

Accordingly, our operating results in any particular period may not be indicative of the results that can be expected for any other period.

Recent Developments

We continually evaluate strategic and business alternatives within our operating segments, which may include the following: operating, growing or acquiring additional assets or businesses related to current or historical operations; or winding down or selling our existing operations. In the longer-term, we may evaluate opportunities to acquire assets or businesses unrelated to our current or historical operations. In the event we were to enter into a strategic transaction to sell any of our existing operations, our intention is to use available proceeds from such transaction to address our capital structure.

In 2025, as part of our strategic process, we engaged in several transactions that had or will have an effect on the results of operations and financial condition of our business and individual segments.

Debt Obligations and Financing

During 2025 thus far, we have refinanced some of our debt, including at the subsidiary level. This financing helped us provide needed capital for our operations and the operations of our subsidiaries.

32

Life Sciences

R2 Technologies has a short-term note with Lancer Capital. The stated interest on the note, as amended, is 20% and is payable monthly in arrears, in cash or, if not paid in cash, accrued and unpaid interest is capitalized monthly into the principal balance. During the first quarter of 2025, with an effective date of December 31, 2024, the maturity date of the note was extended to August 1, 2025, and another additional exit fee of $1.0 million was incurred under the amendment, which continues to increase by $1.0 million each month until maturity. The base exit fee, as amended, and as of March 31, 2025, was equal to 12.41% of the principal amount being repaid and continues to increase by 0.17% each month until maturity. The total new exit fees associated with the notes have been recorded as an original issue discount of $8.7 million and are being amortized over the remaining life of the note, which is assumed to be the maturity date. A corresponding liability for the new exit fees of $8.7 million was recorded for total accrued exit fees amount of $16.5 million which are included within Accrued liabilities in the Condensed Consolidated Balance Sheet as of March 31, 2025. The exit fees are payable on the earliest of the maturity date, the date of the acceleration of the principal amount of the note for any reason or, if any portion of the note is prepaid at any time, the date of such prepayment of the note. In addition, under the recent amendment, a new $5.0 million default fee will be payable on August 1, 2025, in the event all obligations under the note, including principal, any accrued and unpaid interest, and exit fees, are not repaid in full prior to the August 1, 2025, maturity date. The $5.0 million default fee will only be recognized in the event of a default on August 1, 2025.

As of March 31, 2025, the total carrying amount relating to the 20% note was $36.4 million, inclusive of $25.2 million of principal and capitalized interest, partially offset by $5.3 million of unamortized original issue discount, which are included within the Current portion of debt obligations in the Condensed Consolidated Balance Sheet, and $16.5 million in total accrued exit fees which are included within Accrued liabilities in the Condensed Consolidated Balance Sheet.

Refer to Note 11. Debt Obligations included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on the note and the various amendments.

On February 20, 2025, Pansend closed on a new $3.5 million convertible 13.0% note instrument with R2 Technologies. The principal amount of the note, together with any interest then accrued and unpaid, is convertible at the option of Pansend, into shares of a new Series E Preferred Stock ("Series E") in R2 Technologies upon written notice to R2 Technologies and has a maturity date of the earlier of July 31, 2025, or a change in control of R2 Technologies, as defined in the note. The transaction is eliminated on consolidation. Refer to Note 15. Equity and Temporary Equity included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on R2 Technologies' convertible preferred stock and convertible notes.

Non-Operating Corporate

On March 6, 2025, we extended the maturity date of our Revolving Line of Credit with MSD from May 16, 2025, to August 1, 2025, with all other terms substantially unchanged. Refer to Note 11. Debt Obligations included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on our Revolving Line of Credit with MSD.

Equity Method Investments

On January 17, 2025, MediBeacon received approval from the U.S. Food and Drug Administration ("FDA") for its Transdermal GFR Measurement System ("TGFR"). Pursuant to the terms of MediBeacon's convertible notes, upon the FDA approval, Pansend's convertible notes of $11.4 million and the related accrued interest of $1.5 million, together totaling $12.9 million, were converted into Series 3 Preferred Stock. In addition, pursuant to its amended commercial partnership with Huadong and, as a result of FDA approval, a $7.5 million milestone payment from Huadong Medicine Co. Ltd ("Huadong"), a publicly traded company on the Shenzhen Stock Exchange, to MediBeacon for MediBeacon preferred stock was received in the first quarter of 2025. As a result of these transactions, Pansend's ownership in MediBeacon decreased from 45.9% prior to the transactions to 44.7% subsequent to the transactions. On a fully diluted basis, Pansend's ownership in MediBeacon decreased from 40.1% to 39.7%. As a result of these transactions, Pansend recognized a step-up gain of $4.4 million in Other (expense) income, net in the Condensed Consolidated Statements of Operations for the three months ended March 31, 2025, which increased Pansend's carrying amount of its investment in MediBeacon. Concurrently, Pansend recognized equity method losses of $5.9 million, consisting of the $4.4 million step-up gain and $1.5 million of interest from the conversion of the convertible notes, which were previously unrecognized because Pansend's carrying amount of its investment in MediBeacon had been previously reduced to zero.

Financial Presentation Background

In the below section within this Management’s Discussion and Analysis of Financial Condition and Results of Operations, we compare, pursuant to U.S. GAAP and SEC disclosure rules, the Company’s results of operations for the three months ended March 31, 2025, as compared to the three months ended March 31, 2024.

33

Results of Operations

The following table summarizes our results of operations (in millions):

	Three Months Ended March 31,
	2025		2024		Increase / (Decrease)
Revenue
Infrastructure	$	264.9	$	307.9	$	(43.0)
Life Sciences	3.1		1.0		2.1
Spectrum	6.2		6.3		(0.1)
Total revenue	$	274.2	$	315.2	$	(41.0)
Income (loss) from operations
Infrastructure	$	9.1	$	9.3	$	(0.2)
Life Sciences	(3.0)		(3.2)		0.2
Spectrum	0.2		0.2		—
Non-Operating Corporate	(2.9)		(3.5)		0.6
Total income from operations	$	3.4	$	2.8	$	0.6
Interest expense	(20.2)		(17.2)		(3.0)
Loss from equity investees	(5.9)		(1.2)		(4.7)
Other income (expense), net	4.0		(1.2)		5.2
Loss from operations before income taxes	$	(18.7)	$	(16.8)	$	(1.9)
Income tax expense	(7.1)		(3.3)		(3.8)
Net loss	$	(25.8)	$	(20.1)	$	(5.7)
Net loss attributable to non-controlling interests and redeemable non-controlling interests	1.3		2.7		(1.4)
Net loss attributable to INNOVATE Corp.	$	(24.5)	$	(17.4)	$	(7.1)
Less: Preferred dividends	0.3		0.3		—
Net loss attributable to common stockholders and participating preferred stockholders	$	(24.8)	$	(17.7)	$	(7.1)

Revenue: Revenue for the three months ended March 31, 2025, decreased $41.0 million to $274.2 million from $315.2 million for the three months ended March 31, 2024. The decrease was primarily driven by our Infrastructure segment, which was partially offset by an increase at our Life Sciences segment. The decrease at our Infrastructure segment was primarily driven by the timing and size of projects at Banker Steel and the industrial maintenance and repair business, including the effect of changes in estimated costs to complete those projects recognized in the ordinary course of business in the comparable period, which also had increased activity in the prior year on certain large commercial construction projects that have since been completed or are nearing completion in the current period. This was partially offset by an increase at DBMG's commercial structural steel fabrication and erection business as a result of an increase in project work. The increase at our Life Sciences segment was attributable to R2 Technologies, driven by an increase in unit sales of both Glacial fx and Glacial Rx systems and an increase in consumable sales in North America, as well as an increase in Glacial Spa unit sales, consumable sales and Glacial fx unit sales outside North America.

Income from operations: Income from operations for the three months ended March 31, 2025, increased $0.6 million to $3.4 million from $2.8 million for the three months ended March 31, 2024. The improvement was due to a decrease in other operating loss of $2.0 million and a decrease in selling, general and administrative ("SG&A") expenses of $1.7 million, which was partially offset by a net decrease in gross profit of $3.1 million. The net decrease in other operating loss was primarily driven by an unrepeated loss related to a plant closure at our Infrastructure segment in the comparable period. The overall decrease in SG&A was primarily driven by decreases in professional and consulting fees and compensation-related and travel expenses at our Infrastructure segment, which was partially offset by an increase in computer and software related costs in the current period at our Infrastructure segment and an increase in.selling costs at R2 Technologies due to an increase in unit sales. Partially offsetting the above improvements was a net decrease in gross profit, which was primarily driven by our Infrastructure segment due to timing and size of projects that have since been completed or are nearing completion in the current period, including the effect of changes in estimated costs to complete those projects recognized in the ordinary course of business in the comparable period, which was partially offset by an increase in gross profit at our Life Sciences segment primarily driven by R2 Technologies as a result of an increase Glacial unit sales and consumable sales over the comparable period.

34

Interest expense: Interest expense for the three months ended March 31, 2025, increased $3.0 million to $20.2 million from $17.2 million for the three months ended March 31, 2024. The increase was primarily attributable to increases in exit fees and a higher outstanding principal balance at our Life Sciences segment as a result of the capitalization of unpaid interest into the principal balance subsequent to the comparable period, and, to a lesser extent our Spectrum segment. The increase in interest expense was partially offset by our Infrastructure and Non-Operating Corporate segments due to a net decrease in outstanding principal balances.

Loss from equity investees: Loss from equity investees for the three months ended March 31, 2025, increased $4.7 million to $5.9 million from $1.2 million for the three months ended March 31, 2024. The increase in loss was due to an increase in losses recognized from MediBeacon. During the three months ended March 31, 2025, as a result of the equity transactions that occurred upon FDA approval of MediBeacon's TGFR, Pansend's basis in MediBeacon increased by $5.9 million, consisting of a $4.4 million step-up gain and $1.5 million from the conversion of accrued interest on Pansend's convertible notes with MediBeacon, resulting in Pansend recognizing $5.9 million of equity method losses that were previously unrecognized. During the three months ended March 31, 2024, Pansend's basis in MediBeacon increased by $1.2 million due to the issuance of additional convertible note investments, resulting in Pansend recognizing $1.2 million of equity method losses that were previously unrecognized. As of both March 31, 2025 and 2024, Pansend's net carrying amount of its investment in MediBeacon was zero, and Pansend had unrecognized losses from this investment. Refer to Note 6. Investments included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on our equity investments.

Other income (expense), net: Other income, net for the three months ended March 31, 2025, increased $5.2 million to income of $4.0 million from an expense of $1.2 million for the three months ended March 31, 2024. The increase was primarily driven by the $4.4 million step-up gain following MediBeacon's FDA approval in January 2025 and an unrepeated $2.2 million loss on debt extinguishment at R2 Technologies in the comparable period. These increases were partially offset by a decrease in foreign currency translation gains from our Infrastructure segment, and a legal settlement at our Non-Operating Corporate segment in the current period.

Income tax expense: Income tax expense for the three months ended March 31, 2025, increased $3.8 million to $7.1 million from $3.3 million for the three months ended March 31, 2024. The increase was primarily driven by the impact of projected pre-tax results on the annual effective tax rate and the limitations on the utilization of net operating losses ("NOL") by INNOVATE's U.S. consolidated group as a result of the Internal Revenue Code Section 382 and the Tax Cuts and Jobs Act's 80 percent limitation on NOLs incurred after 2017.

The Organization for Economic Cooperation and Development ("OECD") has announced an Inclusive Framework on Base Erosion and Profit Shifting including a Pillar Two Model to provide for a 15% global minimum tax on the earnings of multinational corporations with consolidated revenue over €750 million. Many jurisdictions have enacted Pillar Two legislation that started to become effective in 2024. The OECD, and its member countries, continue to release new guidance and legislation on Pillar Two. Based on current enacted laws, Pillar Two is not expected to materially impact our effective tax rate or cash flows in the next year. We will continue to evaluate the impact on our financial position as new legislation or guidance is introduced which could change our current assessment.

Segment Results of Operations

In the Company's Condensed Consolidated Financial Statements, other operating (income) loss includes: (i) (gain) loss on sale or disposal of assets; (ii) lease termination costs and (gains) losses on lease modifications; (iii) asset impairment expense; (iv) accretion of asset retirement obligations; and (v) Federal Communications Commission (the "FCC") reimbursements, as applicable. Each table summarizes the results of operations of our operating segments (in millions).

Infrastructure Segment

	Three Months Ended March 31,
	2025		2024		Increase / (Decrease)
Revenue	$	264.9	$	307.9	$	(43.0)
Cost of revenue	223.5		263.1		(39.6)
Selling, general and administrative	29.3		30.9		(1.6)
Depreciation and amortization	3.1		3.0		0.1
Other operating (income) loss	(0.1)		1.6		(1.7)
Income from operations	$	9.1	$	9.3	$	(0.2)

Revenue: Revenue for the three months ended March 31, 2025, decreased $43.0 million to $264.9 million from $307.9 million for the three months ended March 31, 2024. The decrease was primarily driven by the timing and size of projects at Banker Steel and the industrial maintenance and repair business, including the effect of changes in estimated costs to complete those projects recognized in the ordinary course of business in the comparable period, which also had increased activity in the prior year on certain large commercial construction projects that have since been completed or are nearing completion in the current period. This was partially offset by an increase at DBMG's commercial structural steel fabrication and erection business as a result of an increase in project work.

35

Cost of revenue: Cost of revenue for the three months ended March 31, 2025, decreased $39.6 million to $223.5 million from $263.1 million for the three months ended March 31, 2024. The decrease was primarily driven by the decrease in revenues at Banker Steel and the industrial maintenance and repair business from the timing of project activity on certain large commercial construction projects and decreases in costs as they wind down and near completion or were completed in the current period, which was partially offset by an increase in costs associated with DBMG's commercial structural steel fabrication and erection business as a result of an increase in project work.

Selling, general and administrative: Selling, general and administrative expense for the three months ended March 31, 2025, decreased $1.6 million to $29.3 million from $30.9 million for the three months ended March 31, 2024. The decrease was primarily driven by decreases in professional and consulting fees, compensation-related and travel expenses, which was partially offset by an increase in computer and software-related costs in the current period.

Other operating (income) loss: Other operating (income) loss for the three months ended March 31, 2025, improved by $1.7 million to income of $0.1 million from a loss of $1.6 million for the three months ended March 31, 2024. The improvement was primarily driven by an unrepeated loss related to a plant closure in the comparable period.

Life Sciences Segment

	Three Months Ended March 31,
	2025		2024		Increase / (Decrease)
Revenue	$	3.1	$	1.0	$	2.1
Cost of revenue	2.3		0.6		1.7
Selling, general and administrative	3.7		3.5		0.2
Depreciation and amortization	0.1		0.1		—
Loss from operations	$	(3.0)	$	(3.2)	$	0.2

Revenue: Revenue for the three months ended March 31, 2025, increased $2.1 million to $3.1 million from $1.0 million for the three months ended March 31, 2024. The increase in revenue was attributable to R2 Technologies, driven by an increase in unit sales of both Glacial fx and Glacial Rx systems and an increase in consumable sales in North America, as well as an increase in Glacial Spa unit sales, consumable sales and Glacial fx unit sales outside North America.

Cost of revenue: Cost of revenue for the three months ended March 31, 2025, increased $1.7 million to $2.3 million from $0.6 million for the three months ended March 31, 2024. The increase in cost of revenue was attributable to R2 Technologies, primarily driven by the increase in revenue from the additional system and consumables sales noted above, and, to a lesser extent, the related increases in warranty expenses, royalty expenses, and freight costs. The increase in cost of revenue was partially offset by changes in product mix sold as the Glacial fx and Glacial Spa systems have a lower production cost per system compared to the Glacial Rx.

Selling, general and administrative: Selling, general and administrative expense for the three months ended March 31, 2025, increased $0.2 million to $3.7 million from $3.5 million for the three months ended March 31, 2024. The increase was primarily driven by R2 Technologies as a result of an increase in selling costs due to an increase in unit sales.

Spectrum Segment

	Three Months Ended March 31,
	2025		2024		Increase / (Decrease)
Revenue	$	6.2	$	6.3	$	(0.1)
Cost of revenue	2.9		2.9		—
Selling, general and administrative	1.9		1.9		—
Depreciation and amortization	1.2		1.3		(0.1)
Income from operations	$	0.2	$	0.2	$	—

Revenue: Revenue for the three months ended March 31, 2025, decreased slightly by $0.1 million to $6.2 million from $6.3 million for the three months ended March 31, 2024. The decrease was primarily driven by the termination of a few networks and individual markets, which was partially offset by the launch of new networks subsequent to the comparable period.

Depreciation and amortization: Depreciation and amortization for the three months ended March 31, 2025, decreased slightly by $0.1 million to $1.2 million from $1.3 million for the three months ended March 31, 2024.

36

Non-Operating Corporate

	Three Months Ended March 31,
	2025		2024		Increase / (Decrease)
Selling, general and administrative	$	2.9	$	3.2	$	(0.3)
Other operating loss	—		0.3		(0.3)
Loss from operations	$	(2.9)	$	(3.5)	$	0.6

Selling, general and administrative: Selling, general and administrative expenses for the three months ended March 31, 2025, decreased $0.3 million to $2.9 million from $3.2 million for the three months ended March 31, 2024, primarily driven by a decrease in legal fees due to legal matters settled subsequent to the comparable period, which was partially offset by an increase in share-based compensation expense related to the issuance of equity awards to our Interim-CEO, which awards had not yet been granted in the comparable period.

Other operating loss: Other operating loss for the three months ended March 31, 2025, decreased $0.3 million to zero from $0.3 million for the three months ended March 31, 2024. Other operating loss in the comparable period related to lease termination costs for two leases the Company exited in the comparable period.

Loss from Equity Investees

	Three Months Ended March 31,
	2025		2024		(Increase) / Decrease
Life Sciences	$	(5.9)	$	(1.2)	$	(4.7)
Loss from equity investees	$	(5.9)	$	(1.2)	$	(4.7)

Life Sciences: Loss from equity investees within our Life Sciences segment for the three months ended March 31, 2025, increased $4.7 million to $5.9 million from $1.2 million for the three months ended March 31, 2024. The increase in loss was due to an increase in losses recognized from MediBeacon. During the three months ended March 31, 2025, as a result of the equity transactions that occurred upon FDA approval of MediBeacon's TGFR, Pansend's basis in MediBeacon increased by $5.9 million, consisting of a $4.4 million step-up gain and $1.5 million from the conversion of accrued interest on Pansend's convertible notes with MediBeacon, resulting in Pansend recognizing $5.9 million of equity method losses that were previously unrecognized. During the three months ended March 31, 2024, Pansend's basis in MediBeacon increased by $1.2 million due to the issuance of additional convertible notes, resulting in Pansend recognizing $1.2 million of equity method losses that were previously unrecognized. As of both March 31, 2025 and 2024, Pansend's net carrying amount of its investment in MediBeacon was zero, and Pansend had unrecognized losses from this investment.

Refer to Note 6. Investments included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on our equity investments.

Non-GAAP Financial Measures and Other Information

Adjusted EBITDA

Adjusted EBITDA is not a measurement recognized under U.S. GAAP. In addition, other companies may define Adjusted EBITDA differently than we do, which could limit its usefulness.

Management believes that Adjusted EBITDA provides investors with meaningful information for gaining an understanding of our results as it is frequently used by the financial community to provide insight into an organization’s operating trends and facilitates comparisons between peer companies, since interest, taxes, depreciation, amortization and the other items listed in the definition of Adjusted EBITDA below can differ greatly between organizations as a result of differing capital structures and tax strategies. Adjusted EBITDA can also be a useful measure of a company’s ability to service debt. While management believes that non-U.S. GAAP measurements are useful supplemental information, such adjusted results are not intended to replace our U.S. GAAP financial results. Using Adjusted EBITDA as a performance measure has inherent limitations as an analytical tool as compared to net income (loss) or other U.S. GAAP financial measures, as this non-U.S. GAAP measure excludes certain items, including items that are recurring in nature, which may be meaningful to investors. As a result of the exclusions, Adjusted EBITDA should not be considered in isolation and does not purport to be an alternative to net income (loss) or other U.S. GAAP financial measures as a measure of our operating performance.

The calculation of Adjusted EBITDA, as defined by us, consists of Net income (loss) attributable to INNOVATE Corp., excluding: discontinued operations, if applicable; depreciation and amortization; other operating (income) loss, which is inclusive of (gain) loss on sale or disposal of assets, lease termination costs, (gains) losses on lease modifications, asset impairment expense and FCC reimbursements; interest expense; other (income) expense, net; income tax expense (benefit); non-controlling interest; share-based compensation expense; and realignment and exit costs.

37

Adjusted EBITDA by segment is summarized as follows:

(in millions):	Three Months Ended March 31,
	2025		2024		Increase / (Decrease)
Infrastructure	$	16.7	$	18.3	$	(1.6)
Life Sciences	(8.7)		(4.2)		(4.5)
Spectrum	1.4		1.6		(0.2)
Non-Operating Corporate	(2.2)		(2.9)		0.7
Other and Eliminations	—		—		—
Adjusted EBITDA	$	7.2	$	12.8	$	(5.6)

The tables below provide reconciliations of net income (loss) attributable to INNOVATE Corp to Adjusted EBITDA for the three months ended March 31, 2025 and 2024:

(in millions)	Three Months Ended March 31, 2025
	Infrastructure		Life Sciences		Spectrum		Non-Operating Corporate		Other and Eliminations		INNOVATE
Net income (loss) attributable to INNOVATE Corp.	$	4.6	$	(7.6)	$	(5.4)	$	(16.1)	$	—	$	(24.5)
Adjustments to reconcile net income (loss) to Adjusted EBITDA:
Depreciation and amortization	3.1		0.1		1.2		—		—		4.4
Depreciation and amortization (included in cost of revenue)	3.5		—		—		—		—		3.5
Other operating income	(0.1)		—		—		—		—		(0.1)
Interest expense	2.1		4.5		3.7		9.9		—		20.2
Other (income) expense, net	(0.3)		(4.5)		2.2		(1.4)		—		(4.0)
Income tax expense	2.3		—		—		4.8		—		7.1
Non-controlling interest	0.4		(1.4)		(0.3)		—		—		(1.3)
Share-based compensation expense	—		0.2		—		0.6		—		0.8
Realignment and exit costs	1.1		—		—		—		—		1.1
Adjusted EBITDA	$	16.7	$	(8.7)	$	1.4	$	(2.2)	$	—	$	7.2

(in millions)	Three Months Ended March 31, 2024
	Infrastructure		Life Sciences		Spectrum		Non-Operating Corporate		Other and Eliminations		INNOVATE
Net income (loss) attributable to INNOVATE Corp.	$	4.4	$	(4.5)	$	(4.8)	$	(12.5)	$	—	$	(17.4)
Adjustments to reconcile net income (loss) to Adjusted EBITDA:
Depreciation and amortization	3.0		0.1		1.3		—		—		4.4
Depreciation and amortization (included in cost of revenue)	4.0		—		—		—		—		4.0
Other operating loss	1.6		—		—		0.3		—		1.9
Interest expense	2.7		0.9		3.4		10.2		—		17.2
Other (income) expense, net	(0.8)		2.0		2.0		(2.0)		—		1.2
Income tax expense	2.5		—		—		0.8		—		3.3
Non-controlling interest	0.4		(2.8)		(0.3)		—		—		(2.7)
Share-based compensation expense	—		0.1		—		0.3		—		0.4
Realignment and exit costs	0.5		—		—		—		—		0.5
Adjusted EBITDA	$	18.3	$	(4.2)	$	1.6	$	(2.9)	$	—	$	12.8

Infrastructure: Net income from our Infrastructure segment for the three months ended March 31, 2025, increased $0.2 million to $4.6 million from $4.4 million for the three months ended March 31, 2024. Adjusted EBITDA from our Infrastructure segment for the three months ended March 31, 2025, decreased $1.6 million to $16.7 million from $18.3 million for the three months ended March 31, 2024. The decrease in Adjusted EBITDA was primarily driven by a decrease in revenue at both Banker Steel and the industrial maintenance and repair businesses due to timing of certain large commercial construction projects that have since been completed or are nearing completion in the current period. The decrease was partially offset by an increase in gross margins at the industrial maintenance and repair business and an increase in gross profit at DBMG's commercial structural steel fabrication and erection business due to an increase in project work, as well as a decrease in recurring SG&A, primarily as a result of decreases in professional and consulting fees and compensation-related and travel expenses, partially offset by an increase in computer and software-related costs in the current period.

38

Life Sciences: Net loss from our Life Sciences segment for the three months ended March 31, 2025, increased $3.1 million to $7.6 million from $4.5 million for the three months ended March 31, 2024. Adjusted EBITDA loss from our Life Sciences segment for the three months ended March 31, 2025, increased $4.5 million to $8.7 million from $4.2 million for the three months ended March 31, 2024. The increase in Adjusted EBITDA loss was primarily due to an increase in equity method losses recognized from MediBeacon, as discussed in the Loss from Equity Investees section above, and an increase in selling costs at R2 Technologies due to the increase in unit sales. The increase in Adjusted EBITDA loss was partially offset by an increase in gross profit at R2 Technologies, driven by an increase in unit sales of both the Glacial fx and Glacial Rx systems and an increase in consumable sales in North America, as well as an increase in Glacial Spa unit sales, consumable sales and Glacial fx unit sales outside North America.

Spectrum: Net loss from our Spectrum segment for the three months ended March 31, 2025, increased $0.6 million to $5.4 million from $4.8 million for the three months ended March 31, 2024. Adjusted EBITDA from our Spectrum segment for the three months ended March 31, 2025, decreased slightly by $0.2 million to $1.4 million from $1.6 million for the three months ended March 31, 2024. The decrease in Adjusted EBITDA was primarily driven by the termination of a few networks and individual markets, which was partially offset by the launch of new networks subsequent to the comparable period.

Non-Operating Corporate: Net loss from our Non-Operating Corporate segment for the three months ended March 31, 2025, increased $3.6 million to $16.1 million from $12.5 million for the three months ended March 31, 2024. Adjusted EBITDA loss from our Non-Operating Corporate segment for the three months ended March 31, 2025, decreased $0.7 million to $2.2 million from $2.9 million for the three months ended March 31, 2024. The decrease in Adjusted EBITDA loss was primarily driven by a decrease in legal fees due to legal matters settled subsequent to the comparable period.

Backlog

Backlog is our estimate of the U.S. dollar amount of future revenues we expect to realize as a result of performing work on projects in backlog. Projects in backlog consist of awarded contracts, letters of intent, notices to proceed, change orders, and purchase orders obtained. Backlog increases as contract commitments are obtained, decreases as revenues are recognized and increases or decreases to reflect modifications in the work to be performed under the contracts. Backlog is converted to sales in future periods as work is performed or projects are completed. Backlog can be significantly affected by the receipt or loss of individual contracts.

Infrastructure Segment

As of March 31, 2025, DBMG's backlog was $1,369.9 million, consisting of $939.0 million under contracts or purchase orders and $430.9 million under letters of intent or notices to proceed. Approximately $714.6 million, representing 52.2% of DBMG’s backlog as of March 31, 2025, was attributable to five contracts, letters of intent, notices to proceed or purchase orders. If one or more of these projects terminate or reduce their scope, DBMG’s backlog could decrease substantially. DBMG includes an additional $12.1 million in its backlog that is not included in the remaining unsatisfied performance obligations disclosed in Note 3. Revenue and Contracts in Process. This additional backlog includes commitments under master service agreements that are estimated amounts of work to be performed based on customer communications, historic performance and knowledge of our customers' intentions.

Liquidity and Capital Resources

Short- and Long-Term Liquidity Considerations and Risks

Our Non-Operating Corporate segment's liquidity needs are primarily for interest payments on its 2026 Senior Secured Notes, 2026 Convertible Notes, Revolving Line of Credit, CGIC Unsecured Note, and dividend payments on its Series A-3 and Series A-4 Preferred Stock and recurring operational expenses. 

On a consolidated basis, as of March 31, 2025, we had $33.3 million of cash and cash equivalents, excluding restricted cash, compared to $48.8 million as of December 31, 2024. On a stand-alone basis, as of March 31, 2025, our Non-Operating Corporate segment had cash and cash equivalents, excluding restricted cash, of $3.0 million and $2.3 million of marketable securities, as compared to cash and cash equivalents, excluding restricted cash, of $13.8 million and $1.8 million of marketable securities as of December 31, 2024.

Our subsidiaries' principal liquidity requirements arise from cash used in operating activities, debt service, and capital expenditures, including purchases of steel construction equipment, OTA broadcast station equipment, development of back-office systems, operating costs and expenses, and income taxes.

As of March 31, 2025, we had $672.0 million of principal indebtedness on a consolidated basis compared to $668.3 million as of December 31, 2024, a net increase of $3.7 million, which was primarily due to a $2.5 million net increase in debt at our Infrastructure segment, and an increase at our Life Sciences segment due to the capitalization of $1.2 million of unpaid accrued interest at R2 Technologies into their outstanding principal balance.

39

On a stand-alone basis, our Non-Operating Corporate segment indebtedness was $429.9 million in principal amount as of both March 31, 2025 and December 31, 2024. The March 31, 2025, indebtedness balance consists of the $330.0 million aggregate principal amount of 2026 Senior Secured Notes, $48.9 million aggregate principal amount of 2026 Convertible Notes (which excludes the $2.9 million 2026 Convertible Notes repurchased in 2024 and retired by the Company in 2025), $31.0 million principal amount of the CGIC Unsecured Note and $20.0 million aggregate principal amount drawn on our Revolving Line of Credit. Our Non-Operating Corporate segment is required to make semi-annual interest payments on the 2026 Senior Secured Notes and 2026 Convertible Notes on February 1st and August 1st of each year, quarterly interest payments on the Revolving Line of Credit, and monthly interest payments on the CGIC Unsecured Note. As described below, the interest rate on the CGIC Unsecured Note increased from 9.0% per annum to 16.0% per annum on May 9, 2024, and will increase from 16.0% per annum to 32.0% per annum on May 9, 2025.

We are required to make dividend payments on our outstanding Series A-3 Preferred Stock and Series A-4 Preferred Stock on January 15th, April 15th, July 15th, and October 15th of each year.

Our Non-Operating Corporate segment received $15.6 million in net tax sharing payments from our Infrastructure segment for the three months ended March 31, 2025.

We have financed our growth and operations to date, and expect to finance our future growth and operations, through public offerings and private placements of debt and equity securities, credit facilities, vendor financing, finance lease financing and other financing arrangements, as well as cash generated from the operations of our subsidiaries. In the future, we may also choose to sell assets or certain investments to generate cash.

Rights Offering and Concurrent Private Placement

On March 8, 2024, the Company commenced a rights offering ("Rights Offering"), in which each holder of the Company’s common stock, Series A-3 Convertible Participating Preferred Stock, Series A-4 Convertible Participating Preferred Stock and the 2026 Convertible Notes as of March 6, 2024 (the “rights offering record date”), were granted rights to purchase common stock. In connection with the Rights Offering, the Company entered into an Investment Agreement with Lancer Capital (the "Investment Agreement"), pursuant to which Lancer Capital agreed to purchase up to $19.0 million of Series C Preferred Stock as a backstop to the Rights Offering (the "Backstop Commitment") and to purchase $16.0 million of Series C Preferred Stock in a private placement transaction ("Concurrent Private Placement"). Lancer Capital is an investment fund led by Avram A. Glazer, the Chairman of the Board and the Company’s largest stockholder. As the Rights Offering had not yet settled by March 28, 2024, in accordance with the Investment Agreement, Lancer Capital purchased $25.0 million of Series C Preferred Stock, referred to as the "equity advance." On April 24, 2024, the Company completed and closed on the Rights Offering and issued a total of 530,611 shares of common stock (5,306,105 shares of common stock on a pre Reverse Stock Split (see below) basis) for $3.7 million. In addition, Lancer Capital purchased an additional approximately 6,286 Series C Preferred Stock for $6.3 million under the Backstop Commitment. In total, the Company received $35.0 million in aggregate gross proceeds related to the Rights Offering and Concurrent Private Placement and incurred $1.8 million in dealer manager fees and other related costs which were capitalized into Additional paid in capital ("APIC"). On June 18, 2024, the Company's shareholders approved the conversion of the Series C Preferred Stock into common stock, and approximately 31,286 shares of Series C Preferred Stock, which were held by Lancer Capital, were converted into 4,469,390 shares of common stock (44,693,895 shares of common stock on a pre Reverse Stock Split basis), and there were no shares of the Series C Preferred Stock outstanding subsequent to their conversion into the Company's common stock.

INNOVATE utilized the net proceeds from the Rights Offering and Concurrent Private Placement for general corporate purposes, including debt service and for working capital. As a result of the closing of the Rights Offering and Concurrent Private Placement, a mandatory prepayment was required on the CGIC Unsecured Note, and on April 26, 2024, INNOVATE redeemed $4.1 million of the CGIC Unsecured Note. See Note 15. Equity and Temporary Equity for additional information.

Going Concern

The accompanying Condensed Consolidated Financial Statements have been prepared assuming that the Company will continue as a going concern. However, as of the date of these financial statements, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.

The principal conditions leading to this conclusion are the upcoming maturities of current debt at our Non-Operating Corporate segment and the Company's subsidiaries as well as from certain cross-default provisions in the Company's Senior Secured Notes. Based on these conditions, the Company may not be able to meet its obligations at maturity and comply with certain cross-default provisions under the Senior Secured Notes over the next twelve months.

Management has evaluated the significance of these conditions in relation to the Company's ability to meet its obligations. The potential inability to refinance or extend the maturity of the aforementioned current debt, or to obtain additional financing, raises substantial doubt about the Company's ability to continue as a going concern.

40

The Company plans to alleviate these conditions through various initiatives it is currently exploring, including potentially refinancing the debt at our Non-Operating Corporate segment and its subsidiaries, pursuing asset sales, and raising additional capital. However, there can be no assurance that the Company will have the ability to raise additional capital when needed, be successful in any asset sales, or refinance its existing debt, on attractive terms, or at all nor any assurances that lenders will provide additional extensions, waivers or amendments in the event of future non-compliance with the Company’s debt covenants or other possible events of default. Further, there can be no assurance that the Company will be able to execute a reduction, extension, or refinancing of the debt, or that the terms of any replacement financing would be as favorable as the terms of the debt prior to the maturity date. There can be no assurance that these plans will be successfully implemented or that they will mitigate the conditions that raise substantial doubt about the Company's ability to continue as a going concern.

The Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q do not include any adjustments to the carrying amounts and classification of assets, liabilities, or expenses that may result if the Company is unable to continue as a going concern.

While the Company has noted the conditions above regarding its ability to continue as a going concern, it is important to note that the Company’s largest subsidiary, DBMG, is operationally profitable, continues to maintain a strong financial position and remains in good standing with its lenders. Under INNOVATE’s Senior Secured Notes Indenture, DBMG is a restricted subsidiary, not a guarantor, and INNOVATE’s equity interests in DBMG are pledged as collateral.

Capital Expenditures

Capital expenditures are set forth in the table below (in millions):

	Three Months Ended March 31,
	2025		2024
Infrastructure	$	4.1	$	5.2
Life Sciences	0.1		0.1
Spectrum	0.5		0.3
Total	$	4.7	$	5.6

Indebtedness

Non-Operating Corporate

2026 Senior Secured Notes

On February 1, 2021, our Non-Operating Corporate segment repaid the senior secured notes that were due in 2021 and issued $330.0 million aggregate principal amount of 8.50% senior secured notes due February 1, 2026 (the "2026 Senior Secured Notes"). The 2026 Senior Secured Notes mature on February 1, 2026, and accrue interest at a rate of 8.50% per year, which interest is paid semi-annually on February 1st and August 1st of each year. If the Company sells certain assets and the net cash proceeds from all applicable asset sales exceed $50.0 million since the issue date of the 2026 Senior Secured Notes, the Company may be required in certain circumstances to make an offer to purchase the notes with the net cash proceeds from such an asset sale in excess of such $50.0 million threshold at a price in cash equal to 101% of the principal amount thereof, together with accrued and unpaid interest, if any, to the date of purchase.

For additional information on the terms and conditions of the 2026 Senior Secured Notes, including guarantees, ranking and collateral, refer to Note 11. Debt Obligations included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, and Note 11. Debt Obligations included in the Consolidated Financial Statements included in our 2024 Annual Report on Form 10-K, which was filed with the SEC on March 31, 2025.

2026 Convertible Notes

The original $51.8 million aggregate principal amount of 7.50% convertible notes (the "2026 Convertible Notes") were issued under a separate indenture dated February 1, 2021, between the Company and U.S. Bank, as trustee (the "Convertible Indenture"). In July 2024, we repurchased $2.9 million principal amount of our 2026 Convertible Notes at a market discount for $1.1 million, which was inclusive of accrued interest of $0.1 million. As of March 31, 2025, we had $48.9 million principal amount of 2026 Convertible Notes outstanding. The 2026 Convertible Notes mature on August 1, 2026, unless earlier converted, redeemed or purchased. The 2026 Convertible Notes accrue interest at a rate of 7.5% per year, which interest is paid semi-annually on February 1st and August 1st of each year.

For additional information on the terms and conditions of the 2026 Convertible Notes, including optional redemption, conversion rights guarantees, ranking and collateral, refer to Note 11. Debt Obligations included in the Consolidated Financial Statements included in our 2024 Annual Report on Form 10-K, which was filed with the SEC on March 31, 2025.

Our debt contains customary events of default which could, subject to certain conditions, cause the 2026 Senior Secured Notes and the 2026 Convertible Notes to become immediately due and payable.

41

Revolving Line of Credit

We have a revolving credit agreement with MSD PCOF Partners IX, LLC ("MSD") which has a maximum commitment of $20.0 million ("Revolving Line of Credit"), of which $20.0 million had been drawn as of March 31, 2025. Interest on loans under the Revolving Line of Credit accrues at SOFR plus 5.75% and is payable quarterly. The Revolving Line of Credit also includes a commitment fee at a per annum rate of 1.0% calculated based off the actual daily amount of unused availability under the Revolving Line of Credit with MSD. The maturity date of the Revolving Line of Credit, as amended on March 6, 2025, is August 1, 2025. The amount outstanding under the Revolving Line of Credit is subject to mandatory prepayment from the net cash proceeds from certain asset sales in excess of $10.0 million.

For additional information on the terms and conditions of the Revolving Line of Credit, including guarantees and ranking and collateral, refer to Note 11. Debt Obligations included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, and Note 11. Debt Obligations included in the Consolidated Financial Statements included in our 2024 Annual Report on Form 10-K, which was filed with the SEC on March 31, 2025.

CGIC Unsecured Note

On May 9, 2023, in connection with the redemption of the DBMGi Series A Preferred Stock, the Company issued a subordinated unsecured promissory note to CGIC in the principal amount of $35.1 million (the "CGIC Unsecured Note"). The CGIC Unsecured Note is due February 28, 2026, and bore interest at 9.0% per annum through May 8, 2024, bears interest at 16.0% per annum from May 9, 2024, to May 8, 2025, and 32.0% per annum thereafter. The CGIC Unsecured Note also requires a mandatory prepayment from the proceeds from certain asset sales and the greater of $3.0 million or 12.5% of the net proceeds from certain equity sales. Other covenants in the CGIC Unsecured Note are generally consistent with the Company's Indenture governing the 8.50% Senior Secured Notes due 2026, dated as of February 1, 2021, by and among the Company, the guarantors party thereto and U.S. Bank National Association. As a result of the closing of the Rights Offering, on April 24, 2024, INNOVATE redeemed $4.1 million of the CGIC Unsecured Note on April 26, 2024.

Refer to Note 11. Debt Obligations included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, and to Note 16. Equity and Temporary Equity and to Note 11. Debt Obligations included in the Consolidated Financial Statements included in our 2024 Annual Report on Form 10-K, which was filed with the SEC on March 31, 2025, for additional information.

Infrastructure

As of March 31, 2025, our Infrastructure segment has aggregate principal outstanding debt, including obligations under finance leases, of $147.2 million.

DBMG has a $135.0 million Revolving Line with UMB that bears interest at a prime rate minus a spread with an interest rate floor of 4.25%. As of March 31, 2025, the outstanding balance was $50.0 million. The effective interest rate on the Revolving Line with UMB was 6.72% as of March 31, 2025. The Revolving Line with UMB matures on August 15, 2025, and interest is paid monthly. The Revolving Line with UMB also includes a commitment fee equal to 0.25% per annum times the average daily unused availability under the line.

DBMG also has a $72.8 million term loan due 2026 (the "3.25% UMB Term Loan"), which expires May 31, 2026, and bears interest at an annual rate of 3.25% with an effective interest rate of 3.3%. Principal payments and interest are paid monthly. On June 28, 2024, DBM and UMB entered into the Third Amendment to the UMB Credit Agreement. The amendment added an incremental separate term loan of $25.0 million to the existing credit facility, of which $24.2 million is outstanding as of March 31, 2025. The incremental term loan bears the same interest rate as the Revolving Line with UMB and has the same maturity date as the initial 3.25% UMB Term Loan.

Refer to Note 11. Debt Obligations included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, and Note 11. Debt Obligations included in the Consolidated Financial Statements included in our 2024 Annual Report on Form 10-K, which was filed with the SEC on March 31, 2025, for additional details regarding the indebtedness of our Infrastructure segment.

Life Sciences

As of March 31, 2025, our Life Sciences segment has aggregate principal outstanding debt of $25.2 million.

42

R2 Technologies has a short-term note with Lancer Capital. Interest on the note, as amended, is payable monthly in arrears, in cash or, if not paid in cash, accrued and unpaid interest is capitalized monthly into the principal balance. During the first quarter of 2025, with an effective date of December 31, 2024, the maturity date of the note was extended to August 1, 2025, and another additional exit fee of $1.0 million was incurred under the amendment, which continues to increase by $1.0 million each month until maturity. The base exit fee, as amended, and as of March 31, 2025, was equal to 12.41% of the principal amount being repaid and continues to increase by 0.17% each month until maturity. The total new exit fees associated with the notes have been recorded as an original issue discount of $8.7 million and are being amortized over the remaining life of the note, which is assumed to be the maturity date. A corresponding liability for the new exit fees of $8.7 million was recorded for total accrued exit fees amount of $16.5 million which are included within Accrued liabilities in the Condensed Consolidated Balance Sheet as of March 31, 2025. The exit fees are payable on the earliest of the maturity date, the date of the acceleration of the principal amount of the note for any reason or, if any portion of the note is prepaid at any time, the date of such prepayment of the note. In addition, under the recent amendment, a new $5.0 million default fee will be payable on August 1, 2025, in the event all obligations under the note, including principal, any accrued and unpaid interest, and exit fees, are not repaid in full prior to the August 1, 2025, maturity date. The $5.0 million default fee will only be recognized in the event of a default on August 1, 2025.

As of March 31, 2025, the total carrying amount relating to the 20% note was $36.4 million, inclusive of $25.2 million of principal and capitalized interest, partially offset by $5.3 million of unamortized original issue discount, which are included within the Current portion of debt obligations in the Condensed Consolidated Balance Sheet, and $16.5 million in total accrued exit fees which are included within Accrued liabilities in the Condensed Consolidated Balance Sheet.

Refer to Note 11. Debt Obligations included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, and Note 11. Debt Obligations included in the Consolidated Financial Statements included in our 2024 Annual Report on Form 10-K, which was filed with the SEC on March 31, 2025, for additional information on the note and the various amendments.

On February 20, 2025, Pansend closed on a new $3.5 million convertible 13.0% note instrument with R2 Technologies. The principal amount of the note, together with any interest then accrued and unpaid, is convertible at the option of Pansend, into shares of a new Series E Preferred Stock ("Series E") in R2 Technologies upon written notice to R2 Technologies and has a maturity date of the earlier of July 31, 2025, or a change in control of R2 Technologies, as defined in the note. The transaction is eliminated on consolidation. Refer to Note 15. Equity and Temporary Equity included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on R2 Technologies' convertible preferred stock and convertible notes.

Spectrum

As of March 31, 2025, our Spectrum segment has aggregate principal outstanding debt of $69.7 million, consisting of 8.50% and 11.45% Notes. Interest is capitalized and payable upon maturity of the notes. The maturity date, as amended, of Spectrum's 8.50% and 11.45% Notes, is August 15, 2025.

The exit fees associated with the notes, which are payable on the earlier of maturity or repayment of the principal, were recorded as original issue discount and are being amortized over the remaining life of the notes, which is assumed to be the maturity date. A corresponding liability of $15.9 million is reflected within Accrued Liabilities in the Condensed Consolidated Balance Sheet as of March 31, 2025. As of March 31, 2025 and December 31, 2024, the weighted-average effective interest rates on the notes, as amended, was 22.9% and 22.8%, respectively.

During November 2023, concurrently with Broadcasting's execution of the Ninth Amendment to Secured Notes, which among other things extended the maturity of the notes, INNOVATE entered into a related side letter with the lenders, whereby INNOVATE agreed to utilize proceeds from the sale of certain of its existing operations, as allowable under the Company's current agreements and indentures and after all other required payments have been made, for repayment of a portion of our Spectrum segment's Senior Secured Notes. Assuming there are sufficient proceeds remaining after such repayment, an additional $2.0 million is payable for payments made after November 9, 2024, and in exchange for the additional fee, the institutional investors will return their equity interests in HC2 Broadcasting Holdings, Inc. and their equity interests in DTV America.

Refer to Note 11. Debt Obligations included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, and Note 11. Debt Obligations included in the Consolidated Financial Statements included in our 2024 Annual Report on Form 10-K, which was filed with the SEC on March 31, 2025, for additional information.

Restrictive Covenants

The indenture governing the 2026 Senior Secured Notes dated February 1, 2021, by and among INNOVATE, the guarantors party thereto and U.S. Bank National Association, a national banking association, as trustee (the "Secured Indenture"), contains certain affirmative and negative covenants limiting, among other things, the ability of the Company, and, in certain cases, the Company’s subsidiaries, to incur additional indebtedness; create liens; engage in sale-leaseback transactions; pay dividends or make distributions in respect of capital stock; make certain restricted payments; sell assets; engage in transactions with affiliates; or consolidate or merge with, or sell substantially all of its assets to, another person. These covenants are subject to a number of important exceptions and qualifications.

43

The Company is also required to comply with certain financial maintenance covenants, which are similarly subject to a number of important exceptions and qualifications. These covenants include maintenance of (1) liquidity and (2) collateral coverage.

The maintenance of liquidity covenant provides that the Company will not permit the aggregate amount of (i) all unrestricted cash and Cash Equivalents of the Company and the Subsidiary Guarantors, (ii) amounts available for drawing under revolving credit facilities and undrawn letters of credit of the Company and the Subsidiary Guarantors and (iii) dividends, distributions or payments that are immediately available to be paid to the Company by any of its Restricted Subsidiaries to be less than the Company’s obligation to pay interest for the next six months on the 2026 Senior Secured Notes and all other Debt, including Convertible Series A-3 and Series A-4 Preferred Stock mandatory cash dividends or any other mandatory cash pay Series A-3 and Series A-4 Preferred Stock but excluding any obligation to pay interest on Series A-3 and Series A-4 Preferred Stock or any other mandatory cash payments on Series A-3 and Series A-4 Preferred Stock which, in each case, may be paid by accretion or in-kind in accordance with its terms of the Company and its Subsidiary Guarantors. As of March 31, 2025, the Company was in compliance with this covenant.

The maintenance of collateral coverage provides that the certain subsidiaries' Collateral Coverage Ratio (as defined in the Secured Indenture as the ratio of (i) the Loan Collateral to (ii) Consolidated Secured Debt (each as defined therein)) calculated on a pro forma basis as of the last day of each fiscal quarter may not be less than 1.50 to 1.00. As of March 31, 2025, the Company was in compliance with this covenant.

The instruments governing the Company’s Series A-3 Preferred Stock and Series A-4 Preferred Stock also limit the Company’s and its subsidiaries ability to take certain actions, including, among other things, to incur additional indebtedness; issue additional Series A-3 Preferred Stock and Series A-4 Preferred Stock; engage in transactions with affiliates; and make certain restricted payments. These limitations are subject to a number of important exceptions and qualifications.

The Company has conducted its operations in a manner that has resulted in compliance with the Secured Indenture; however, compliance with certain financial covenants for future periods may depend on the Company or one or more of the Company’s subsidiaries undertaking one or more non-operational transactions, such as the management of operating cash outflows, a monetization of assets, a debt incurrence or refinancing, the raising of equity capital, or similar transactions. If the Company is unable to remain in compliance and does not make alternate arrangements, an event of default would occur under the Company’s Secured Indenture which, among other remedies, could result in the outstanding obligations under the indenture becoming immediately due and payable and permitting the exercise of remedies with respect to the collateral. There is no assurance the Company will be able to complete any non-operational transaction it may undertake to maintain compliance with covenants under the Secured Indenture or, even if the Company completes any such transaction, that it will be able to maintain compliance for any subsequent period.

The UMB term loans and Revolving Line with UMB associated with our Infrastructure segment contain customary restrictive and financial covenants related to debt levels and performance, including a Fixed Charge Coverage Ratio covenant, as defined in the agreement.

As of March 31, 2025, we were in compliance with the covenants of our debt agreements.

Summary of Consolidated Cash Flows

The below table summarizes the cash provided by or used in our activities (in millions):

	Three Months Ended March 31,				Increase / (Decrease)
	2025		2024
Cash used in operating activities	$	(14.1)	$	(25.4)	$	11.3
Cash used in investing activities	(3.9)		(3.3)		(0.6)
Cash provided by (used in) financing activities	2.4		(12.9)		15.3
Effects of exchange rate changes on cash, cash equivalents and restricted cash	0.2		(0.8)		1.0
Net decrease in cash and cash equivalents, including restricted cash	$	(15.4)	$	(42.4)	$	27.0

Operating Activities

Cash used in operating activities was $14.1 million for the three months ended March 31, 2025, as compared to $25.4 million for the three months ended March 31, 2024, a decrease in cash used in operating activities of $11.3 million. Cash flows from operations are primarily influenced by changes in the timing of demand for services and by operating margins, but can also be affected by working capital needs associated with our operations. For the three months ended March 31, 2025, the decrease in cash used in operating activities was primarily driven by a decrease in working capital outflows at our Infrastructure segment, partially offset by an increase in cash used in operating activities at our Non-Operating Corporate segment. The decrease in working capital outflows at our Infrastructure segment was primarily due to normal business fluctuations in accounts receivable, accounts payable, contract-related assets and liabilities, and other accrued liabilities due to the timing of regular billing and collection activities and changes in contract assets and liabilities due to ordinary course business project activity. Our Non-Operating Corporate segment's increase in cash used in operating activities was primarily due to an increase in net loss and increases in working capital outflows primarily for taxes and interest.

44

Investing Activities

Cash used in investing activities was $3.9 million for the three months ended March 31, 2025, as compared to $3.3 million for the three months ended March 31, 2024, an increase in cash used in investing activities of $0.6 million. Capital expenditures totaled $4.7 million, or $3.6 million net of proceeds from disposals, for the three months ended March 31, 2025, as compared to $5.6 million, or $2.5 million net of proceeds from disposals, for the three months ended March 31, 2024, for an increase in cash used in investing activities of $1.1 million. The increase was primarily driven by our Infrastructure segment, which had more PP&E sales in the comparable period due to a plant closure in the first quarter of 2024, partially offset by fewer PP&E additions in the current period, and a slight increase in PP&E additions at our Spectrum segment in the current period. In addition, our Corporate segment purchased marketable investments for $0.3 million during the three months ended March 31, 2025, and other investing activities for the comparable period included unrepeated proceeds of $0.4 million which primarily related to a note receivable at our Life Sciences segment. These increases in cash used in investing activities were partially offset by unrepeated loans made by our Life Sciences segment to MediBeacon of $1.2 million in the comparable period.

Financing Activities

Cash provided by financing activities was $2.4 million for the three months ended March 31, 2025, as compared to cash used in financing activities of $12.9 million for the three months ended March 31, 2024, an improvement in financing cash flows of $15.3 million. The improvement was primarily driven by our Infrastructure segment's payment activity on its Revolving Line with UMB, which had a $35.0 million net decrease in revolving credit line outflows due to payments made in the comparable period to reduce the outstanding balance. For the three months ended March 31, 2025, principal payments for other debt obligations at our Infrastructure segment totaled $2.2 million, as compared to $7.6 million in the comparable period, a decrease of $5.4 million. These improvements were partially offset by our Non-Operating Corporate segment, which had completed the issuance of the $25.0 million Convertible Series C Preferred Stock in the comparable period related to the 2024 Rights Offering and Concurrent Private Placement.

Infrastructure

Cash Flows

Cash flows from operating activities are the principal source of cash used to fund DBMG’s operating expenses, interest payments on debt, and capital expenditures. DBMG's short-term cash needs are primarily for working capital to support operations including receivables, inventories, and other costs incurred in performing on its contracts. DBMG attempts to structure the payment arrangements under its contracts to match costs incurred under the project. To the extent it is able to bill in advance of costs incurred, DBMG generates working capital through billings in excess of costs and recognized earnings on uncompleted contracts. DBMG relies on its credit facilities to meet its working capital needs. DBMG believes that its available funds, cash generated by operating activities and funds available under its bank credit facilities will be adequate to meet all funding requirements for its operating expenses, working capital needs, interest payments on debt and capital expenditures for the foreseeable future. However, DBMG may expand its operations through future acquisitions and may require additional equity or debt financing.

DBMG is required to make monthly interest payments on all of its debt. Based upon the March 31, 2025 debt balance, DBMG anticipates that its interest payments will be approximately $1.5 million for each quarter of 2025.

New Accounting Pronouncements

For information on new accounting pronouncements, refer to Note 2. Summary of Significant Accounting Policies included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

Critical Accounting Estimates

There have been no material changes in the Company’s critical accounting policies during the period ended March 31, 2025. For information about critical accounting policies and estimates, refer to “Critical Accounting Estimates” under Item 7 of our 2024 Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 31, 2025.

Related Party Transactions

For a discussion of our Related Party Transactions, refer to Note 16. Related Parties included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

45

Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains or incorporates a number of "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are based on current expectations, and are not strictly historical statements. In some cases, you can identify forward-looking statements by terminology such as "if," "may," "should," "believe," "anticipate," "future," "forward," "potential," "estimate," "opportunity," "goal," "objective," "growth," "outcome," "could," "expect," "intend," "plan," "strategy," "provide," "commitment," "result," "seek," "pursue," "ongoing," "include" or in the negative of such terms or comparable terminology. These forward-looking statements inherently involve certain risks and uncertainties and are not guarantees of performance, results, or the creation of stockholder value, although they are based on our current plans or assessments which we believe to be reasonable as of the date hereof.

Factors that could cause actual results, events and developments to differ include, without limitation: the ability of our subsidiaries (including, target businesses following their acquisition) to generate sufficient net income and cash flows to make upstream cash distributions, capital market conditions, our and our subsidiaries’ ability to identify any suitable future acquisition opportunities, efficiencies/cost avoidance, cost savings, income and margins, growth, economies of scale, combined operations, future economic performance, conditions to, and the timetable for, completing future acquisitions and dispositions and the successful integration of acquisitions, litigation, potential and contingent liabilities, management’s plans, changes in regulations and taxes.

We claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 for all forward-looking statements.

Forward-looking statements are not guarantees of performance. You should understand that the following important factors, in addition to those discussed under the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 31, 2025, and the documents incorporated herein by reference, could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in the forward-looking statements. You should also understand that many factors described under one heading below may apply to more than one section in which we have grouped them for the purpose of this presentation. As a result, you should consider all of the following factors, together with all of the other information presented herein, in evaluating our business and that of our subsidiaries.

INNOVATE Corp. and Subsidiaries

Our actual results or other outcomes may differ from those expressed or implied by forward-looking statements contained herein due to a variety of important factors, including, without limitation, the following:

•our dependence on distributions from our subsidiaries to fund our operations and payments on our obligations;

•substantial doubt about our ability to continue operating as a going concern;

•the impact on our business and financial condition of our substantial indebtedness and the significant additional indebtedness and other financing obligations we may incur;

•the impact of covenants in the Indenture governing INNOVATE’s 2026 Senior Secured Notes, 2026 Convertible Notes, CGIC Unsecured Note and Revolving Line of Credit, the Certificates of Designation governing INNOVATE’s Series A-3 Preferred Stock and Series A-4 Preferred Stock and all other subsidiary debt obligations as summarized in Note 11. Debt Obligations to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC March 31, 2025, and future financing agreements on our ability to operate our business and finance our pursuit of acquisition opportunities;

•our possible inability to generate sufficient liquidity, margins, earnings per share, cash flow and working capital from our operating segments;

•our dependence on certain key personnel including the passing in 2023 of Mr. Barr, our former CEO, President and Director and the successful transition of his management responsibilities;

•bank failures or other similar events that could adversely affect our and our customers' and vendors' liquidity and financial performance;

•our possible inability to hire and retain qualified executive management, sales, technical and other personnel;

•the potential for, and our ability to, remediate future material weaknesses in our internal controls over financial reporting;

•changes in market conditions, including from political regulatory or market uncertainty, changes in foreign exchange rates, interest rates or inflation, supply chain disruptions, labor shortages and increases in overall price levels, including in transportation costs;

•the uncertain effects of U.S. and foreign government actions affecting international trade and economic policy, including changes in volatility in tariffs and trade policies and retaliatory actions, on credit markets, customers, and customer retention, and demand for our products and services;

•increased competition in the markets in which our operating segments conduct their businesses;

•limitations on our ability to successfully identify any strategic acquisitions or business opportunities and to compete for these opportunities with others who have greater resources;

•our ability to effectively increase the size of our organization, if needed, and manage our growth;

•the impact of expending significant resources in considering acquisition targets or business opportunities that are not consummated;

•our expectations and timing with respect to our ordinary course acquisition activity and whether such acquisitions are accretive or dilutive to stockholders;

46

•the effect any interests our officers, directors, stockholders and their respective affiliates may have in certain transactions in which we are involved;

•uncertain global economic conditions in the markets in which our operating segments conduct their businesses;

•the effects related to or resulting from ongoing and recent geopolitical events, such as the political unrest and military conflicts in the Middle East, Russia and Ukraine, including the imposition of additional sanctions and export controls, as well as the broader impact to financial markets and the global macroeconomic and geopolitical environment;

•the impact of catastrophic events, including natural disasters, pandemic illness and the outbreak of war, or acts of terrorism;

•potential impacts on our business resulting from climate change, greenhouse gas regulations, and the impact of climate change-related changes in the frequency and severity of weather patterns;

•the impact of additional material charges associated with our oversight of acquired or target businesses and the integration of our financial reporting;

•tax consequences associated with our acquisition, holding and disposition of target companies and assets;

•our ability to remain in compliance with the listing standards of the NYSE;

•the Reverse Stock Split may not result in a sustained increase in the per share price of our common stock;

•the ability of our operating segments to attract and retain customers;

•our expectations regarding the timing, extent and effectiveness of our cost reduction initiatives and management’s ability to moderate or control discretionary spending;

•management’s plans, goals, forecasts, expectations, guidance, objectives, strategies and timing for future operations, acquisitions, synergies, asset dispositions, fixed asset and goodwill impairment charges, tax and withholding expense, selling, general and administrative expenses, product plans, performance and results;

•management’s assessment of market factors and competitive developments, including pricing actions and regulatory rulings;

•our expectations and timing with respect to any strategic dispositions and sales of our operating subsidiaries, or businesses, that we may make in the future and the effect of any such dispositions or sales on our results of operations;

•the possibility of indemnification claims arising out of divestitures of businesses; and

•our possible inability to raise additional capital when needed or refinance our existing debt, on attractive terms, or at all.

Infrastructure / DBM Global Inc.

Our actual results or other outcomes of DBMG, and, thus, our Infrastructure segment, may differ from those expressed or implied by forward-looking statements contained herein due to a variety of important factors, including, without limitation, the following:

•adverse impacts from weather affecting DBMG’s performance and timeliness of completion of projects, which could lead to increased costs and affect the quality, costs or availability of, or delivery schedule for, equipment, components, materials, labor or subcontractors;

•cost overruns on fixed-price or similar contracts or failure to receive timely or proper payments on cost-reimbursable contracts, whether as a result of improper estimates, performance, disputes, or otherwise;

•uncertain timing and funding of new contract awards, as well as project cancellations;

•potential impediments and limitations on our ability to complete ordinary course acquisitions in anticipated time frames or at all;

•changes in the costs or availability of, or delivery schedule for, equipment, components, materials, labor or subcontractors;

•changes in economic conditions, including from the impact of inflationary pressures and changes in interest rates;

•adverse outcomes of pending claims or litigation or the possibility of new claims or litigation, and the potential effect of such claims or litigation on DBMG’s business, financial condition, results of operations or cash flow;

•risks associated with labor productivity, including performance of subcontractors that DBMG hires to complete projects;

•its ability to realize cost savings from expected performance of contracts, whether as a result of improper estimates, performance, or otherwise;

•its ability to settle or negotiate unapproved change orders and claims;

•fluctuating revenue resulting from a number of factors, including the cyclical nature of the individual markets in which our customers operate;

•our possible inability to raise additional capital when needed or refinance our existing debt, on attractive terms, or at all; and

•lack of necessary liquidity to provide bid, performance, advance payment and retention bonds, guarantees, or letters of credit securing DBMG’s obligations under bids and contracts or to finance expenditures prior to the receipt of payment for the performance of contracts.

Life Sciences / Pansend Life Sciences, LLC

Our actual results or other outcomes of Pansend Life Sciences, LLC, and, thus, our Life Sciences segment, may differ from those expressed or implied by forward-looking statements contained herein due to a variety of important factors, including, without limitation, the following:

•our Life Sciences segment’s ability to invest in development stage companies;

•our Life Sciences segment’s ability to develop products and treatments related to its portfolio companies;

•medical advances in healthcare and biotechnology;

•governmental regulation in the healthcare industry; and

•our Life Sciences segment's possible inability to raise additional capital when needed or refinance its existing debt, on attractive terms, or at all.

47

Spectrum / HC2 Broadcasting Holdings Inc.

Our actual results or other outcomes of Broadcasting, and, thus, our Spectrum segment, may differ from those expressed or implied by forward-looking statements contained herein due to a variety of important factors, including, without limitation, the following:

•our Spectrum segment’s ability to operate in highly competitive markets and maintain market share;

•our Spectrum segment’s ability to effectively implement its business strategy or be successful in the operation of its business;

•our Spectrum segment's possible inability to raise additional capital when needed or refinance its existing debt, on attractive terms, or at all;

•new and growing sources of competition in the broadcasting industry; and

•FCC regulation of the television broadcasting industry.

We caution the reader that undue reliance should not be placed on any forward-looking statements, which speak only as of the date of this document. Neither we nor any of our subsidiaries undertake any duty or responsibility to update any of these forward-looking statements to reflect events or circumstances after the date of this document or to reflect actual outcomes, except as required by applicable law.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management evaluated, with the participation of our Interim Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 as amended (the "Exchange Act") as of the end of the period covered by this report. Based on this evaluation, our Interim Chief Executive Officer and Chief Financial Officer have concluded that, as of March 31, 2025, our disclosure controls and procedures were effective. Disclosure controls and procedures mean our controls and other procedures that are designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Company’s Condensed Consolidated Financial Statements. The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its Condensed Consolidated Financial Statements. The Company records a liability in its Condensed Consolidated Financial Statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amounts of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary for the Condensed Consolidated Financial Statements not to be misleading. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in its Condensed Consolidated Financial Statements. Refer to Note 13. Commitments and Contingencies of the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, which is incorporated herein by reference for additional information.

ITEM 1A. RISK FACTORS

There have been no material changes in our risk factors from those disclosed in Part 1, Item 1A of our Fiscal Year 2024 Form 10-K, which was filed with the SEC on March 31, 2025. See "Risk Factors" in Item 1A of Part I of such Fiscal Year 2024 Form 10-K for a complete description of the material risks we face.

48

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities

Equity Award Share Withholding

Shares of common stock withheld as payment of withholding taxes in connection with the vesting or exercise of equity awards are treated as common stock repurchases. Those withheld shares of common stock are not considered common stock repurchases under an authorized common stock repurchase plan. During the quarter ended March 31, 2025, there were 15,042 shares withheld in connection with the vesting of employee equity awards at a weighted-average price of $7.53 per share.

ITEM 5. OTHER INFORMATION

(c) None of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as those terms are defined in Item 408(c) of Regulation S-K) during the three months ended March 31, 2025.

ITEM 6. EXHIBITS

(a) Exhibits

Please note that the agreements included as exhibits to this Form 10-Q are included to provide information regarding their terms and are not intended to provide any other factual or disclosure information about INNOVATE Corp. or the other parties to the agreements. The agreements may contain representations and warranties by each of the parties to the applicable agreement that have been made solely for the benefit of the other parties to the applicable agreement and may not describe the actual state of affairs as of the date they were made or at any other time.

Exhibit Number	Description
31.1	Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer (filed herewith)
31.2	Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer (filed herewith)
32.1*	Section 1350 Certification of Chief Executive Officer and Chief Financial Officer (furnished herewith)
101	The following materials from the registrant’s Quarterly Report on Form 10-Q for the fiscal periods ended March 31, 2025, and March 31, 2024, formatted in extensible business reporting language (XBRL); (i) Condensed Consolidated Statements of Operations for the three months ended March 31, 2025 and 2024, (ii) Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2025 and 2024, (iii) Condensed Consolidated Balance Sheets as of March 31, 2025 and December 31, 2024, (iv) Condensed Consolidated Statements of Stockholders’ Deficit for the three months ended March 31, 2025 and 2024, (v) Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2025 and 2024, and (vi) Notes to Condensed Consolidated Financial Statements (filed herewith).
104	The cover page from the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2025, formatted in Inline XBRL (included as Exhibit 101).

*

These certifications are being "furnished" and will not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Such certifications will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.

^

Indicates management contract or compensatory plan or arrangement.

49

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

INNOVATE Corp.

By:	/S/ MICHAEL J. SENA
	Michael J. Sena Chief Financial Officer (Duly Authorized Officer and Principal Financial and Accounting Officer)
Date:	May 6, 2025

50

EX-31.1

Exhibit 31.1

CERTIFICATIONS

I, Paul K. Voigt, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of INNOVATE Corp.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: May 6, 2025	By:	/s/ Paul K. Voigt
		Name:	Paul K. Voigt
		Title:	Interim President and Chief Executive Officer
			(Principal Executive Officer)

EX-31.2

Exhibit 31.2

CERTIFICATIONS

I, Michael J. Sena, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of INNOVATE Corp.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: May 6, 2025	By:	/s/ Michael J. Sena
		Name:	Michael J. Sena
		Title:	Chief Financial Officer
			(Principal Financial and Accounting Officer)

EX-32.1

Exhibit 32.1

CERTIFICATION

Pursuant to Section 906 of the Public Company Accounting Reform and Investor Protection Act of 2002 (18 U.S.C. §1350, as adopted), Paul K. Voigt, the Interim President and Chief Executive Officer (Principal Executive Officer) of INNOVATE Corp. (the “Company”), and Michael J. Sena, the Chief Financial Officer (Principal Financial and Accounting Officer) of the Company, each hereby certifies that, to the best of his knowledge:

1. The Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2025, to which this Certification is attached as Exhibit 32 (the “Quarterly Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition of the Company at the end of the periods covered by the Quarterly Report and results of operations of the Company for the periods covered by the Quarterly Report.

Dated: May 6, 2025

/s/ Paul K. Voigt	/s/ Michael J. Sena
Paul K. Voigt	Michael J. Sena
Interim President and Chief Executive Officer (Principal Executive Officer)	Chief Financial Officer (Principal Financial and Accounting Officer)

XML

Cover Page - shares	3 Months Ended
	Mar. 31, 2025	May 02, 2025
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2025
Document Transition Report	false
Entity File Number	001-35210
Entity Registrant Name	INNOVATE CORP.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	54-1708481
Entity Address, Address Line One	295 Madison Ave.
Entity Address, Address Line Two	12th Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10017
City Area Code	212
Local Phone Number	235-2691
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		13,283,218
Amendment Flag	false
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001006837
Current Fiscal Year End Date	--12-31
Common Stock, par value $0.001 per share
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	VATE
Security Exchange Name	NYSE
Preferred Stock Purchase Rights
Document Information [Line Items]
Title of 12(b) Security	Preferred Stock Purchase Rights
No Trading Symbol	true
Security Exchange Name	NYSE

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2025	Mar. 31, 2024
Income Statement [Abstract]
Revenue		$ 274.2	$ 315.2
Cost of revenue		228.7	266.6
Gross profit		45.5	48.6
Operating expenses:
Selling, general and administrative		37.8	39.5
Depreciation and amortization		4.4	4.4
Other operating (income) loss		(0.1)	1.9
Income (loss) from operations		3.4	2.8
Other (expense) income:
Interest expense		(20.2)	(17.2)
Loss from equity investees		(5.9)	(1.2)
Other income (expense), net		4.0	(1.2)
Loss from operations before income taxes		(18.7)	(16.8)
Income tax expense		(7.1)	(3.3)
Net loss		(25.8)	(20.1)
Net loss attributable to non-controlling interests and redeemable non-controlling interests		1.3	2.7
Net loss attributable to INNOVATE Corp.		(24.5)	(17.4)
Less: Preferred dividends		0.3	0.3
Net loss attributable to common stockholders and participating preferred stockholders, basic		(24.8)	(17.7)
Net loss attributable to common stockholders and participating preferred stockholders, diluted		$ (24.8)	$ (17.7)
Loss per common share - basic (in usd per share)	[1]	$ (1.89)	$ (2.21)
Loss per common share - diluted (in usd per share)	[1]	$ (1.89)	$ (2.21)
Weighted-average common shares outstanding - basic (in shares)	[1]	13,114,804	7,865,361
Weighted-average common shares outstanding - diluted (in shares)	[1]	13,114,804	7,865,361

[1] Basic and diluted loss per common share and weighted-average common shares outstanding for the three months ended March 31, 2024, have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on August 8, 2024.

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)	Aug. 08, 2024
Income Statement [Abstract]
Reverse stock split, conversion ratio	0.1

XML

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Statement of Comprehensive Income [Abstract]
Net loss	$ (25.8)	$ (20.1)
Other comprehensive income (loss)
Foreign currency translation adjustment, net of tax	0.2	(1.1)
Other comprehensive income (loss)	0.2	(1.1)
Comprehensive loss	(25.6)	(21.2)
Comprehensive loss attributable to non-controlling interests and redeemable non-controlling interests	1.3	2.8
Comprehensive loss attributable to INNOVATE Corp.	$ (24.3)	$ (18.4)

XML

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Current assets
Cash and cash equivalents	$ 33.3	$ 48.8
Accounts receivable, net	164.5	194.0
Contract assets	135.3	106.3
Inventory	19.7	20.8
Other current assets	18.7	21.0
Total current assets	371.5	390.9
Investments	4.1	3.6
Deferred tax asset	1.6	1.6
Property, plant and equipment, net	132.6	133.6
Goodwill	126.7	126.7
Intangibles, net	170.4	172.4
Other assets	61.1	62.3
Total assets	868.0	891.1
Current liabilities
Accounts payable	104.7	84.8
Accrued liabilities	106.8	109.7
Current portion of debt obligations	523.5	162.2
Contract liabilities	95.3	109.1
Other current liabilities	17.3	17.2
Total current liabilities	847.6	483.0
Deferred tax liability	4.5	4.4
Debt obligations	139.9	500.6
Other liabilities	44.9	46.8
Total liabilities	1,036.9	1,034.8
Commitments and contingencies (Note 13)
Temporary equity
Redeemable non-controlling interest	(0.7)	(0.5)
Total temporary equity	15.4	15.6
Stockholders’ deficit
Common stock	0.0	0.0
Additional paid-in capital	350.7	350.1
Treasury stock, at cost: 163,842 and 148,800 shares, respectively	(5.5)	(5.4)
Accumulated deficit	(546.4)	(521.9)
Accumulated other comprehensive loss	(3.0)	(3.2)
Total INNOVATE Corp. stockholders’ deficit	(204.2)	(180.4)
Non-controlling interest	19.9	21.1
Total stockholders’ deficit	(184.3)	(159.3)
Total liabilities, temporary equity and stockholders’ deficit	868.0	891.1
Series A-3 , A-4 Preferred Stock
Temporary equity
Preferred stock	$ 16.1	$ 16.1

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2025	Dec. 31, 2024
Preferred stock, par value (in usd per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, par value (in usd per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	250,000,000
Common stock, shares issued (in shares)	13,447,060	13,410,179
Common stock, shares outstanding (in shares)	13,283,218	13,261,379
Treasury stock, common shares (in shares)	163,842	148,800
Series A-3 , A-4 Preferred Stock
Preferred stock, par value (in usd per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Series A-3 Preferred Stock
Preferred stock, shares issued (in shares)	6,125	6,125
Preferred stock, shares outstanding (in shares)	6,125	6,125
Series A-4 Preferred Stock
Preferred stock, shares issued (in shares)	10,000	10,000
Preferred stock, shares outstanding (in shares)	10,000	10,000

XML

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT - USD ($) $ in Millions		Total	Temporary Equity	Total INNOVATE Stockholders' (Deficit) Equity	Common Stock		Additional Paid-In Capital	Treasury Stock	Accumulated Deficit	Accumulated Comprehensive Income (Loss)	[2]	Non-Controlling Interest
Beginning balance at Dec. 31, 2023			$ 15.4
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of preferred stock in private placement			25.0
Net (loss) income			(0.2)
Ending balance at Mar. 31, 2024			38.6
Beginning balance (in shares) at Dec. 31, 2023	[1]				7,923,500
Beginning balance at Dec. 31, 2023		$ (151.7)		$ (165.5)	$ 0.0	[1]	$ 328.3	$ (5.4)	$ (487.3)	$ (1.1)		$ 13.8
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation		0.4		0.4			0.4
Preferred stock dividends		(0.3)	(0.3)	(0.3)			(0.3)
Issuance of common stock (in shares)	[1]				65,100
Rights offering, net of transaction costs		(0.5)	(1.3)	(0.5)			(0.5)
Other		(0.1)		(0.1)			(0.1)
Net loss		(19.9)		(17.4)					(17.4)			(2.5)
Other comprehensive income		(1.1)		(1.0)						(1.0)		(0.1)
Ending balance (in shares) at Mar. 31, 2024	[1]				7,988,600
Ending balance at Mar. 31, 2024		(173.2)		(184.4)	$ 0.0	[1]	327.8	(5.4)	(504.7)	(2.1)		11.2
Beginning balance at Dec. 31, 2023			15.4
Ending balance at Dec. 31, 2024		15.6	15.6
Beginning balance (in shares) at Dec. 31, 2023	[1]				7,923,500
Beginning balance at Dec. 31, 2023		$ (151.7)		(165.5)	$ 0.0	[1]	328.3	(5.4)	(487.3)	(1.1)		13.8
Ending balance (in shares) at Dec. 31, 2024		13,261,379			13,261,400	[1]
Ending balance at Dec. 31, 2024		$ (159.3)		(180.4)	$ 0.0		350.1	(5.4)	(521.9)	(3.2)		21.1
Increase (Decrease) in Temporary Equity [Roll Forward]
Net (loss) income			(0.2)
Ending balance at Mar. 31, 2025		15.4	$ 15.4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation		0.8		0.8			0.8
Shares received for taxes paid for share-based compensation (in shares)	[1]				(15,100)
Shares received for taxes paid for share-based compensation		(0.1)		(0.1)				(0.1)
Preferred stock dividends		(0.3)		(0.3)			(0.3)
Issuance of common stock (in shares)	[1]				36,900
Transactions with non-controlling interests		0.0		0.1			0.1					(0.1)
Net loss		(25.6)		(24.5)					(24.5)			(1.1)
Other comprehensive income		$ 0.2		0.2						0.2
Ending balance (in shares) at Mar. 31, 2025		13,283,218			13,283,200	[1]
Ending balance at Mar. 31, 2025		$ (184.3)		$ (204.2)	$ 0.0		$ 350.7	$ (5.5)	$ (546.4)	$ (3.0)		$ 19.9

[1] The number and amount of shares and Additional Paid-in Capital as of December 31, 2023, and as of and for three month period ended March 31, 2024, have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on August 8, 2024. Refer to Note 15. Equity and Temporary Equity.

[2] Inclusive of other comprehensive loss, foreign currency cumulative translation adjustments totaled a loss of $4.2 million and $4.5 million as of March 31, 2025 and December 31, 2024, respectively.

XML

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT (Parenthetical) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)
Other comprehensive loss	$ (0.2)
Foreign Currency Cumulative Translation Adjustments
Other comprehensive loss	$ 4.2	$ 4.5

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Cash flows from operating activities
Net loss	$ (25.8)	$ (20.1)
Adjustments to reconcile net loss to cash used in operating activities
Share-based compensation expense	0.8	0.4
Depreciation and amortization (including amounts in cost of revenue)	7.9	8.4
Amortization of deferred financing costs and debt discount	5.6	1.7
Net loss on extinguishment of debt	0.0	2.2
Loss from equity investees	5.9	1.2
Step-up of equity method investments and unrealized gains on marketable securities	(4.6)	0.0
Deferred income tax expense	0.1	0.1
Other operating activities, net	0.3	1.2
Changes in assets and liabilities:
Accounts receivable	29.2	9.0
Contract assets	(29.0)	36.4
Other current assets	1.4	0.6
Inventory	1.1	0.6
Other assets	2.4	2.8
Accounts payable	19.3	(20.0)
Accrued liabilities	(10.9)	(20.6)
Contract liabilities	(13.8)	(28.1)
Other current liabilities	0.0	0.3
Other liabilities	(4.0)	(1.5)
Cash used in operating activities	(14.1)	(25.4)
Cash flows from investing activities
Purchase of property, plant and equipment	(4.7)	(5.6)
Proceeds from disposal of property, plant and equipment	1.1	3.1
Loans to equity method investee	0.0	(1.2)
Purchase of investments	(0.3)	0.0
Other investing activities	0.0	0.4
Cash used in investing activities	(3.9)	(3.3)
Cash flows from financing activities
Proceeds from issuance of preferred stock	0.0	25.0
Proceeds from lines of credit	20.0	0.0
Payments on lines of credit	(15.0)	(30.0)
Principal payments for other debt obligations	(2.2)	(7.6)
Dividend payments	(0.3)	(0.3)
Other financing activities	(0.1)	0.0
Cash provided by (used in) financing activities	2.4	(12.9)
Effects of exchange rate changes on cash, cash equivalents and restricted cash	0.2	(0.8)
Net decrease in cash and cash equivalents, including restricted cash	(15.4)	(42.4)
Cash, cash equivalents and restricted cash, beginning of period	49.3	82.3
Cash, cash equivalents and restricted cash, end of period	$ 33.9	$ 39.9

XML

Organization and Business

3 Months Ended

Mar. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Business

1. Organization and Business

INNOVATE Corp. ("INNOVATE" and, together with its consolidated subsidiaries, the "Company", "we" and "our") is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments. The Company seeks to grow these businesses so that they can generate long-term sustainable free cash flow and attractive returns in order to maximize value for all stakeholders. While the Company generally intends to acquire controlling equity interests in its operating subsidiaries, the Company may invest to a limited extent in a variety of non-controlling equity interest positions or debt instruments. The Company’s shares of common stock trade on the New York Stock Exchange ("NYSE") under the symbol "VATE".

The Company currently has three reportable segments, plus our Other segment, based on management’s organization of the enterprise: Infrastructure, Life Sciences, Spectrum, and Other which includes businesses that do not meet the separately reportable segment thresholds.

1.The Company's Infrastructure segment is comprised of DBM Global Inc. ("DBMG") and its wholly-owned subsidiaries. DBMG is a fully integrated industrial construction, structural steel and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services and also fabricates trusses and girders and specializes in the fabrication and erection of large-diameter water pipe and water storage tanks, as well as 3-D Building Information Modeling (“BIM”) and detailing. DBMG provides these services on commercial, industrial, and infrastructure construction projects such as high- and low-rise buildings and office complexes, hotels and casinos, convention centers, sports arenas and stadiums, shopping malls, hospitals, dams, bridges, mines, metal processing, refineries, pulp and paper mills and power plants. Through GrayWolf Industrial Inc. ("GrayWolf"), DBMG provides integrated solutions for digital engineering, modeling and detailing, construction, heavy equipment installation and facility services including maintenance, repair, and installation to a diverse range of end markets. Through Aitken Manufacturing, Inc., DBMG manufactures pollution control scrubbers, tunnel liners, pressure vessels, strainers, filters, separators and a variety of customized products. Through Banker Steel, a division of Schuff Steel Company, DBMG provides full-service fabricated structural steel and erection services primarily for the U.S. East Coast and Southeast commercial and industrial construction markets, in addition to full design-assist services. The Company maintains a 91.2% controlling interest in DBMG.

2.The Company's Life Sciences segment is comprised of Pansend Life Sciences, LLC ("Pansend"), its subsidiaries and its equity investments. Pansend maintains a controlling interest of 80.0% in Genovel Orthopedics, Inc. ("Genovel"), which seeks to develop products to treat early osteoarthritis of the knee, and also has a controlling interest of 81.0% (81.4% as of December 31, 2024) in R2 Technologies, Inc. ("R2 Technologies"), which develops aesthetic and medical technologies for the skin. Pansend also invests in other early stage or developmental stage healthcare companies and, as of March 31, 2025, had a 44.7% interest (45.9% as of December 31, 2024) in MediBeacon Inc. ("MediBeacon"), a medical technology company specializing in the advances of fluorescent tracer agents and transdermal measurement, potentially enabling real-time, direct monitoring of kidney function, and maintained a 1.6% fully diluted interest in Triple Ring Technologies, Inc. ("Triple Ring"), a science and technology co-development company, and a 20.1% interest in Scaled Cell Solutions, Inc. ("Scaled Cell"), an immunotherapy company developing a novel autologous cell therapy system to potentially improve current CAR-T treatments.

3.The Company's Spectrum segment is comprised of HC2 Broadcasting Holdings Inc. ("Broadcasting") and its subsidiaries. Broadcasting strategically acquires and operates over-the-air broadcasting stations across the United States. The Company maintains a 98.0% controlling interest in Broadcasting and maintains a controlling interest of approximately 69.2%, inclusive of 2.8% proxy rights from minority holders of DTV America Corporation ("DTV"). On a fully diluted basis, the Company would have an 85.8% controlling interest in Broadcasting.

4.The Company's Other segment represents all other businesses or investments that do not meet the definition of a segment individually or in the aggregate. The Other segment primarily includes legacy businesses or holding companies such as the holding company of the Company's former Marine Services segment, Global Marine Holdings, LLC ("GMH") in which the Company had a 72.8% controlling interest until its dissolution on December 13, 2024, and TIC Holdco, Inc. ("TIC"), which was dissolved on May 23, 2024.

XML

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2025

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of the Company, its wholly owned subsidiaries and all other subsidiaries over which the Company exerts control. All intercompany profits, transactions and balances have been eliminated in consolidation. The remaining interests not owned by the Company are presented as a non-controlling interest component of total equity.

Basis of Presentation

The accompanying interim unaudited Condensed Consolidated Financial Statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). The financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair statement of such information. All such adjustments are of a normal recurring nature. Certain information and note disclosures, including a description of significant accounting policies normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"), have been condensed or omitted in these interim unaudited Condensed Consolidated Financial Statements pursuant to such rules and regulations.

These interim unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Company’s annual audited Consolidated Financial Statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025. The results of operations for the three months ended March 31, 2025, are not necessarily indicative of the results for any subsequent periods or the entire fiscal year ending December 31, 2025. Certain prior amounts have been reclassified or combined to conform to the current year presentation.

Where applicable, information presented within these Condensed Consolidated Financial Statements has been retroactively adjusted to reflect the 1-for-10 reverse stock split of the Company's issued and outstanding common stock that occurred in August 2024 (the “Reverse Stock Split”). Refer to Note 15. Equity and Temporary Equity for additional information.

Going Concern

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared assuming that the Company will continue as a going concern. However, as of the date of these financial statements, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.

The principal conditions leading to this conclusion are the upcoming maturities and covenants of the Company's Non-Operating Corporate segment's Senior Secured Notes, other current debt at the Non-Operating Corporate segment and the Company's subsidiaries, as well as from certain cross-default provisions in the Company's Senior Secured Notes. Based on these conditions, the Company may not be able to meet its obligations at maturity and comply with certain cross-default provisions under the Senior Secured Notes over the next twelve months.

Management has evaluated the significance of these conditions in relation to the Company's ability to meet its obligations. The potential inability to refinance or extend the maturity of the aforementioned current debt, or to obtain additional financing, raises substantial doubt about the Company's ability to continue as a going concern.

The Company plans to alleviate these conditions through various initiatives it is currently exploring, including refinancing the debt at the Non-Operating Corporate segment and its subsidiaries, pursuing asset sales, and raising additional capital. However, there can be no assurance that the Company will have the ability to raise additional capital when needed, be successful in any asset sales, or refinance its existing debt, on attractive terms, or at all nor any assurances that lenders will provide additional extensions, waivers or amendments in the event of future non-compliance with the Company’s debt covenants or other possible events of default. Further, there can be no assurance that the Company will be able to execute a reduction, extension, or refinancing of the debt, or that the terms of any replacement financing would be as favorable as the terms of the debt prior to the maturity date. There can be no assurance that these plans will be successfully implemented or that they will mitigate the conditions that raise substantial doubt about the Company's ability to continue as a going concern.

These unaudited Condensed Consolidated Financial Statements do not include any adjustments to the carrying amounts and classification of assets, liabilities, or expenses that may result if the Company is unable to continue as a going concern.

Use of Estimates and Assumptions

The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and various disclosures within these Condensed Consolidated Financial Statements as of the date of the Condensed Consolidated Financial Statements and the reported amounts of net revenue and expenses during the reporting period. These estimates are based on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Actual results may differ from these estimates.

Recent Accounting Pronouncements

Accounting Pronouncements Issued But Pending Adoption

On November 26, 2024, the FASB issued ASU 2024-04, Debt - Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments ("ASU 2024-04"). The amendments in this update affect entities that settle convertible debt instruments for which the conversion privileges were changed to induce conversion. The amendments clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. ASU 2024-04 is effective for fiscal years beginning after December 15, 2025, and interim periods within those annual reporting periods. Entities may apply the amendments retrospectively for all prior periods presented in the financial statements or prospectively. The Company expects that it will apply the new guidance prospectively and is currently evaluating the potential effect of this ASU on future transactions and the Company’s Condensed Consolidated Financial Statements.

On November 4, 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03"). The amendments in this ASU require disclosure, in the notes to financial statements, of specified information about certain costs and expenses, including the total amount of selling expenses incurred in the period and an entity's definition of selling expenses. ASU 2024-03, with effective dates as clarified by ASU 2025-01 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating this ASU, which will only have an effect on the disclosures within the Company’s Condensed Consolidated Financial Statements.

On January 1, 2025, ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), became effective and requires, among other things, greater disaggregation of information in the rate reconciliation and for paid income taxes to be disaggregated by jurisdiction. ASU 2023-09 affects financial statement disclosure only, which is not required until year end 2025 and, as a result, does not affect our results of operations or financial condition.

Subsequent Events

ASC 855, Subsequent Events requires the Company to evaluate events that occur after the balance sheet date as of which the financial statements are issued, and to determine whether adjustments to or additional disclosures in the financial statements are necessary. Refer to Note 21. Subsequent Events.

XML

Revenue and Contracts in Process

3 Months Ended

Mar. 31, 2025

Revenue from Contract with Customer [Abstract]

Revenue and Contracts in Process

3. Revenue and Contracts in Process

Revenue from contracts with customers consisted of the following (in millions):

	Three Months Ended March 31,
	2025		2024
Infrastructure	$	264.9	$	307.9
Life Sciences	3.1		1.0
Spectrum	6.2		6.3
Total revenue	$	274.2	$	315.2

Accounts receivables, net, from contracts with customers consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Infrastructure	$	156.3	$	184.8
Life Sciences	2.1		1.5
Spectrum	2.0		1.9
Total accounts receivables with customers	$	160.4	$	188.2

As of January 1, 2024, accounts receivable, net, from contracts with customers totaled $273.2 million.

Infrastructure Segment

The following table disaggregates DBMG's revenue by market (in millions):

	Three Months Ended March 31,
	2025		2024
Industrial	$	74.6	$	84.1
Commercial	53.8		77.3
Healthcare	52.0		34.3
Transportation	44.7		100.4
Government	24.8		2.7
Leisure	6.6		1.0
Convention	5.9		5.5
Energy	1.9		2.2
Total revenue from contracts with customers	$	264.3	$	307.5
Other revenue	0.6		0.4
Total Infrastructure segment revenue	$	264.9	$	307.9

Contract assets and contract liabilities consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Costs incurred on contracts in progress	$	1,245.9	$	1,435.2
Estimated earnings	97.5		75.8
Contract revenue earned on uncompleted contracts	1,343.4		1,511.0
Less: progress billings	1,303.4		1,513.8
	$	40.0	$	(2.8)
The above is included in the accompanying Condensed Consolidated Balance Sheets under the following line items:
Contract assets	$	135.3	$	106.3
Contract liabilities	(95.3)		(109.1)
	$	40.0	$	(2.8)

	March 31, 2025		December 31, 2024
Cost in excess of billings and estimated earnings	$	71.2	$	50.8
Conditional retainage	64.1		55.5
Contract assets	$	135.3	$	106.3
Billings in excess of costs and estimated earnings	$	(127.4)	$	(147.7)
Conditional retainage	32.1		38.6
Contract liabilities	$	(95.3)	$	(109.1)

As of January 1, 2024, contract assets were $118.6 million and contract liabilities were $153.5 million.

The change in contract assets during the three months ended March 31, 2025 and 2024, is a result of the recording of $74.6 million and $15.7 million, respectively, of contract assets driven by new commercial projects, partially offset by $45.6 million and $52.1 million, respectively, of contract assets transferred to receivables from contract assets recognized at the beginning of the year, including from certain large projects completed or nearing completion and the corresponding billing of amounts previously recorded as contract assets.

The change in contract liabilities during the three months ended March 31, 2025 and 2024, is a result of the recording of periodic contract liabilities of $54.0 million and $62.9 million, respectively, driven largely by new commercial projects, partially offset by revenue recognized that was included in the contract liability balance at the beginning of the year in the amount of $67.8 million and $91.0 million, respectively, including from certain large projects completed or nearing completion.

Transaction Price Allocated to Remaining Unsatisfied Performance Obligations

As of March 31, 2025, the transaction price allocated to remaining unsatisfied performance obligations consisted of the following (in millions):

	Within One Year		Within Five Years		Total
Commercial	$	333.8	$	107.6	$	441.4
Industrial	250.8		34.7		285.5
Healthcare	176.2		70.9		247.1
Transportation	114.6		78.8		193.4
Government	162.0		5.3		167.3
Leisure	17.0		1.9		18.9
Convention	2.6		—		2.6
Energy	1.6		—		1.6
Remaining unsatisfied performance obligations	$	1,058.6	$	299.2	$	1,357.8

DBMG's remaining unsatisfied performance obligations increase with awards of new contracts and decrease as it performs work and recognizes revenue on existing contracts. DBMG includes a project within its remaining unsatisfied performance obligations at such time the project is awarded and agreement on contract terms has been reached. DBMG's remaining unsatisfied performance obligations include amounts related to contracts for which a fixed price contract value is not assigned when a reasonable estimate of total transaction price can be made. DBMG expects to recognize this revenue approximately within the next 2.0 years.

Remaining unsatisfied performance obligations include unrecognized revenues to be realized from uncompleted construction contracts. Although many of DBMG's contracts are subject to cancellation at the election of its customers, in accordance with industry practice, DBMG does not limit the amount of unrecognized revenue included within its remaining unsatisfied performance obligations due to the inherent substantial economic penalty that would be incurred by its customers upon cancellation.

Life Sciences Segment

The following table disaggregates the Life Sciences segment's revenue by type (in millions):

	Three Months Ended March 31,
	2025		2024
Systems and consumables revenue	$	3.1	$	1.0
Total Life Sciences segment revenue	$	3.1	$	1.0

Spectrum Segment

The following table disaggregates the Spectrum segment's revenue by type (in millions):

	Three Months Ended March 31,
	2025		2024
Broadcast station	$	6.2	$	6.3
Total Spectrum segment revenue	$	6.2	$	6.3

Transaction Price Allocated to Remaining Unsatisfied Performance Obligations

As of March 31, 2025, the transaction price allocated to remaining unsatisfied performance obligations consisted of $14.6 million of broadcast station revenues of which $8.8 million is expected to be recognized within one year and $5.8 million is expected to be recognized within the next 3 years.

XML

Accounts Receivable, Net

3 Months Ended

Mar. 31, 2025

Receivables [Abstract]

Accounts Receivable, Net

4. Accounts Receivable, Net

Accounts receivable, net, consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Contracts in progress	$	156.3	$	184.9
Unbilled retentions	0.1		0.1
Trade receivables	4.1		3.3
Other receivables	4.1		5.8
Allowance for expected credit losses	(0.1)		(0.1)
Total	$	164.5	$	194.0

As of January 1, 2024, accounts receivable, net totaled $278.4 million.

XML

Inventory

3 Months Ended

Mar. 31, 2025

Inventory Disclosure [Abstract]

Inventory

5. Inventory

Inventory consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Raw materials and consumables	$	18.5	$	19.6
Work in process	0.4		0.4
Finished goods	0.8		0.8
Total inventory	$	19.7	$	20.8

XML

Investments

3 Months Ended

Mar. 31, 2025

Investments, Debt and Equity Securities [Abstract]

Investments

6. Investments

The carrying values of the Company's investments, by category, were as follows (in millions):

Date	Equity Method (1)		Fair Value (2)		Measurement Alternative (3)		Total
March 31, 2025	$	0.9	$	2.3	$	0.9	$	4.1
December 31, 2024	$	0.9	$	1.8	$	0.9	$	3.6

(1) The Company's equity method investments were comprised of MediBeacon and Scaled Cell as of both March 31, 2025 and December 31, 2024.

(2) The Company's fair value investments in common stock are comprised of marketable equity securities in two publicly traded companies that were purchased in October 2024 and March 2025.

(3) The Company's measurement alternative method investment was comprised of Triple Ring as of both March 31, 2025 and December 31, 2024.

The Company's share of net losses from its equity method investments was $5.9 million and $1.2 million for the three months ended March 31, 2025 and 2024, respectively.

MediBeacon

Pansend accounts for its preferred stock investment in MediBeacon under the equity method of accounting, inclusive of any fixed maturity securities (notes) issued by MediBeacon to Pansend.

On January 17, 2025, MediBeacon received approval from the U.S. Food and Drug Administration ("FDA") for its Transdermal GFR Measurement System ("TGFR"). Pursuant to the terms of MediBeacon's convertible notes, upon the FDA approval, Pansend's convertible notes of $11.4 million and the related accrued interest of $1.5 million, together totaling $12.9 million, were converted into Series 3 Preferred Stock. In addition, pursuant to its amended commercial partnership with Huadong and, as a result of FDA approval, a $7.5 million milestone payment from Huadong Medicine Co. Ltd ("Huadong"), a publicly traded company on the Shenzhen Stock Exchange, to MediBeacon for MediBeacon preferred stock was received in the first quarter of 2025. As a result of these transactions, Pansend's ownership in MediBeacon decreased from 45.9% prior to the transactions to 44.7% subsequent to the transactions. On a fully diluted basis, Pansend's ownership in MediBeacon decreased from 40.1% to 39.7%. As a result of these transactions, Pansend recognized a step-up gain of $4.4 million in Other (expense) income, net in the Condensed Consolidated Statements of Operations for the three months ended March 31, 2025, which increased Pansend's carrying amount of its investment in MediBeacon. Concurrently, Pansend recognized equity method losses of $5.9 million, driven by the $4.4 million step-up gain and $1.5 million of interest from the conversion of the convertible notes, which were previously unrecognized because Pansend's carrying amount of its investment in MediBeacon had been previously reduced to zero.

MediBeacon's total outstanding principal amount of notes due to Pansend was $0.5 million and $12.0 million, as of March 31, 2025, and December 31, 2024, respectively. Interest income earned by Pansend from the MediBeacon notes totaled $0.1 million and $0.3 million for the three months ended March 31, 2025 and 2024, respectively, and the related accrued interest receivable was $0.3 million and $1.7 million, as of March 31, 2025 and December 31, 2024, respectively.

As of March 31, 2025, Pansend's carrying amount of its investment in MediBeacon remained at zero, inclusive of the $0.5 million in secured promissory notes which were offset against recognized equity method losses, and Pansend has cumulative unrecognized equity method losses relating to MediBeacon of $15.4 million.

Marketable Securities

In October 2024, the Company purchased common shares in the open market of a publicly traded company for approximately $2.0 million, which represents less than 1% of the total outstanding common stock of the issuer. In March 2025, the Company purchased common shares in the open market of another publicly traded company for $0.3 million, which represents less than 1% of the total outstanding equity of the issuer. These securities are remeasured at fair value each reporting period using the externally quoted market prices, Fair Value Level 1 inputs. For the three months ended March 31, 2025, unrealized fair value gains of $0.2 million related to these securities were included in Other income (expense), net in the Condensed Consolidated Financial Statements.

XML

Property, Plant and Equipment, Net

3 Months Ended

Mar. 31, 2025

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment, Net

7. Property, Plant and Equipment, Net

Property, plant and equipment, net, ("PP&E") consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Equipment, furniture and fixtures, and software	$	212.6	$	211.0
Building and leasehold improvements	36.9		36.8
Land	18.6		18.6
Construction in progress	10.9		8.0
Plant and transportation equipment	7.4		7.4
	$	286.4	$	281.8
Less: Accumulated depreciation	153.8		148.2
Total	$	132.6	$	133.6

Depreciation expense was $5.9 million and $6.5 million for the three months ended March 31, 2025 and 2024, respectively. These amounts included $3.5 million and $4.0 million of depreciation expense recognized within cost of revenue for the three months ended March 31, 2025 and 2024, respectively.

As of March 31, 2025 and December 31, 2024, the net book value of equipment held under finance leases included in PP&E was $0.1 million and $0.5 million, respectively. As of both March 31, 2025 and December 31, 2024, the gross value of capitalized internal-use software included in PP&E was $20.7 million, and the net book value as of March 31, 2025 and December 31, 2024, was $9.0 million and $9.8 million, respectively.

Assets held-for-sale are included within Other current assets in the Condensed Consolidated Balance Sheets. As of March 31, 2025, there were $6.0 million in assets held-for-sale, which primarily consisted of one building, equipment and land and the associated improvements at the Company's Infrastructure segment. As of December 31, 2024, there were $7.0 million in assets held-for-sale, which primarily consisted of one building, equipment and land and the associated building improvements at the Company's Infrastructure segment.

XML

Goodwill and Intangibles, Net

3 Months Ended

Mar. 31, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangibles, Net

8. Goodwill and Intangibles, Net

Goodwill

The carrying amounts of goodwill by segment were as follows (in millions):

	Infrastructure		Spectrum		Total
Balance as of December 31, 2024	$	105.3	$	21.4	$	126.7
Balance as of March 31, 2025	$	105.3	$	21.4	$	126.7

Indefinite-lived Intangible Assets

The carrying amounts of indefinite-lived intangible assets were as follows (in millions):

	March 31, 2025		December 31, 2024
FCC licenses	$	107.7	$	107.7
Total	$	107.7	$	107.7

Definite Lived Intangible Assets

The gross carrying amounts and accumulated amortization of definite lived intangible assets by major intangible asset class were as follows (in millions):

	Weighted-Average Original Useful Life	March 31, 2025
		Gross Carrying Amount		Accumulated Amortization			Net
Trade names	15 years	$	25.1		$	(11.4)	$	13.7
Customer relationships and contracts	11 years	87.4			(50.4)		37.0
Channel sharing arrangements	35 years	12.6			(2.3)		10.3
Other	10 years	3.7			(2.0)		1.7
Total		$	128.8		$	(66.1)	$	62.7

	Weighted-Average Original Useful Life	December 31, 2024
		Gross Carrying Amount		Accumulated Amortization			Net
Trade names	15 years	$	25.1		$	(11.0)	$	14.1
Customer relationships and contracts	11 years	87.4			(49.1)		38.3
Channel sharing arrangements	35 years	12.6			(2.2)		10.4
Other	10 years	3.9			(2.0)		1.9
Total		$	129.0		$	(64.3)	$	64.7

Amortization expense for definite lived intangible assets was $2.0 million and $1.9 million for the three months ended March 31, 2025 and 2024, respectively. Amortization expense is included in Depreciation and amortization in the Condensed Consolidated Statements of Operations.

XML

Leases

3 Months Ended

Mar. 31, 2025

Leases [Abstract]

Leases

9. Leases

The Company has entered into operating leases for land, office space, and certain Company vehicles and equipment and has entered into finance leases for certain Company vehicles and equipment. The leases will expire between 2025 and 2045. Right-of-use lease assets and lease liabilities consisted of the following (in millions):

	Balance Sheet Location	March 31, 2025		December 31, 2024
Right-of-use assets:
Operating lease	Other assets (non-current)	$	53.0	$	53.7
Finance lease	Property, plant and equipment, net	0.1		0.5
Total right-of-use assets		$	53.1	$	54.2
Lease liabilities:
Current portion of operating lease	Other current liabilities	$	12.9	$	12.9
Non-current portion of operating lease	Other liabilities	41.9		43.5
Finance lease	Debt obligations	0.2		0.6
Total lease liabilities		$	55.0	$	57.0

The following table summarizes the components of lease expense (in millions):

	Three Months Ended March 31,
	2025		2024
Finance lease cost:
Amortization of right-of-use assets	$	0.1	$	0.1
Net finance lease cost	0.1		0.1
Operating lease cost	4.2		4.5
Variable lease cost	0.2		0.1
Sublease income	—		(0.2)
Total non-current lease cost	4.5		4.5
Short-term lease costs	8.0		7.2
Total lease cost	$	12.5	$	11.7

Cash flow information related to leases is as follows (in millions):

	Three Months Ended March 31,
	2025		2024
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	5.2	$	5.0
Financing cash flows for finance leases	$	0.1	$	0.1
Right-of-use assets obtained in exchange for new lease liabilities:
Operating leases	$	2.5	$	2.6

The weighted-average remaining lease term and the weighted-average discount rate for the Company's leases were as follows:

	March 31, 2025		December 31, 2024
Weighted-average remaining lease term (years) - operating leases	7.3		7.4
Weighted-average remaining lease term (years) - finance leases	2.6		2.7
Weighted-average discount rate - operating leases	6.2	%	6.1	%
Weighted-average discount rate - finance leases	5.0	%	5.3	%

Future minimum lease commitments (undiscounted) as of March 31, 2025, were as follows (in millions):

	Operating Leases		Finance Leases
2025 (remaining period)	$	11.4	$	0.1
2026	12.7		0.1
2027	10.0		—
2028	7.4		—
2029	4.7		—
Thereafter	21.4		—
Total future minimum lease payments	67.6		0.2
Less: amounts representing interest	(12.8)		—
Total lease liability	$	54.8	$	0.2

On May 1, 2024, a subsidiary of DBMG amended the termination date of three property leases that had an original expiry date of March 31, 2031. In exchange, and as an inducement for DBMG to early terminate, the landlord agreed to pay DBMG $12.0 million in surrender fees in three equal installments, contingent on timely vacate and inspection milestones, of which DBMG received $4.0 million in surrender fees in 2024, with the remaining two $4.0 million payments due to DBMG due within five business days of the vacate dates in 2025 and 2027, respectively. After final surrender of the properties, DBMG will have no further obligations under these leases.

Leases

9. Leases

The Company has entered into operating leases for land, office space, and certain Company vehicles and equipment and has entered into finance leases for certain Company vehicles and equipment. The leases will expire between 2025 and 2045. Right-of-use lease assets and lease liabilities consisted of the following (in millions):

	Balance Sheet Location	March 31, 2025		December 31, 2024
Right-of-use assets:
Operating lease	Other assets (non-current)	$	53.0	$	53.7
Finance lease	Property, plant and equipment, net	0.1		0.5
Total right-of-use assets		$	53.1	$	54.2
Lease liabilities:
Current portion of operating lease	Other current liabilities	$	12.9	$	12.9
Non-current portion of operating lease	Other liabilities	41.9		43.5
Finance lease	Debt obligations	0.2		0.6
Total lease liabilities		$	55.0	$	57.0

The following table summarizes the components of lease expense (in millions):

	Three Months Ended March 31,
	2025		2024
Finance lease cost:
Amortization of right-of-use assets	$	0.1	$	0.1
Net finance lease cost	0.1		0.1
Operating lease cost	4.2		4.5
Variable lease cost	0.2		0.1
Sublease income	—		(0.2)
Total non-current lease cost	4.5		4.5
Short-term lease costs	8.0		7.2
Total lease cost	$	12.5	$	11.7

Cash flow information related to leases is as follows (in millions):

	Three Months Ended March 31,
	2025		2024
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	5.2	$	5.0
Financing cash flows for finance leases	$	0.1	$	0.1
Right-of-use assets obtained in exchange for new lease liabilities:
Operating leases	$	2.5	$	2.6

The weighted-average remaining lease term and the weighted-average discount rate for the Company's leases were as follows:

	March 31, 2025		December 31, 2024
Weighted-average remaining lease term (years) - operating leases	7.3		7.4
Weighted-average remaining lease term (years) - finance leases	2.6		2.7
Weighted-average discount rate - operating leases	6.2	%	6.1	%
Weighted-average discount rate - finance leases	5.0	%	5.3	%

Future minimum lease commitments (undiscounted) as of March 31, 2025, were as follows (in millions):

	Operating Leases		Finance Leases
2025 (remaining period)	$	11.4	$	0.1
2026	12.7		0.1
2027	10.0		—
2028	7.4		—
2029	4.7		—
Thereafter	21.4		—
Total future minimum lease payments	67.6		0.2
Less: amounts representing interest	(12.8)		—
Total lease liability	$	54.8	$	0.2

On May 1, 2024, a subsidiary of DBMG amended the termination date of three property leases that had an original expiry date of March 31, 2031. In exchange, and as an inducement for DBMG to early terminate, the landlord agreed to pay DBMG $12.0 million in surrender fees in three equal installments, contingent on timely vacate and inspection milestones, of which DBMG received $4.0 million in surrender fees in 2024, with the remaining two $4.0 million payments due to DBMG due within five business days of the vacate dates in 2025 and 2027, respectively. After final surrender of the properties, DBMG will have no further obligations under these leases.

XML

Other Assets, Accrued Liabilities and Other Liabilities

3 Months Ended

Mar. 31, 2025

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Other Assets, Accrued Liabilities and Other Liabilities

10. Other Assets, Accrued Liabilities and Other Liabilities

Other Current Assets

Other current assets consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Prepaid assets	$	9.8	$	10.9
Assets held-for-sale	6.0		7.0
Income tax receivable	0.5		0.6
Other	2.4		2.5
Total other current assets	$	18.7	$	21.0

Other Assets

Other assets, which are reflected within non-current assets in the Condensed Consolidated Balance Sheets, consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Right-of-use assets	$	53.0	$	53.7
Restricted cash - non-current	0.6		0.5
Other	7.5		8.1
Total other assets	$	61.1	$	62.3

Accrued Liabilities

Accrued liabilities consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Accrued expenses	$	12.3	$	13.4
Accrued payroll and employee benefits	22.9		34.1
Accrued interest and exit fees (current portion)	64.3		61.0
Accrued sales and use taxes	0.3		0.4
Accrued income taxes	7.0		0.8
Total accrued liabilities	$	106.8	$	109.7

Other Current Liabilities

Other current liabilities consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Operating lease liability, current portion	$	12.9	$	12.9
Other	4.4		4.3
Total other current liabilities	$	17.3	$	17.2

Other Liabilities

Other liabilities, which are reflected within non-current liabilities in the Condensed Consolidated Balance Sheets, consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Operating lease liability, net of current portion	$	41.9	$	43.5
Accrued interest (non-current portion)	—		0.7
Other	3.0		2.6
Total other liabilities	$	44.9	$	46.8

XML

Debt Obligations

3 Months Ended

Mar. 31, 2025

Debt Disclosure [Abstract]

Debt Obligations

11. Debt Obligations

Debt obligations, including finance lease obligations, consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Infrastructure
PRIME minus 1.00% Line of Credit due 2025	$	50.0	$	45.0
3.25% Term Loan due 2026	72.8		74.6
PRIME minus 1.00% Term Loan due 2026	24.2		24.5
Obligations under finance leases	0.2		0.6
Total Infrastructure	$	147.2	$	144.7
Spectrum
8.50% Note due 2025	$	19.3	$	19.3
11.45% Notes due 2025	50.4		50.4
Total Spectrum	$	69.7	$	69.7
Life Sciences
20.00% Notes due 2025	$	25.2	24.0
Total Life Sciences	$	25.2	$	24.0
Non-Operating Corporate
8.50% Senior Secured Notes due 2026	$	330.0	$	330.0
7.50% Convertible Senior Notes due 2026	48.9		48.9
SOFR plus 5.75% Line of Credit due 2025	20.0		20.0
CGIC Unsecured Note due 2026	31.0		31.0
Total Non-Operating Corporate	$	429.9	$	429.9
Total outstanding principal	$	672.0	$	668.3
Unamortized issuance discount, issuance premium, and deferred financing costs	(8.6)		(5.5)
Less: current portion of debt obligations	(523.5)		(162.2)
Debt obligations, net of current portion	$	139.9	$	500.6

As of March 31, 2025, estimated future aggregate finance lease and debt payments, including interest, were as follows (in millions):

	Finance Leases		Debt		Total
2025 (remaining period) (1)	$	0.1	$	234.5	$	234.6
2026	0.1		507.6		507.7
Total minimum principal and interest payments	0.2		742.1		742.3
Less: Amount representing interest (1)	—		(70.3)		(70.3)
Total aggregate finance lease and debt payments	$	0.2	$	671.8	$	672.0

(1) Excludes exit fees for Spectrum and R2 Technologies.

The interest rates on finance leases ranged from approximately 3.0% to 6.8%.

Infrastructure

DBMG has a $135.0 million Revolving Line with UMB that bears interest at a prime rate minus a spread with an interest rate floor of 4.25%. The Revolving Line with UMB matures on August 15, 2025. The outstanding balance was $50.0 million and $45.0 million, as of March 31, 2025 and December 31, 2024, respectively, and availability for revolving loans was $84.9 million and $89.9 million as of March 31, 2025 and December 31, 2024, respectively. Interest is paid monthly, and the effective interest rate on the Revolving Line with UMB was 6.72% and 6.98% as of March 31, 2025 and December 31, 2024, respectively. The Revolving Line with UMB also includes a commitment fee equal to 0.25% per annum times the average daily unused availability under the line.

DBMG also has a $72.8 million 3.25% term loan due 2026 (the "3.25% UMB Term Loan"), which matures May 31, 2026, and bears interest, which is paid monthly, at an annual rate of 3.25% with an effective interest rate of 3.3%.

On June 28, 2024, DBM and UMB entered into the Third Amendment to the UMB Credit Agreement, which added an incremental separate term loan of $25.0 million to the existing credit facility ("PRIME minus 1.00% Term Loan due 2026"), with the same interest rate as the Revolving Line with UMB and the same maturity date as the initial 3.25% UMB Term Loan. Principal payments and interest are paid monthly.

The UMB term loans and Revolving Line with UMB associated with the Infrastructure segment contain customary restrictive and financial covenants related to debt levels and performance, including a Fixed Charge Coverage Ratio covenant, as defined in their agreements.

DBMG is in compliance with its debt covenants as of March 31, 2025.

Spectrum

The maturity date of Spectrum's 8.50% and 11.45% Notes is August 15, 2025, as amended in November 2023. As a result of amendments to extend the maturity date during the year ended December 31, 2023, additional exit fees of $8.3 million were incurred. The exit fees associated with the notes, which are payable on the earlier of maturity or repayment of the principal, were recorded as original issue discount and are being amortized over the remaining life of the notes, which is assumed to be the maturity date. A corresponding liability for the total exit fees of $15.9 million is reflected within Accrued Liabilities in the Condensed Consolidated Balance Sheets as of both March 31, 2025 and December 31, 2024. Interest is capitalized and payable upon maturity of the notes, of which there was $22.4 million and $20.5 million of accrued but unpaid interest as of March 31, 2025 and December 31, 2024, respectively. As of March 31, 2025 and December 31, 2024, the weighted-average effective interest rate on the notes, as amended, was 22.9% and 22.8% per annum, respectively.

During November 2023, concurrently with Broadcasting's execution of the Ninth Amendment to Secured Notes, which among other things extended the maturity of the notes, INNOVATE entered into a related side letter with the lenders, whereby INNOVATE agreed to utilize proceeds from a sale of certain of its existing operations, as allowable under the Company's current agreements and indentures and after all other required payments have been made, for repayment of a portion of Broadcasting's Senior Secured Notes. Assuming there are sufficient proceeds remaining after such repayment, an additional $2.0 million fee is payable for payments made after November 9, 2024, and in exchange for the additional $2.0 million fee, the institutional investors will return their equity interests in HC2 Broadcasting Holdings, Inc. and their equity interests in DTV America. The lenders hold warrants to purchase 145,825 shares of common stock of HC2 Broadcasting Holdings, Inc which can be exercised at any time until August 2027 at an exercise price of $0.01 per share.

Life Sciences

Effective January 31, 2024, a 20% note was entered into with Lancer Capital, which replaced the prior 20% note. The new note had an aggregate original principal amount of $20.0 million, which was comprised of all prior outstanding principal amounts of $17.4 million and unpaid accrued interest of $2.6 million which was capitalized into the new principal balance. The 20% $20.0 million note also included an exit fee, which would be 10.5% of the principal amount being repaid as of April 30, 2024. As a result of the addition of the exit fee effective January 31, 2024, the transaction was determined to be an extinguishment of debt under ASC 470-50, Debt - Modifications and Extinguishments ("ASC 470-50"), and the $2.2 million exit fee payable to the existing lender was included as a loss on debt extinguishment within Other income (expense), net on the Condensed Consolidated Statement of Operations for the three months ended March 31, 2024. The original maturity date of the 20% $20.0 million note was April 30, 2024, or within five business days of the date on which R2 Technologies receives an aggregate $20.0 million from the consummation of a debt or equity financing or has a change in control, as defined in the agreement, with an optional prepayment of the entire then-outstanding and unpaid principal and accrued interest upon five-days written notice to Lancer Capital. Effective May 17, 2024, the maturity date of the note was extended to December 31, 2024, and the exit fees were amended. The May 17, 2024, amendment was determined to be a modification of debt under ASC 470-50 as the terms of the debt were not determined to be substantially different, including taking into consideration the ability to prepay the debt at anytime, and, therefore, the additional exit fees were amortized using the effective interest method.

During the first quarter of 2025, with an effective date of December 31, 2024, the maturity date of the note was extended to August 1, 2025, and another additional exit fee of $1.0 million was incurred under the amendment, which continues to increase by $1.0 million each month until maturity. The base exit fee, as amended, and as of March 31, 2025, was equal to 12.41% of the principal amount being repaid and continues to increase by 0.17% each month until maturity. The total new exit fees associated with the notes have been recorded as an original issue discount of $8.7 million and are being amortized over the remaining life of the note, which is assumed to be the maturity date. A corresponding liability for the new exit fees of $8.7 million was recorded for total accrued exit fees amount of $16.5 million which are included within Accrued liabilities in the Condensed Consolidated Balance Sheet as of March 31, 2025. The exit fees are payable on the earliest of the maturity date, the date of the acceleration of the principal amount of the note for any reason or, if any portion of the note is prepaid at any time, the date of such prepayment of the note. In addition, under the recent amendment, a new $5.0 million default fee will be payable on August 1, 2025, in the event all obligations under the note, including principal, any accrued and unpaid interest, and exit fees, are not repaid in full prior to the August 1, 2025, maturity date. The $5.0 million default fee will only be recognized in the event of a default on August 1, 2025.

The amendment, which is effective as of December 31, 2024, was determined to be a modification of debt under ASC 470-50, as the terms of the debt were not determined to be substantially different, including taking into consideration the ability to prepay the debt at anytime, and, therefore, the additional exit fees are being amortized over the term of the note using the effective interest rate method and are included in interest expense.

Interest on the note, as amended, is payable monthly in arrears, in cash or, if not paid in cash, accrued and unpaid interest is capitalized monthly into the principal balance. Interest expense, including amortization of all exit fees, related to the note with Lancer Capital was $4.5 million and $0.9 million for the three months ended March 31, 2025 and 2024, respectively. For the three months ended March 31, 2025 and 2024, in accordance with the 20% note agreement, $1.2 million and $0.7 million, respectively, of interest was capitalized into the principal balance.

As of March 31, 2025, the total carrying amount relating to the note was $36.4 million, inclusive of $25.2 million of principal and capitalized interest, partially offset by $5.3 million of unamortized original issue discount, which are included within the Current portion of debt obligations in the Condensed Consolidated Balance Sheet, and $16.5 million in total accrued exit fees which are included within Accrued liabilities in the Condensed Consolidated Balance Sheet. As of December 31, 2024, the total outstanding amount relating to the note was $31.9 million, inclusive of $24.0 million of principal and capitalized interest, which total was included within Current portion of debt obligations in the Condensed Consolidated Balance Sheet, and $7.9 million in total accrued exit fees which were included within Accrued liabilities in the Condensed Consolidated Balance Sheet. As of March 31, 2025 and December 31, 2024, the effective interest rate on the note, as amended, was 51.3% and 57.8%, respectively.

Non-Operating Corporate

2026 Senior Secured Notes

The Company has $330.0 million aggregate principal amount of 8.50% senior secured notes due February 1, 2026 (the "2026 Senior Secured Notes"), which were issued in 2021 at 100% of par. The 2026 Senior Secured Notes have a stated annual interest rate of 8.50% and have an effective interest rate of 9.3%, which reflects the initial $10.8 million of deferred financing fees, including underwriting fees. Interest is payable semi-annually in arrears on February 1st and August 1st of each year. Aggregate interest expense, including the contractual interest coupon and amortization of the deferred financing fees was $7.6 million for both the three months ended March 31, 2025 and 2024, respectively. There were $2.2 million and $2.8 million of unamortized deferred financing fees as of March 31, 2025 and December 31, 2024, respectively.

2026 Convertible Notes

The original $51.8 million aggregate principal amount of 7.50% convertible notes (the "2026 Convertible Notes") were issued under a separate indenture dated February 1, 2021, between the Company and U.S. Bank, as trustee (the "Convertible Indenture"). The 2026 Convertible Notes mature on August 1, 2026, unless earlier converted, redeemed or purchased. The 2026 Convertible Notes were issued at 100% of par with a stated annual interest rate of 7.50%. The fair value of the embedded conversion feature contained in the 2026 Convertible Notes had a fair value of $12.3 million, which was recorded as a premium on the 2026 Convertible Notes. The 2026 Convertible Notes have an effective interest rate of 3.21%, which reflects the initial $12.3 million premium and $1.1 million of deferred financing fees.

During July 2024, INNOVATE repurchased $2.9 million principal amount of its 2026 Convertible Notes at a market discount for $1.1 million, which was inclusive of accrued interest of $0.1 million. As of March 31, 2025, the 2026 Convertible Notes had a net carrying value of $51.8 million inclusive of the remaining unamortized premium of $3.2 million and unamortized deferred financing costs of $0.3 million. As of December 31, 2024, the 2026 Convertible Notes had a net carrying value of $52.3 million, inclusive of an unamortized premium of $3.8 million and unamortized deferred financing costs of $0.4 million.

Interest is payable semi-annually in arrears on February 1st and August 1st of each year. Aggregate interest expense recognized relating to both the contractual interest coupon and amortization of discount net of premium and deferred financing costs was $0.4 million and $0.5 million, for the three months ended March 31, 2025 and 2024, respectively.

Each $1,000 of principal of the 2026 Convertible Notes is convertible into 23.6327 shares of our common stock, which is equivalent to a conversion price of approximately $42.31 per share, both as adjusted for the 2024 Reverse Stock Split and subject to further adjustment upon the occurrence of specified events. Based on the closing price of our common stock of $7.83 on March 31, 2025, the if-converted value of the 2026 Convertible Notes did not exceed its principal value.

Revolving Line of Credit

The Company has a revolving credit agreement with MSD PCOF Partners IX, LLC ("MSD"), which has a maximum commitment of $20.0 million ("Revolving Line of Credit"). As of both March 31, 2025 and December 31, 2024, the outstanding balance was $20.0 million. The maturity date of the Revolving Line of Credit was amended on March 6, 2025, from May 16, 2025, to August 1, 2025. The Revolving Line of Credit has an interest rate margin applicable to loans borrowed under the Revolving Line of Credit of 5.75%, and the benchmark rates for the interest are SOFR-based rates. As of March 31, 2025 and December 31, 2024, the effective interest rate on the Revolving Line of Credit, as amended, was 10.3% and 10.6%, respectively. Interest is paid quarterly in arrears. The Revolving Line of Credit also includes a commitment fee at a per annum rate of 1.0% calculated based off the actual daily amount of unused availability under the Revolving Line of Credit with MSD, and also includes a requirement for a prepayment if net cash proceeds from certain asset sales in excess of $10.0 million are received. The affirmative and negative covenants governing the Revolving Line of Credit are substantially consistent with the affirmative and negative covenants contained in the indenture that governs the 2026 Senior Secured Notes.

CGIC Unsecured Note Due 2026

The Company has a subordinated unsecured promissory note with Continental General Insurance Company ("CGIC") in the original principal amount of $35.1 million (the "CGIC Unsecured Note"). The CGIC Note, which is due February 28, 2026, bore interest at 9.0% per annum through May 8, 2024, bears interest at 16.0% per annum from May 9, 2024, to May 8, 2025, and 32.0% per annum thereafter. As of both March 31, 2025 and December 31, 2024, the effective interest rate on the note, as adjusted, was 17.5%. The CGIC Unsecured Note also requires a mandatory prepayment from the proceeds from certain asset sales and the greater of $3.0 million or 12.5% of the net proceeds from certain equity sales. As a result of the closing of the rights offering and concurrent private placement in 2024 (refer to Note 15. Equity and Temporary Equity), INNOVATE redeemed $4.1 million of the CGIC Unsecured Note on April 26, 2024. Other covenants in the CGIC Unsecured Note are generally consistent with the Company's Indenture governing the 8.50% Senior Secured Notes due 2026, dated as of February 1, 2021, by and among the Company, the guarantors party thereto and U.S. Bank National Association.

For the three months ended March 31, 2025 and 2024, interest expense recognized relating to the CGIC Unsecured Note was $1.4 million and $1.6 million, respectively, and cash paid for interest to CGIC was $1.2 million and $0.8 million, respectively. Accrued interest related to the CGIC notes was $3.6 million and $3.4 million as of March 31, 2025, and December 31, 2024, respectively.

INNOVATE is in compliance with its debt covenants as of March 31, 2025.

XML

Income Taxes

3 Months Ended

Mar. 31, 2025

Income Tax Disclosure [Abstract]

Income Taxes

12. Income Taxes

Income tax expense of $7.1 million and $3.3 million for the three months ended March 31, 2025 and 2024, primarily relates to tax expense as calculated for taxpaying entities, including the tax expense associated with the INNOVATE Corp. U.S. consolidated group due to the Tax Cut and Jobs Act's 80 percent limitation on net operating losses incurred after 2017. Additionally, the tax benefits associated with losses generated by certain other businesses have been reduced by a full valuation allowance as management does not believe it is more-likely-than-not that the losses will be utilized.

Net Operating Losses

At December 31, 2024, the Company had gross U.S. net operating loss ("NOL") carryforwards available to reduce future taxable income of the U.S. consolidated group in the amount of $174.3 million. The Company expects that approximately $117.7 million of the gross U.S. NOL carryforwards would be available to offset taxable income in 2025 and later periods. This estimate may change based on changes to actual results reported on the 2024 U.S. tax return. The amount of U.S. NOL carryforwards reflected in the financial statements differ from the amounts reported on the U.S. tax return due to uncertain tax positions related to tax laws and regulations that are subject to varied interpretation by the Internal Revenue Service ("IRS").

Additionally, as of December 31, 2024, the Company had $149.4 million of gross U.S. NOL carryforwards from its subsidiaries that do not qualify to be included in the INNOVATE U.S. consolidated income tax return, including $102.8 million from R2, $44.1 million from DTV America, and other entities of $2.5 million. Of the $149.4 million of gross U.S. NOL carryforwards, $113.3 million was generated after 2017 and will have an indefinite carryforward period; the remaining $36.1 million was generated prior to 2018 and will expire, if unused, by 2037.

Unrecognized Tax Benefits

The Company follows the provision of ASC 740 which prescribes a comprehensive model for how a company should recognize, measure, present, and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on a tax return. The Company is subject to challenge from various taxing authorities relative to certain tax planning strategies, including certain intercompany transactions as well as regulatory taxes.

The Company did not have any unrecognized tax benefits as of March 31, 2025 and 2024, related to uncertain tax positions that would impact the effective income tax rate if recognized. The Company has reduced the NOL carryforward by $58.7 million for uncertain tax positions based on our interpretation of tax laws and regulations that are subject to varied interpretation by the IRS.

Examinations

The Company conducts business globally, and as a result, INNOVATE or one or more of its subsidiaries files income tax returns in the United States federal jurisdiction and various state and foreign jurisdictions. In the normal course of business, the Company is subject to examination by taxing authorities throughout the world. Tax years 2002-2023 remain open for examination.

The Company is currently under examination in various domestic and foreign tax jurisdictions. The open tax years contain matters that could be subject to differing interpretations of applicable tax laws and regulations as they relate to the amount, character, timing or inclusion of revenue and expenses or the applicability of income tax credits for the relevant tax period. Given the nature of tax audits, there is a risk that disputes may arise.

XML

Commitments and Contingencies

3 Months Ended

Mar. 31, 2025

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

13. Commitments and Contingencies

Litigation

The Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Company’s Condensed Consolidated Financial Statements. Such legal matters may include, but is not limited to, actions or claims relating to sensitive data, including proprietary business information and intellectual property, personally identifiable information of employees and contractors, cyber-attacks, data breaches and non-compliance with contractual or other legal obligations. Litigation and other legal matters are inherently unpredictable and subject to substantial uncertainties and adverse resolutions could occur. In addition, litigation and other legal matters, including class-action lawsuits, government investigations and regulatory proceedings can be costly to defend and, depending on the class size and claims, could be costly to settle. The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its Condensed Consolidated Financial Statements. The Company records a liability in its Condensed Consolidated Financial Statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated as well as any legal costs incurred related to the litigation. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary for its Condensed Consolidated Financial Statements not to be misleading. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in the Company's Condensed Consolidated Financial Statements. Any legal or other expenses associated with the litigation are accrued for as the expenses are incurred. The Company maintains liability insurance that insures it against workers’ compensation, personal and bodily injury, property damage, directors’ and officers’ liability, errors and omissions, cyber liability, employment practices liability. There can be no assurance that the liability insurance will cover all events or that the limits of coverage will be sufficient to fully cover all liabilities.

Based on a review of the current facts and circumstances with counsel in each of the matters disclosed, management has provided for what is believed to be a reasonable estimate of loss exposure. While acknowledging the uncertainties of litigation, management believes that the ultimate outcome of litigation will not have a material effect on its financial position and will defend itself vigorously.

Marin General Hospital Replacement Litigation

On October 20, 2022, McCarthy Building Companies, Inc. (“McCarthy”) filed suit against Schuff Steel Company (“Schuff”), a subsidiary of DBMG, and Quality Assurance Engineering, Inc. dba Consolidated Engineering Laboratories (“CEL”) in the Superior Court of the State of California for the County of Marin, styled McCarthy Building Companies, Inc. v. Schuff Steel Company; Quality Engineering, Inc. dba Consolidated Engineering Laboratories, et al., Case No. CIV2203963 (the “Action”). In the Action, McCarthy alleges damages and delays caused by alleged failures in fabrication, erection, welding, and quality control by Schuff and improper quality assurance responsibilities by CEL on the Marin General Hospital Replacement Building (the “Project”). McCarthy asserts claims against Schuff for breach of contract, express indemnity, breach of express warranties, negligence, equitable implied indemnity, breach of implied warranties, and declaratory relief. On February 13, 2023, Schuff filed its response denying liability to McCarthy and asserting a Cross-Complaint against McCarthy, and other companies involved in the design, construction, and quality assurance, who potentially are liable for damages and delays alleged by McCarthy on the Project. In the Cross-Complaint, Schuff asserts claims for breach of contract, violation of statute, equitable indemnity apportionment, and contribution and express indemnity (the “Cross-Complaint”). Schuff intends to vigorously defend this Action and aggressively pursue the Cross-Complaint and cannot reasonably estimate any range of potential loss at this time.

Other Commitments and Contingencies

Letters of Credit and Performance Bonds

As of March 31, 2025, DBMG had outstanding letters of credit of $0.1 million under credit and security agreements and performance bonds of $259.1 million. As of December 31, 2024, DBMG had outstanding letters of credit of $0.1 million under credit and security agreements and performance bonds of $183.9 million. DBMG’s contract arrangements with customers sometimes require DBMG to provide performance bonds to partially secure its obligations under its contracts. Bonding requirements typically arise in connection with private contracts and sometimes with respect to certain public work projects. DBMG’s performance bonds are obtained through surety companies and typically cover the entire project price. The ratings of the bonding companies utilized by DBMG are highly rated, ranging from A-, A, A+ and AA.

Concentrations of Credit Risk

The Company's revenue concentrations of 10% and greater were as follows:

		Three Months Ended March 31,
		2025	2024
	Segment	Revenue	Revenue
Customer A	Infrastructure	*	27.6%

*Less than 10% concentration

XML

Share-based Compensation

3 Months Ended

Mar. 31, 2025

Share-Based Payment Arrangement [Abstract]

Share-based Compensation

14. Share-based Compensation

Total share-based compensation expense recognized by the Company and its subsidiaries under all equity compensation arrangements was $0.8 million and $0.4 million for the three months ended March 31, 2025 and 2024, respectively, which is reflected as a component of Selling, general and administrative expenses in the Condensed Consolidated Statements of Operations.

All grants are time based and vest either immediately or over a period established at grant, typically with a requisite service period of one to three years for a member of the Board of Directors or an employee to vest in the share-based award, subject to discretion by Compensation Committee. There are no other substantive conditions for vesting. The Company recognizes compensation expense for equity awards, reduced by actual forfeitures as they are incurred, using the straight-line basis.

Restricted Stock and Restricted Stock Units

A summary of INNOVATE’s restricted stock and restricted stock unit activity is as follows:

	Number of Shares	Weighted-Average Grant Date Fair Value
Unvested - December 31, 2024	294,663	$	8.12
Granted	36,881	$	7.66
Vested	(38,835)	$	18.46
Unvested - March 31, 2025	292,709	$	6.70

The aggregate vesting date fair value of the restricted stock and restricted stock units which vested during the three months ended March 31, 2025 and 2024, was $0.3 million and $0.2 million, respectively. As of March 31, 2025, the total unrecognized share-based compensation expense related to unvested restricted stock and restricted stock units was $1.2 million and is expected to be recognized over the remaining weighted-average period of 1.4 years.

Stock Options

A summary of INNOVATE’s stock option activity is as follows:

	Number of Stock Options	Weighted-Average Exercise Price
Outstanding - December 31, 2024	217,733	$	16.94
Outstanding - March 31, 2025	217,733	$	16.94
Exercisable - March 31, 2025 and December 31, 2024	117,733	$	27.74

As of March 31, 2025, the intrinsic value and weighted-average remaining life of the Company's outstanding and exercisable stock options were zero and approximately 7.7 years, respectively. The maximum contractual term of the Company's exercisable stock options is approximately ten years. As of March 31, 2025, there were 100,000 unvested stock options and $0.2 million of unrecognized share-based compensation expense related to unvested stock options and is expected to be recognized over the remaining period of 0.5 years.

XML

Equity and Temporary Equity

3 Months Ended

Mar. 31, 2025

Equity [Abstract]

Equity and Temporary Equity

15. Equity and Temporary Equity

2024 Rights Offering and Concurrent Private Placement

On March 8, 2024, the Company commenced a rights offering ("Rights Offering"), in which each holder of the Company’s common stock, Series A-3 Convertible Participating Preferred Stock, Series A-4 Convertible Participating Preferred Stock and the 2026 Convertible Notes as of March 6, 2024 (the “rights offering record date”), were granted rights to purchase common stock. In connection with the Rights Offering, the Company entered into an Investment Agreement with Lancer Capital (the "Investment Agreement"), pursuant to which Lancer Capital agreed to purchase up to $19.0 million of Series C Preferred Stock as a backstop to the Rights Offering (the "Backstop Commitment") and to purchase $16.0 million of Series C Preferred Stock in a private placement transaction ("Concurrent Private Placement"). Lancer Capital is an investment fund led by Avram A. Glazer, the Chairman of the Board and the Company’s largest stockholder. As the Rights Offering had not yet settled by March 28, 2024, in accordance with the Investment Agreement, Lancer Capital purchased $25.0 million of Series C Preferred Stock, referred to as the "equity advance." On April 24, 2024, the Company completed and closed on the Rights Offering and issued a total of 530,611 shares of common stock (5,306,105 shares of common stock on a pre Reverse Stock Split (see below) basis) for $3.7 million. In addition, Lancer Capital purchased an additional approximately 6,286 Series C Preferred Stock for $6.3 million under the Backstop Commitment. In total, the Company received $35.0 million in aggregate gross proceeds related to the Rights Offering and Concurrent Private Placement and incurred $1.8 million in dealer manager fees and other related costs which were capitalized into Additional paid in capital ("APIC"). On June 18, 2024, the Company's shareholders approved the conversion of the Series C Preferred Stock into common stock, and approximately 31,286 shares of Series C Preferred Stock, which were held by Lancer Capital, were converted into 4,469,390 shares of common stock (44,693,895 shares of common stock on a pre Reverse Stock Split basis), and there were no shares of the Series C Preferred Stock outstanding subsequent to their conversion into the Company's common stock.

Reverse Stock Split

On August 8, 2024, the Company effected a 1-for-10 reverse stock split of its issued and outstanding common stock (the “Reverse Stock Split”) following stockholder approval. The Reverse Stock Split was implemented for the primary purpose of regaining compliance with the minimum bid price requirement for continued listing of the Company’s common stock on the NYSE. The Reverse Stock Split did not change the $0.001 par value per share of the common stock. As a result of the Reverse Stock Split, the number of outstanding common shares was reduced from 130,529,931 to 13,166,057, inclusive of an additional 113,064 incremental whole shares issued for fractional shares. Unless noted, all share and per share amounts of common stock, options and restricted stock and any associated debt or preferred stock conversion rates contained in the historical periods, prior to the date of the Reverse Stock Split, presented within these Condensed Consolidated Financial Statements have been retroactively adjusted to reflect the 1-for-10 Reverse Stock Split as if it had occurred at the beginning of the earliest period presented.

Preferred Shares

The Company’s preferred shares authorized, issued and outstanding consisted of the following:

	March 31, 2025	December 31, 2024
Preferred shares authorized, $0.001 par value	20,000,000	20,000,000
Series A-3 shares issued and outstanding	6,125	6,125
Series A-4 shares issued and outstanding	10,000	10,000

Series A-3 and Series A-4 Shares

Issuance and Conversion. On July 1, 2021, (the "Exchange Date") as a part of the sale of Continental Insurance Group ("CIG"), INNOVATE entered into an exchange agreement (the "Exchange Agreement") with CGIC, also a former subsidiary, which held the remaining shares of the Company's previous Series A and Series A-2 Preferred Stock and was eliminated in consolidation prior to the sale of the Company's former Insurance segment on July 1, 2021. Per the Exchange Agreement, INNOVATE exchanged 6,125 shares of the Series A and 10,000 shares of the Series A-2 shares that CGIC held for an equivalent number of Series A-3 Convertible Participating Preferred Stock ("Series A-3") and Series A-4 Convertible Participating Preferred Stock ("Series A-4"), respectively. The terms remained substantially the same, except that the Series A-3 and Series A-4 mature on July 1, 2026.

Since the time of issuance of the Series A-3 and Series A-4 Preferred Stock on July 1, 2021, the Series A-3 and Series A-4 Preferred Stock have been classified as temporary equity in the Company's Condensed Consolidated Balance Sheet, with a combined redemption value of $16.1 million and with a current fair value of $16.4 million as of March 31, 2025, which is inclusive of the $0.3 million accrued dividend payable on April 15, 2025.

Dividends. The Series A-3 and Series A-4 Preferred Stock accrue a cumulative quarterly cash dividend at an annualized rate of 7.50%. The accrued values of the Series A-3 and Series A-4 Preferred Stock accrete quarterly at an annualized rate of 4.00% that is reduced to 2.00% or 0.0% if the Company achieves specified rates of growth measured by increases in its net asset value; provided, that the accreting dividend rate will be 7.25% in the event that (A) the daily volume weighted-average price ("VWAP") of the Company's common stock is less than a certain threshold amount, (B) the Company's common stock is not registered under Section 12(b) of the Securities Exchange Act of 1934, as amended, (C) the Company's common stock is not listed on certain national securities exchanges or the Company is delinquent in the payment of any cash dividends. The Series A-3 and Series A-4 Preferred Stock is also entitled to participate in cash and in-kind distributions to holders of shares of Company's common stock on an as-converted basis.

Subsequent Measurement. The Company elected to account for the Series A-3 and Series A-4 Preferred Stock by immediately recognizing changes in the redemption value as they occur. The carrying values of the Series A-3 and Series A-4 Preferred Stock are adjusted to equal what the redemption amount would be as if the redemption were to occur at the end of the reporting period as if it were also the redemption date for the Series A-3 and Series A-4 Preferred Stock. Any cash dividends paid directly reduce the carrying value of the Series A-3 and Series A-4 Preferred Stock until the carrying value equals the redemption value. Once the carrying value is equal to the redemption value, the dividends declared are accrued by debiting retained earnings, or if retained earnings is a deficit, then by debiting additional paid in capital. The Company has a history of paying dividends on its Series A-3 and Series A-4 Preferred Stock and expects to continue to pay such dividends each quarter.

Optional Conversion. Each share of Series A-3 and Series A-4 may be converted by the holder into shares of the Company's common stock at any time based on the then-applicable conversion price. As of March 31, 2025, each share of the Series A-3 Preferred Stock was convertible at an accrued value of $1,000 per share, divided by the conversion price of $23.63 (as it may be adjusted from time to time, the "Series A-3 Conversion Price"), and each share of Series A-4 Preferred Stock was convertible at an accrued value of $1,000 per share divided by the conversion price of $34.40 (as it may be adjusted from time to time, the "Series A-4 Conversion Price") (collectively the “Conversion Prices”). The Conversion Prices have historically been adjusted from time to time and continue to be subject to potential adjustment for dividends, certain distributions, stock splits, combinations, reclassifications, reorganizations, mergers, recapitalizations and similar events, as well as in connection with issuances of equity or equity-linked or other comparable securities by the Company at a price per share (or with a conversion or exercise price or effective issue price) that is below the Conversion Prices’ (which adjustment shall be made on a weighted-average basis).

Redemption by the Holders / Automatic Conversion. On July 1, 2026, holders of the Series A-3 and Series A-4 shall be entitled to cause the Company to redeem the Series A-3 and Series A-4 at the accrued value per share plus accrued but unpaid dividends (to the extent not included in the accrued value of Series A-3 and Series A-4). Each share of Series A-3 and Series A-4 that is not so redeemed will be automatically converted into shares of the Company's common stock at the Conversion Price then in effect.

Upon a change of control (as defined in each Certificate of Designation) holders of the Series A-3 and Series A-4 shall be entitled to cause the Company to redeem their shares of Series A-3 and Series A-4 at a price per share of Series A-3 and Series A-4 equal to the greater of (i) the accrued value of the Series A-3 and Series A-4, plus any accrued and unpaid dividends (to the extent not included in the accrued value of Series A-3 and Series A-4 Preferred Stock), and (ii) the value that would be received if the share of Series A-3 and Series A-4 were converted into shares of the Company's common stock immediately prior to the change of control.

Redemption by the Company / "Company Call Option". At any time, the Company may redeem the Series A-3 and Series A-4, in whole but not in part, at a price per share generally equal to 150% of the accrued value per share, plus accrued but unpaid dividends (to the extent not included in the accrued value of the Series A-3 and Series A-4), subject to the holder's right to convert prior to such redemption.

Forced Conversion. The Company may force conversion of the Series A-3 and Series A-4 into shares of the Company's common stock if the common stock's thirty-day VWAP exceeds 150% of the then-applicable Conversion Price and the common stock’s daily VWAP exceeds 150% of the then-applicable Conversion Price for at least 20 trading days out of the thirty trading day period used to calculate the 30-day VWAP. In the event of a forced conversion, the holders of Series A-3 and Series A-4 will have the ability to elect cash settlement in lieu of conversion if certain market liquidity thresholds for the Company's common stock are not achieved.

Liquidation Preference. In the event of any liquidation, dissolution or winding up of the Company (any such event, a “Liquidation Event”), the holders of Series A-3 and Series A-4 will be entitled to receive per share the greater of (i) the accrued value of the Series A-3 and Series A-4, plus any accrued and unpaid dividends (to the extent not included in the accrued value of Series A-3 and Series A-4), and (ii) the value that would be received if the share of Series A-4 and Series A-4 were converted into shares of the Company's common stock immediately prior to such occurrence. The Series A-3 and Series A-4 will rank junior to any existing or future indebtedness but senior to the Company's common stock and any future equity securities other than any future senior or pari passu preferred stock issued in compliance with each Certificate of Designation. The Series A-3 Preferred Stock and the Series A-4 Preferred Stock rank at parity.

Voting Rights. Except as required by applicable law, the holders of the shares of the Series A-3 and Series A-4 will be entitled to vote on an as-converted basis with the holders of the Company’s common stock on all matters submitted to a vote of the holders of the Company's common stock with the holders of Series A-3 Preferred Stock and Series A-4 Preferred Stock on certain matters, and separately as a class on certain limited matters.

Consent Rights. For so long as any of the Series A-3 and Series A-4 is outstanding, consent of the holders of shares representing at least 75% of certain of the Series A-3 and Series A-4 then outstanding is required for certain material actions.

Participation Rights. Pursuant to the securities purchase agreements entered into with the initial purchasers of the Series A-3 Preferred Stock and the Series A-4 Preferred Stock, subject to meeting certain ownership thresholds, certain purchasers of the Series A-3 Preferred Stock and the Series A-4 Preferred Stock are entitled to participate, on a pro-rata basis in accordance with their ownership percentage, determined on an as-converted basis, in issuances of equity and equity linked securities by the Company. In addition, subject to meeting certain ownership thresholds, certain initial purchasers of the Series A-3 Preferred Stock and the Series A-4 Preferred Stock will be entitled to participate in issuances of preferred securities and in debt transactions of the Company.

As of both March 31, 2025 and December 31, 2024, the Series A-3 Preferred Stock and Series A-4 Preferred Stock were convertible into 259,212 and 290,672 shares, respectively of INNOVATE's common stock.

Series A-3 and Series A-4 Preferred Share Dividends

During the three months ended March 31, 2025 and 2024, INNOVATE's Board of Directors (the "Board") declared cash dividends with respect to INNOVATE’s issued and outstanding Series A-3 Preferred Stock and Series A-4 Preferred Stock, as presented in the following tables (in millions):

2025
Declaration Date and Holders of Record Date	March 31, 2025
Payment Date	April 15, 2025
Total Dividend	$	0.3

2024
Declaration Date and Holders of Record Date	March 31, 2024
Payment Date	April 15, 2024
Total Dividend	$	0.3

R2 Technologies Non-Controlling Interests

The Company has non-redeemable and redeemable non-controlling interests related to R2 Technologies in the form of common stock as well as convertible preferred stock that is redeemable upon the occurrence of a change in control, as defined in the respective agreements. If an event is not solely within the control of the Company, it is classified outside of permanent equity in the mezzanine section of the Company's Condensed Consolidated Balance Sheets. The Company adjusts the carrying value of the non-controlling interests based on an allocation of subsidiary earnings (losses) based on ownership interests. As of March 31, 2025 and December 31, 2024, it was not deemed probable that the amounts relating to convertible preferred stock in non-controlling interests will become redeemable as no change in control has occurred or is expected to occur; therefore, no additional adjustments or remeasurements were required under ASC 480-10, Distinguishing Liabilities from Equity.

On February 20, 2025, Pansend closed on a new $3.5 million convertible 13.0% note instrument with R2 Technologies. The principal amount of the note, together with any interest then accrued and unpaid, is convertible at the option Pansend, into shares of a new Series E Convertible Preferred Stock ("Series E") in R2 Technologies upon written notice to R2 Technologies and has a maturity date of the earlier of July 31, 2025, or a change in control of R2 Technologies, as defined in the note. The transaction is eliminated on consolidation.

As a result of the allocation of losses, the redeemable non-controlling interest related to R2 Technologies was negative $0.7 million and negative $0.5 million as of March 31, 2025 and December 31, 2024, respectively. As of March 31, 2025 and December 31, 2024, the Company had negative $6.2 million and negative $4.9 million, respectively, of R2 Technologies non-controlling interests reflected within Non-controlling interests within the Condensed Consolidated Balance Sheets.

Liquidation Preference

R2 Technologies has issued multiple A, B, C and D-series, and, in the future potentially E-series, participating convertible preferred stock (the "R2 Technologies Preferred Shares"), all of which contain a liquidation preference. In the event of a liquidation event, each Preferred Share has a liquidation preference to be paid out of the assets legally available for distribution, which entitles the holder of each series A, series C, series D and series E (upon conversion of the aforementioned $3.5 million note that is convertible into Series E) R2 Technologies Preferred Shares to receive, before any payments to holders of junior securities, the sum of the following: (i) the accrued value in cash; (ii) all accrued and unpaid dividends, including basic dividends and accreting dividends, if any, and (iii) an amount, in cash or otherwise, equivalent to what the holder would receive if they had converted the R2 Technologies Preferred Shares into R2 Technologies common stock or reference property just before the liquidation event. Series B R2 Technologies Preferred Shareholders would be entitled to receive, before any payments to holders of junior securities, the greater of (i) the sum of (A) the accrued value in cash, plus (B) all accrued and unpaid dividends, including basic dividends and accreting dividends, if any, or (ii) an amount, in cash or otherwise, equivalent to what the holder would receive if they had converted the R2 Technologies Preferred Shares into R2 Technologies common stock or reference property just before the liquidation event.

If the assets of R2 Technologies legally available for distribution are insufficient to pay these obligations in full, R2 Technologies Preferred Shareholders and holders of any parity securities share the remaining assets in proportion to the full respective amounts to which they are entitled. After receiving the full liquidation preference, R2 Technologies Preferred Shareholders have no further claim to R2 Technologies' assets, except for any new securities or instruments received as part of the liquidation preference. The value of non-cash assets distributed equals their fair market value on the distribution date. No holder of junior securities receives any payment unless the entire liquidation preference of R2 Technologies Preferred Shares is paid. If there is insufficient cash to pay the entire liquidation preference and any liquidation preference in respect of any parity securities in full in cash upon a liquidation event, R2 Technologies Preferred Shareholders and parity securities holders will share available cash proportionally.

R2 Technologies' total liquidation preference upon a hypothetical liquidation event, including the liquidation preference for Pansend Life Sciences, LLC, was $146.3 million and $143.5 million as of March 31, 2025 and December 31, 2024, respectively, of which $52.8 million and $51.8 million as of March 31, 2025 and December 31, 2024, respectively, was attributable to redeemable and non-redeemable non-controlling interests, inclusive of initial preferred stock and unpaid accreted dividends. However, as of both March 31, 2025 and December 31, 2024, R2 Technologies had negative net assets after consideration of intercompany and third party debt, as applicable, and, therefore, there would be no legally available funds to satisfy such liquidation preferences upon a hypothetical liquidation event.

XML

Related Parties

3 Months Ended

Mar. 31, 2025

Related Party Transactions [Abstract]

Related Parties

16. Related Parties

Non-Operating Corporate

During the first quarter of 2024, in connection with the Rights Offering, the Company entered into an Investment Agreement with Lancer Capital, an entity controlled by Avram A. Glazer, pursuant to which Lancer Capital agreed to the Backstop Commitment to purchase up to $19.0 million of Series C Preferred Stock in connection with the Rights Offering and to purchase $16.0 million of Series C Preferred Stock in a private placement transaction ("Concurrent Private Placement"), of which $25.0 million would be purchased before the closing of the Rights Offering if the Rights Offering did not close by March 28, 2024. As a result of the extension of the Rights Offering, on March 28, 2024, Lancer Capital funded the equity advance of $25.0 million to the Company and received 25,000 shares of Series C Preferred Stock. As a result, Mr. Glazer's beneficial ownership increased from 29.1% as of March 5, 2024, immediately prior to the start of the Rights Offering, to 48.8% as of March 31, 2024. On April 24, 2024, as a result of the closing of the Rights Offering and Concurrent Private Placement, Lancer Capital purchased an additional approximately 6,286 shares of Series C Preferred Stock for $6.3 million, increasing Mr. Glazer's beneficial ownership to 52.1%. On June 18, 2024, the Company held its annual shareholder meeting where the Company's shareholders approved the conversion of the Series C Preferred Stock into common stock. As a result, approximately 31,286 Series C Preferred Stock held by Lancer Capital were converted into 4,469,390 shares of INNOVATE's common stock (44,693,895 on a pre Reverse Stock Split basis), and there were no shares of the Series C Preferred Stock outstanding subsequent to their conversion into the Company's common stock. Refer to Note 15. Equity and Temporary Equity for additional information. As of March 31, 2025, Mr. Glazer's beneficial ownership was 51.1%.

Lancer Capital held $2.0 million of principal amount of the Company's 7.50% 2026 Convertible Notes, as of both March 31, 2025 and December 31, 2024. As of both March 31, 2025 and December 31, 2024, the $2.0 million in 7.50% 2026 Convertible Notes are convertible into 47,265 shares of common stock of INNOVATE. Refer to Note 11. Debt Obligations for additional information on the 7.50% 2026 Convertible Notes. During both the three months ended March 31, 2025 and 2024, Lancer Capital earned $37.5 thousand in interest relating to these notes.

On May 9, 2023, the Company entered into a Stock Purchase Agreement and Subordinated Unsecured Promissory Note with CGIC in the principal amount of $35.1 million. CGIC is a former significant shareholder and is the shareholder of the Series A-3 Preferred Stock and Series A-4 Preferred Stock. As a result of the closing of the Rights Offering and Concurrent Private Placement in April 2024, a mandatory prepayment was required, and INNOVATE redeemed $4.1 million of the CGIC Unsecured Note on April 26, 2024. Refer to Note 11. Debt Obligations for additional information.

Infrastructure

DBMG and Banker Steel, jointly and severally, had a subordinated 4.0% note payable to Banker Steel's former owner, in which Donald Banker's family trust has a 25% interest. The 4.0% note and associated accrued interest matured on March 31, 2024, and was fully redeemed on April 2, 2024. During the three months ended March 31, 2024, DBMG made $2.5 million in scheduled principal payments on the 4.0% note.

Life Sciences

As of March 31, 2025 and December 31, 2024, R2 Technologies had $25.2 million and $24.0 million, respectively, in principal amount of a 20.0% senior secured promissory note due to Lancer Capital. Refer to Note 11. Debt Obligations for additional information on the 20.0% senior secured promissory note due to Lancer Capital.

For the three months ended March 31, 2025 and 2024, R2 Technologies recognized $0.4 million and $0.2 million, respectively, of revenue from sales and profit sharing agreements with a subsidiary of Huadong, a related party of R2 Technologies. There were $0.2 million and $0.1 million of related receivables from this subsidiary of Huadong as of March 31, 2025 and December 31, 2024, respectively.

Share-based compensation and royalty expenses related to Blossom Innovations, LLC, an investor of R2 Technologies since 2014, totaled $0.3 million and $0.1 million, for the three months ended March 31, 2025 and 2024, respectively.

Refer to Note 6. Investments for transactions with equity method investees of the Company.

XML

Operating Segments and Related Information

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Operating Segments and Related Information

17. Operating Segments and Related Information

The Company currently has one primary reportable geographic segment - United States, and primarily all revenue is derived in the United States, and primarily all PP&E and intangible assets reside in the United States. The reportable segments are identified based on the nature of the services and products provided, the organizational structure, and the internal reporting system used by the Chief Operating Decision Maker ("CODM") to assess performance and allocate resources. The Company has three reportable operating segments, plus the Other segment, based on management’s organization of the enterprise - Infrastructure, Life Sciences, Spectrum, and Other. The Company also has a Non-Operating Corporate segment. All inter-segment transactions are eliminated on consolidation. There are no inter-segment revenues. Refer to Note 1. Organization and Business for additional information on the organizational structure of the business and Note 3. Revenue and Contracts in Process for additional information on revenue by segment.

The Chief Operating Decision Maker ("CODM") for the Company is the Interim CEO, Paul Voigt. The CODM is primarily responsible for allocating resources at all levels that do not require board approval. The CODM monitors the performance of each segment and is responsible for making strategic decisions regarding capital and resource allocation. The CODM uses a combination of monthly reports, which detail revenue and income (loss) from operations, and quarterly summaries, which include detailed breakdowns of each segment's income (loss) from operations, to evaluate segment performance, allocate resources and make strategic decisions. These financial metrics are used to view operating trends, perform analytical comparisons and benchmark performance between periods and to monitor budget-to-actual variances on a monthly basis. The primary U.S. GAAP metric used by the CODM in assessing segment performance is income (loss) from operations.

Financial information, including revenue and expenses, with respect to the Company’s operating segments, is as follows (in millions):

	Three Months Ended March 31, 2025
	Infrastructure		Life Sciences		Spectrum		Non-Operating Corporate		Other and Eliminations		INNOVATE
Revenue	$	264.9	$	3.1	$	6.2	$	—			$	274.2
Cost of revenue	223.5		2.3		2.9		—		—		228.7
Selling, general and administrative expenses	29.3		3.7		1.9		2.9		—		37.8
Depreciation and amortization	3.1		0.1		1.2		—		—		4.4
Other operating income	(0.1)		—		—		—		—		(0.1)
Income (loss) from operations	$	9.1	$	(3.0)	$	0.2	$	(2.9)	$	—	$	3.4
Other data:
Capital expenditures (1)	$	4.1	$	0.1	$	0.5	$	—	$	—	$	4.7
Investments (2)	$	—	$	1.8	$	—	$	2.3	$	—	$	4.1
Total assets	$	671.9	$	11.7	$	178.3	$	6.1	$	—	$	868.0

(1) Capital expenditures reflect cash expenditures for the three months ended March 31, 2025.

(2) The Company's equity method investments in the Life Sciences segment totaled $0.9 million as of March 31, 2025.

	Three Months Ended March 31, 2024
	Infrastructure		Life Sciences		Spectrum		Non-Operating Corporate		Other and Eliminations		INNOVATE
Revenue	$	307.9	$	1.0	$	6.3	$	—	$	—	$	315.2
Cost of revenue	263.1		0.6		2.9		—		—		266.6
Selling, general and administrative expenses	30.9		3.5		1.9		3.2		—		39.5
Depreciation and amortization	3.0		0.1		1.3		—		—		4.4
Other operating loss (1)	1.6		—		—		0.3		—		1.9
Income (loss) from operations	$	9.3	$	(3.2)	$	0.2	$	(3.5)	$	—	$	2.8
Other data:
Capital expenditures (2)	$	5.2	$	0.1	$	0.3	$	—	$	—	$	5.6
	December 31, 2024
	Infrastructure		Life Sciences		Spectrum		Non-Operating Corporate		Other and Eliminations		INNOVATE
Investments (3)	$	—	$	1.8	$	—	$	1.8	$	—	$	3.6
Total assets	$	683.6	$	11.9	$	178.9	$	16.7	$	—	$	891.1

(1) Other operating loss for the three months ended March 31, 2024, primarily consisted of a loss on disposal related to a plant closure at our Infrastructure segment.

(2) Capital expenditures reflect cash expenditures for the three months ended March 31, 2024.

(3) The Company's equity method investments in the Life Sciences segment totaled $0.9 million as of December 31, 2024.

	Three Months Ended March 31,
	2025		2024
Reconciliation of the consolidated segment income from operations to consolidated loss from operations before income taxes:
Income from operations	$	3.4	$	2.8
Interest expense	(20.2)		(17.2)
Loss from equity investees	(5.9)		(1.2)
Other income (expense), net	4.0		(1.2)
Loss from operations before income taxes	$	(18.7)	$	(16.8)

XML

Basic and Diluted Loss Per Common Share

3 Months Ended

Mar. 31, 2025

Earnings Per Share [Abstract]

Basic and Diluted Loss Per Common Share

18. Basic and Diluted Loss Per Common Share

Earnings (loss) per share ("EPS") is calculated using the two-class method, which allocates earnings among common stock and participating securities to calculate EPS when an entity's capital structure includes either two or more classes of common stock or common stock and participating securities. Unvested share-based payment awards, and, previously, the Series C Preferred Stock, that contain non-forfeitable rights to dividends or dividend equivalents (whether paid or unpaid) are participating securities. As such, shares of any unvested restricted stock, and, previously, the Series C Preferred Stock, of the Company are considered participating securities; however, unvested shares of restricted stock do not participate in losses and, as such, are excluded from the computation of basic earnings (loss) per share during periods of net losses. The dilutive effect, if applicable, of stock options and their equivalents (including non-vested stock issued under share-based compensation plans), is computed using the "if-converted method" if this measurement is determined to be more dilutive than the treasury stock method in a period.

The Company had no dilutive common stock equivalents during the three months ended March 31, 2025 and 2024, due to the results from continuing operations being a loss, net of tax. For the three months ended March 31, 2025 and 2024, 294,329 and 70,299, respectively, of common stock equivalents from unvested restricted stock awards and unvested restricted stock units were excluded from the weighted-average number of shares used to calculate diluted loss per share as their inclusion would have been anti-dilutive. Other instruments that may, in the future, if the average market price of the Company's stock exceeds the conversion prices, have a dilutive effect on EPS, but were excluded from the computations of diluted net loss per share, and may be excluded from computations of diluted EPS in the future, are: convertible preferred stock, convertible debt, and stock options. Refer to Note 14. Share-based Compensation and Note 15. Equity and Temporary Equity for additional information on INNOVATE's equity instruments.

The following table presents a reconciliation of net loss to net loss used in the basic and diluted EPS calculations (in millions, except shares and per share amounts):

	Three Months Ended March 31,
	2025			2024
Net loss	$	(25.8)		$	(20.1)
Net loss attributable to non-controlling interest and redeemable non-controlling interest	1.3			2.7
Net loss attributable to INNOVATE Corp.	(24.5)			(17.4)
Less: Preferred dividends	0.3			0.3
Net loss attributable to common stockholders and participating preferred stockholders	$	(24.8)		$	(17.7)
Participating shares
Weighted-average common shares outstanding (1)	13,114,804			7,865,361
Series C Preferred stock (1)	—			156,986
Total	13,114,804			8,022,347
Percentage of loss allocated to:
Common stock	100.0		%	98.0		%
Series C Preferred stock	—		%	2.0		%
Numerator for loss per share:
Net loss attributable to common stock holders, basic and diluted	$	(24.8)		$	(17.3)
Net loss attributable to Series C holder, basic and diluted	—			(0.4)
Denominator for loss per share:
Weighted-average common shares outstanding - basic and diluted (1)	13,114,804			7,865,361
Weighted-average Series C shares outstanding - basic and diluted (1)	—			156,986
Loss per share
Loss per common share - basic and diluted (1)	$	(1.89)		$	(2.21)
Loss per Series C share - basic and diluted (1)	$	(1.89)		$	(2.21)

(1) Basic and diluted loss per common share and weighted-average common shares outstanding for the three months ended March 31, 2024, in the table above have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on August 8, 2024.

XML

Fair Value of Financial Instruments

3 Months Ended

Mar. 31, 2025

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

19. Fair Value of Financial Instruments

Fair Value of Financial Instruments Not Measured at Fair Value

Our financial instruments primarily include cash and cash equivalents, restricted cash, accounts receivable and contract assets, marketable and non-marketable securities, including equity investments and certain other investments, notes receivable, accounts payable and other current and non-current liabilities, redeemable non-controlling interests and debt obligations. The following tables presents the carrying amounts and estimated fair values of the Company’s financial instruments, which were not measured at fair value on a recurring basis and not measured using the equity method of accounting, with fair values shown according to the fair value hierarchy. The tables exclude carrying amounts for cash and cash equivalents and restricted cash (Level 1 measurements), accounts receivable and contract assets, accounts payable, contract liabilities and other current liabilities, and other assets and liabilities (Level 2 measurements) that approximate fair value due to the relatively short periods to maturity (in millions):

March 31, 2025					Fair Value Measurement Using:
	Carrying Value		Estimated Fair Value		Quoted Prices (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets
Measurement alternative investment (1)	$	0.9	$	0.9	$	—	$	—	$	0.9
Total assets not accounted for at fair value	$	0.9	$	0.9	$	—	$	—	$	0.9
Liabilities
Debt obligations (2)	$	663.2	$	618.4	$	—	$	618.4	$	—
Total liabilities not accounted for at fair value	$	663.2	$	618.4	$	—	$	618.4	$	—

(1) Refer to Note 6. Investments for additional information.

(2) Excludes lease obligations accounted for under ASC 842, Leases.

December 31, 2024					Fair Value Measurement Using:
	Carrying Value		Estimated Fair Value		Quoted Prices (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets
Measurement alternative investment (1)	$	0.9	$	0.9	$	—	$	—	$	0.9
Total assets not accounted for at fair value	$	0.9	$	0.9	$	—	$	—	$	0.9
Liabilities
Debt obligations (2)	$	662.2	$	577.1	$	—	$	577.1	$	—
Total liabilities not accounted for at fair value	$	662.2	$	577.1	$	—	$	577.1	$	—

(1) Refer to Note 6. Investments for additional information.

(2) Excludes lease obligations accounted for under ASC 842, Leases.

Debt Obligations. The fair value of the Company’s long-term obligations was determined using reporting from externally quoted market prices for INNOVATE's 8.50% 2026 Senior Secured Notes and for INNOVATE's 7.50% Convertible Senior Notes due 2026, which are reflected as Level 2 fair value measurements due to limited recently available observable trading activity for these instruments. All other long-term obligations of the Company are also reflected as Level 2 fair value measurements, as this methodology combines direct recent transaction activity or, if available, market observations from contributed sources with quantitative pricing models or fair value reports from valuation providers to generate evaluated prices and are classified as Level 2 fair value measurements. Certain long-term obligations have a fair value estimate equal to their carrying value due to recent transaction activity. The fair value of the debt instruments is disclosed for informational purposes and does not necessarily represent the amount that would be realized upon settlement or transfer.

Fair Value of Financial Instruments Measured at Fair Value

The Company's investments in marketable securities are measured at fair value, using publicly available quoted market prices, a Level 1 input. Refer to Note 6. Investments.

XML

Supplementary Financial Information

3 Months Ended

Mar. 31, 2025

Offsetting [Abstract]

Supplementary Financial Information

20. Supplementary Financial Information

Other income (expense), net

The following table provides information relating to Other income (expense), net (in millions):

	Three Months Ended March 31,
	2025		2024
Gain on step-up of equity method investment	4.4		—
Net loss on extinguishment of debt	—		(2.2)
Interest income	0.4		0.5
Foreign currency translation (loss) gain	(0.4)		0.5
Other	(0.4)		—
Total other income (expense), net	$	4.0	$	(1.2)

Supplemental Cash Flow Information

The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts reported within the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Cash Flows (in millions):

	Three Months Ended March 31,
	2025		2024
Cash and cash equivalents, beginning of the period	$	48.8	$	80.8
Restricted cash included in other current assets	—		0.9
Restricted cash included in other assets (non-current)	0.5		0.6
Total cash, cash equivalents and restricted cash, beginning of the period	$	49.3	$	82.3
Cash and cash equivalents, end of the period	$	33.3	$	38.4
Restricted cash included in other current assets	—		0.9
Restricted cash included in other assets (non-current)	0.6		0.6
Total cash and cash equivalents and restricted cash, end of the period	$	33.9	$	39.9
Supplemental cash flow information:
Cash paid for interest	$	19.5	$	19.6
Cash paid for income taxes (proceeds from tax refunds), net	$	0.8	$	(0.8)
Non-cash investing and financing activities:
Accrued interest capitalized into principal debt	$	1.2	$	3.3
Property, plant and equipment included in accounts payable or accrued expenses	$	1.1	$	0.9

XML

Subsequent Events

3 Months Ended

Mar. 31, 2025

Subsequent Events [Abstract]

Subsequent Events

21. Subsequent Events

None.

XML

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Pay vs Performance Disclosure
Net Income (Loss)	$ (24.5)	$ (17.4)

XML

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2025
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2025

Accounting Policies [Abstract]

Principles of Consolidation

Principles of Consolidation

The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of the Company, its wholly owned subsidiaries and all other subsidiaries over which the Company exerts control. All intercompany profits, transactions and balances have been eliminated in consolidation. The remaining interests not owned by the Company are presented as a non-controlling interest component of total equity.

Basis of Presentation

Basis of Presentation

The accompanying interim unaudited Condensed Consolidated Financial Statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). The financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair statement of such information. All such adjustments are of a normal recurring nature. Certain information and note disclosures, including a description of significant accounting policies normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"), have been condensed or omitted in these interim unaudited Condensed Consolidated Financial Statements pursuant to such rules and regulations.

These interim unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Company’s annual audited Consolidated Financial Statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025. The results of operations for the three months ended March 31, 2025, are not necessarily indicative of the results for any subsequent periods or the entire fiscal year ending December 31, 2025. Certain prior amounts have been reclassified or combined to conform to the current year presentation.

Going Concern

Going Concern

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared assuming that the Company will continue as a going concern. However, as of the date of these financial statements, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.

The principal conditions leading to this conclusion are the upcoming maturities and covenants of the Company's Non-Operating Corporate segment's Senior Secured Notes, other current debt at the Non-Operating Corporate segment and the Company's subsidiaries, as well as from certain cross-default provisions in the Company's Senior Secured Notes. Based on these conditions, the Company may not be able to meet its obligations at maturity and comply with certain cross-default provisions under the Senior Secured Notes over the next twelve months.

Management has evaluated the significance of these conditions in relation to the Company's ability to meet its obligations. The potential inability to refinance or extend the maturity of the aforementioned current debt, or to obtain additional financing, raises substantial doubt about the Company's ability to continue as a going concern.

The Company plans to alleviate these conditions through various initiatives it is currently exploring, including refinancing the debt at the Non-Operating Corporate segment and its subsidiaries, pursuing asset sales, and raising additional capital. However, there can be no assurance that the Company will have the ability to raise additional capital when needed, be successful in any asset sales, or refinance its existing debt, on attractive terms, or at all nor any assurances that lenders will provide additional extensions, waivers or amendments in the event of future non-compliance with the Company’s debt covenants or other possible events of default. Further, there can be no assurance that the Company will be able to execute a reduction, extension, or refinancing of the debt, or that the terms of any replacement financing would be as favorable as the terms of the debt prior to the maturity date. There can be no assurance that these plans will be successfully implemented or that they will mitigate the conditions that raise substantial doubt about the Company's ability to continue as a going concern.

These unaudited Condensed Consolidated Financial Statements do not include any adjustments to the carrying amounts and classification of assets, liabilities, or expenses that may result if the Company is unable to continue as a going concern.

Use of Estimates and Assumptions

Use of Estimates and Assumptions

The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and various disclosures within these Condensed Consolidated Financial Statements as of the date of the Condensed Consolidated Financial Statements and the reported amounts of net revenue and expenses during the reporting period. These estimates are based on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Actual results may differ from these estimates.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Accounting Pronouncements Issued But Pending Adoption

On November 26, 2024, the FASB issued ASU 2024-04, Debt - Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments ("ASU 2024-04"). The amendments in this update affect entities that settle convertible debt instruments for which the conversion privileges were changed to induce conversion. The amendments clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. ASU 2024-04 is effective for fiscal years beginning after December 15, 2025, and interim periods within those annual reporting periods. Entities may apply the amendments retrospectively for all prior periods presented in the financial statements or prospectively. The Company expects that it will apply the new guidance prospectively and is currently evaluating the potential effect of this ASU on future transactions and the Company’s Condensed Consolidated Financial Statements.

On November 4, 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03"). The amendments in this ASU require disclosure, in the notes to financial statements, of specified information about certain costs and expenses, including the total amount of selling expenses incurred in the period and an entity's definition of selling expenses. ASU 2024-03, with effective dates as clarified by ASU 2025-01 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating this ASU, which will only have an effect on the disclosures within the Company’s Condensed Consolidated Financial Statements.

On January 1, 2025, ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), became effective and requires, among other things, greater disaggregation of information in the rate reconciliation and for paid income taxes to be disaggregated by jurisdiction. ASU 2023-09 affects financial statement disclosure only, which is not required until year end 2025 and, as a result, does not affect our results of operations or financial condition.

Subsequent Events

Subsequent Events

ASC 855, Subsequent Events requires the Company to evaluate events that occur after the balance sheet date as of which the financial statements are issued, and to determine whether adjustments to or additional disclosures in the financial statements are necessary.

XML

Revenue and Contracts in Process (Tables)

3 Months Ended

Mar. 31, 2025

Revenue from Contract with Customer [Abstract]

Schedule of Reconciliation of Revenue from Segments to Consolidated

Revenue from contracts with customers consisted of the following (in millions):

	Three Months Ended March 31,
	2025		2024
Infrastructure	$	264.9	$	307.9
Life Sciences	3.1		1.0
Spectrum	6.2		6.3
Total revenue	$	274.2	$	315.2

Schedule of Accounts Receivable, net

Accounts receivables, net, from contracts with customers consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Infrastructure	$	156.3	$	184.8
Life Sciences	2.1		1.5
Spectrum	2.0		1.9
Total accounts receivables with customers	$	160.4	$	188.2

Accounts receivable, net, consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Contracts in progress	$	156.3	$	184.9
Unbilled retentions	0.1		0.1
Trade receivables	4.1		3.3
Other receivables	4.1		5.8
Allowance for expected credit losses	(0.1)		(0.1)
Total	$	164.5	$	194.0

Schedule of Disaggregation of Revenue

The following table disaggregates DBMG's revenue by market (in millions):

	Three Months Ended March 31,
	2025		2024
Industrial	$	74.6	$	84.1
Commercial	53.8		77.3
Healthcare	52.0		34.3
Transportation	44.7		100.4
Government	24.8		2.7
Leisure	6.6		1.0
Convention	5.9		5.5
Energy	1.9		2.2
Total revenue from contracts with customers	$	264.3	$	307.5
Other revenue	0.6		0.4
Total Infrastructure segment revenue	$	264.9	$	307.9

The following table disaggregates the Life Sciences segment's revenue by type (in millions):

	Three Months Ended March 31,
	2025		2024
Systems and consumables revenue	$	3.1	$	1.0
Total Life Sciences segment revenue	$	3.1	$	1.0

The following table disaggregates the Spectrum segment's revenue by type (in millions):

	Three Months Ended March 31,
	2025		2024
Broadcast station	$	6.2	$	6.3
Total Spectrum segment revenue	$	6.2	$	6.3

Schedule of Costs and Recognized Earnings in Excess of Billings and Billings in Excess of Costs and Recognized Earnings on Uncompleted Contracts

Contract assets and contract liabilities consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Costs incurred on contracts in progress	$	1,245.9	$	1,435.2
Estimated earnings	97.5		75.8
Contract revenue earned on uncompleted contracts	1,343.4		1,511.0
Less: progress billings	1,303.4		1,513.8
	$	40.0	$	(2.8)
The above is included in the accompanying Condensed Consolidated Balance Sheets under the following line items:
Contract assets	$	135.3	$	106.3
Contract liabilities	(95.3)		(109.1)
	$	40.0	$	(2.8)

Schedule of Contract with Customer, Asset and Liability

	March 31, 2025		December 31, 2024
Cost in excess of billings and estimated earnings	$	71.2	$	50.8
Conditional retainage	64.1		55.5
Contract assets	$	135.3	$	106.3
Billings in excess of costs and estimated earnings	$	(127.4)	$	(147.7)
Conditional retainage	32.1		38.6
Contract liabilities	$	(95.3)	$	(109.1)

Schedule of Remaining Performance Obligations

As of March 31, 2025, the transaction price allocated to remaining unsatisfied performance obligations consisted of the following (in millions):

	Within One Year		Within Five Years		Total
Commercial	$	333.8	$	107.6	$	441.4
Industrial	250.8		34.7		285.5
Healthcare	176.2		70.9		247.1
Transportation	114.6		78.8		193.4
Government	162.0		5.3		167.3
Leisure	17.0		1.9		18.9
Convention	2.6		—		2.6
Energy	1.6		—		1.6
Remaining unsatisfied performance obligations	$	1,058.6	$	299.2	$	1,357.8

XML

Accounts Receivable, Net (Tables)

3 Months Ended

Mar. 31, 2025

Receivables [Abstract]

Schedule of Accounts Receivable, net

Accounts receivables, net, from contracts with customers consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Infrastructure	$	156.3	$	184.8
Life Sciences	2.1		1.5
Spectrum	2.0		1.9
Total accounts receivables with customers	$	160.4	$	188.2

Accounts receivable, net, consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Contracts in progress	$	156.3	$	184.9
Unbilled retentions	0.1		0.1
Trade receivables	4.1		3.3
Other receivables	4.1		5.8
Allowance for expected credit losses	(0.1)		(0.1)
Total	$	164.5	$	194.0

XML

Inventory (Tables)

3 Months Ended

Mar. 31, 2025

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Raw materials and consumables	$	18.5	$	19.6
Work in process	0.4		0.4
Finished goods	0.8		0.8
Total inventory	$	19.7	$	20.8

XML

Investments (Tables)

3 Months Ended

Mar. 31, 2025

Investments, Debt and Equity Securities [Abstract]

Schedule of Investments

The carrying values of the Company's investments, by category, were as follows (in millions):

Date	Equity Method (1)		Fair Value (2)		Measurement Alternative (3)		Total
March 31, 2025	$	0.9	$	2.3	$	0.9	$	4.1
December 31, 2024	$	0.9	$	1.8	$	0.9	$	3.6

(1) The Company's equity method investments were comprised of MediBeacon and Scaled Cell as of both March 31, 2025 and December 31, 2024.

(2) The Company's fair value investments in common stock are comprised of marketable equity securities in two publicly traded companies that were purchased in October 2024 and March 2025.

(3) The Company's measurement alternative method investment was comprised of Triple Ring as of both March 31, 2025 and December 31, 2024.

XML

Property, Plant and Equipment, Net (Tables)

3 Months Ended

Mar. 31, 2025

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant, and Equipment, net

Property, plant and equipment, net, ("PP&E") consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Equipment, furniture and fixtures, and software	$	212.6	$	211.0
Building and leasehold improvements	36.9		36.8
Land	18.6		18.6
Construction in progress	10.9		8.0
Plant and transportation equipment	7.4		7.4
	$	286.4	$	281.8
Less: Accumulated depreciation	153.8		148.2
Total	$	132.6	$	133.6

XML

Goodwill and Intangibles, Net (Tables)

3 Months Ended

Mar. 31, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of the Changes in the Carrying Amount of Goodwill by Reporting Unit

The carrying amounts of goodwill by segment were as follows (in millions):

	Infrastructure		Spectrum		Total
Balance as of December 31, 2024	$	105.3	$	21.4	$	126.7
Balance as of March 31, 2025	$	105.3	$	21.4	$	126.7

Schedule of Indefinite-Lived Intangible Assets

The carrying amounts of indefinite-lived intangible assets were as follows (in millions):

	March 31, 2025		December 31, 2024
FCC licenses	$	107.7	$	107.7
Total	$	107.7	$	107.7

Schedule of Intangible Assets Subject to Amortization

The gross carrying amounts and accumulated amortization of definite lived intangible assets by major intangible asset class were as follows (in millions):

	Weighted-Average Original Useful Life	March 31, 2025
		Gross Carrying Amount		Accumulated Amortization			Net
Trade names	15 years	$	25.1		$	(11.4)	$	13.7
Customer relationships and contracts	11 years	87.4			(50.4)		37.0
Channel sharing arrangements	35 years	12.6			(2.3)		10.3
Other	10 years	3.7			(2.0)		1.7
Total		$	128.8		$	(66.1)	$	62.7

	Weighted-Average Original Useful Life	December 31, 2024
		Gross Carrying Amount		Accumulated Amortization			Net
Trade names	15 years	$	25.1		$	(11.0)	$	14.1
Customer relationships and contracts	11 years	87.4			(49.1)		38.3
Channel sharing arrangements	35 years	12.6			(2.2)		10.4
Other	10 years	3.9			(2.0)		1.9
Total		$	129.0		$	(64.3)	$	64.7

XML

Leases (Tables)

3 Months Ended

Mar. 31, 2025

Leases [Abstract]

Schedule of Lease ROUs and Lease Liabilities

Right-of-use lease assets and lease liabilities consisted of the following (in millions):

	Balance Sheet Location	March 31, 2025		December 31, 2024
Right-of-use assets:
Operating lease	Other assets (non-current)	$	53.0	$	53.7
Finance lease	Property, plant and equipment, net	0.1		0.5
Total right-of-use assets		$	53.1	$	54.2
Lease liabilities:
Current portion of operating lease	Other current liabilities	$	12.9	$	12.9
Non-current portion of operating lease	Other liabilities	41.9		43.5
Finance lease	Debt obligations	0.2		0.6
Total lease liabilities		$	55.0	$	57.0

Schedule of Components of Lease Expense

The following table summarizes the components of lease expense (in millions):

	Three Months Ended March 31,
	2025		2024
Finance lease cost:
Amortization of right-of-use assets	$	0.1	$	0.1
Net finance lease cost	0.1		0.1
Operating lease cost	4.2		4.5
Variable lease cost	0.2		0.1
Sublease income	—		(0.2)
Total non-current lease cost	4.5		4.5
Short-term lease costs	8.0		7.2
Total lease cost	$	12.5	$	11.7

Cash flow information related to leases is as follows (in millions):

	Three Months Ended March 31,
	2025		2024
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	5.2	$	5.0
Financing cash flows for finance leases	$	0.1	$	0.1
Right-of-use assets obtained in exchange for new lease liabilities:
Operating leases	$	2.5	$	2.6

The weighted-average remaining lease term and the weighted-average discount rate for the Company's leases were as follows:

	March 31, 2025		December 31, 2024
Weighted-average remaining lease term (years) - operating leases	7.3		7.4
Weighted-average remaining lease term (years) - finance leases	2.6		2.7
Weighted-average discount rate - operating leases	6.2	%	6.1	%
Weighted-average discount rate - finance leases	5.0	%	5.3	%

Schedule of Operating Lease, Liability, Maturity

Future minimum lease commitments (undiscounted) as of March 31, 2025, were as follows (in millions):

	Operating Leases		Finance Leases
2025 (remaining period)	$	11.4	$	0.1
2026	12.7		0.1
2027	10.0		—
2028	7.4		—
2029	4.7		—
Thereafter	21.4		—
Total future minimum lease payments	67.6		0.2
Less: amounts representing interest	(12.8)		—
Total lease liability	$	54.8	$	0.2

Schedule of Finance Lease, Liability, Maturity

Future minimum lease commitments (undiscounted) as of March 31, 2025, were as follows (in millions):

	Operating Leases		Finance Leases
2025 (remaining period)	$	11.4	$	0.1
2026	12.7		0.1
2027	10.0		—
2028	7.4		—
2029	4.7		—
Thereafter	21.4		—
Total future minimum lease payments	67.6		0.2
Less: amounts representing interest	(12.8)		—
Total lease liability	$	54.8	$	0.2

XML

Other Assets, Accrued Liabilities and Other Liabilities (Tables)

3 Months Ended

Mar. 31, 2025

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Other Current Assets

Other current assets consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Prepaid assets	$	9.8	$	10.9
Assets held-for-sale	6.0		7.0
Income tax receivable	0.5		0.6
Other	2.4		2.5
Total other current assets	$	18.7	$	21.0

Schedule of Other Assets

Other assets, which are reflected within non-current assets in the Condensed Consolidated Balance Sheets, consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Right-of-use assets	$	53.0	$	53.7
Restricted cash - non-current	0.6		0.5
Other	7.5		8.1
Total other assets	$	61.1	$	62.3

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Accrued expenses	$	12.3	$	13.4
Accrued payroll and employee benefits	22.9		34.1
Accrued interest and exit fees (current portion)	64.3		61.0
Accrued sales and use taxes	0.3		0.4
Accrued income taxes	7.0		0.8
Total accrued liabilities	$	106.8	$	109.7

Schedule of Other Current Liabilities

Other current liabilities consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Operating lease liability, current portion	$	12.9	$	12.9
Other	4.4		4.3
Total other current liabilities	$	17.3	$	17.2

Schedule of Other Liabilities

Other liabilities, which are reflected within non-current liabilities in the Condensed Consolidated Balance Sheets, consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Operating lease liability, net of current portion	$	41.9	$	43.5
Accrued interest (non-current portion)	—		0.7
Other	3.0		2.6
Total other liabilities	$	44.9	$	46.8

XML

Debt Obligations (Tables)

3 Months Ended

Mar. 31, 2025

Debt Disclosure [Abstract]

Schedule of Debt and Finance Lease Obligations

Debt obligations, including finance lease obligations, consisted of the following (in millions):

	March 31, 2025		December 31, 2024
Infrastructure
PRIME minus 1.00% Line of Credit due 2025	$	50.0	$	45.0
3.25% Term Loan due 2026	72.8		74.6
PRIME minus 1.00% Term Loan due 2026	24.2		24.5
Obligations under finance leases	0.2		0.6
Total Infrastructure	$	147.2	$	144.7
Spectrum
8.50% Note due 2025	$	19.3	$	19.3
11.45% Notes due 2025	50.4		50.4
Total Spectrum	$	69.7	$	69.7
Life Sciences
20.00% Notes due 2025	$	25.2	24.0
Total Life Sciences	$	25.2	$	24.0
Non-Operating Corporate
8.50% Senior Secured Notes due 2026	$	330.0	$	330.0
7.50% Convertible Senior Notes due 2026	48.9		48.9
SOFR plus 5.75% Line of Credit due 2025	20.0		20.0
CGIC Unsecured Note due 2026	31.0		31.0
Total Non-Operating Corporate	$	429.9	$	429.9
Total outstanding principal	$	672.0	$	668.3
Unamortized issuance discount, issuance premium, and deferred financing costs	(8.6)		(5.5)
Less: current portion of debt obligations	(523.5)		(162.2)
Debt obligations, net of current portion	$	139.9	$	500.6

Schedule of Maturities of Debt and Finance Lease Obligations

As of March 31, 2025, estimated future aggregate finance lease and debt payments, including interest, were as follows (in millions):

	Finance Leases		Debt		Total
2025 (remaining period) (1)	$	0.1	$	234.5	$	234.6
2026	0.1		507.6		507.7
Total minimum principal and interest payments	0.2		742.1		742.3
Less: Amount representing interest (1)	—		(70.3)		(70.3)
Total aggregate finance lease and debt payments	$	0.2	$	671.8	$	672.0

(1) Excludes exit fees for Spectrum and R2 Technologies.

XML

Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2025

Commitments and Contingencies Disclosure [Abstract]

Schedule of Concentration of Risk, by Risk Factor

The Company's revenue concentrations of 10% and greater were as follows:

		Three Months Ended March 31,
		2025	2024
	Segment	Revenue	Revenue
Customer A	Infrastructure	*	27.6%

*Less than 10% concentration

XML

Share-based Compensation (Tables)

3 Months Ended

Mar. 31, 2025

Share-Based Payment Arrangement [Abstract]

Schedule of Company's Restricted Stock Activity

A summary of INNOVATE’s restricted stock and restricted stock unit activity is as follows:

	Number of Shares	Weighted-Average Grant Date Fair Value
Unvested - December 31, 2024	294,663	$	8.12
Granted	36,881	$	7.66
Vested	(38,835)	$	18.46
Unvested - March 31, 2025	292,709	$	6.70

Schedule of Company's Stock Option Activity

A summary of INNOVATE’s stock option activity is as follows:

	Number of Stock Options	Weighted-Average Exercise Price
Outstanding - December 31, 2024	217,733	$	16.94
Outstanding - March 31, 2025	217,733	$	16.94
Exercisable - March 31, 2025 and December 31, 2024	117,733	$	27.74

XML

Equity and Temporary Equity (Tables)

3 Months Ended

Mar. 31, 2025

Equity [Abstract]

Schedule of Stock by Class

The Company’s preferred shares authorized, issued and outstanding consisted of the following:

	March 31, 2025	December 31, 2024
Preferred shares authorized, $0.001 par value	20,000,000	20,000,000
Series A-3 shares issued and outstanding	6,125	6,125
Series A-4 shares issued and outstanding	10,000	10,000

Schedule of Cash, PIK and Special Cash Dividends

During the three months ended March 31, 2025 and 2024, INNOVATE's Board of Directors (the "Board") declared cash dividends with respect to INNOVATE’s issued and outstanding Series A-3 Preferred Stock and Series A-4 Preferred Stock, as presented in the following tables (in millions):

2025
Declaration Date and Holders of Record Date	March 31, 2025
Payment Date	April 15, 2025
Total Dividend	$	0.3

2024
Declaration Date and Holders of Record Date	March 31, 2024
Payment Date	April 15, 2024
Total Dividend	$	0.3

XML

Operating Segments and Related Information (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Schedule of Company's Operating Segments

Financial information, including revenue and expenses, with respect to the Company’s operating segments, is as follows (in millions):

	Three Months Ended March 31, 2025
	Infrastructure		Life Sciences		Spectrum		Non-Operating Corporate		Other and Eliminations		INNOVATE
Revenue	$	264.9	$	3.1	$	6.2	$	—			$	274.2
Cost of revenue	223.5		2.3		2.9		—		—		228.7
Selling, general and administrative expenses	29.3		3.7		1.9		2.9		—		37.8
Depreciation and amortization	3.1		0.1		1.2		—		—		4.4
Other operating income	(0.1)		—		—		—		—		(0.1)
Income (loss) from operations	$	9.1	$	(3.0)	$	0.2	$	(2.9)	$	—	$	3.4
Other data:
Capital expenditures (1)	$	4.1	$	0.1	$	0.5	$	—	$	—	$	4.7
Investments (2)	$	—	$	1.8	$	—	$	2.3	$	—	$	4.1
Total assets	$	671.9	$	11.7	$	178.3	$	6.1	$	—	$	868.0

(1) Capital expenditures reflect cash expenditures for the three months ended March 31, 2025.

(2) The Company's equity method investments in the Life Sciences segment totaled $0.9 million as of March 31, 2025.

	Three Months Ended March 31, 2024
	Infrastructure		Life Sciences		Spectrum		Non-Operating Corporate		Other and Eliminations		INNOVATE
Revenue	$	307.9	$	1.0	$	6.3	$	—	$	—	$	315.2
Cost of revenue	263.1		0.6		2.9		—		—		266.6
Selling, general and administrative expenses	30.9		3.5		1.9		3.2		—		39.5
Depreciation and amortization	3.0		0.1		1.3		—		—		4.4
Other operating loss (1)	1.6		—		—		0.3		—		1.9
Income (loss) from operations	$	9.3	$	(3.2)	$	0.2	$	(3.5)	$	—	$	2.8
Other data:
Capital expenditures (2)	$	5.2	$	0.1	$	0.3	$	—	$	—	$	5.6
	December 31, 2024
	Infrastructure		Life Sciences		Spectrum		Non-Operating Corporate		Other and Eliminations		INNOVATE
Investments (3)	$	—	$	1.8	$	—	$	1.8	$	—	$	3.6
Total assets	$	683.6	$	11.9	$	178.9	$	16.7	$	—	$	891.1

(1) Other operating loss for the three months ended March 31, 2024, primarily consisted of a loss on disposal related to a plant closure at our Infrastructure segment.

(2) Capital expenditures reflect cash expenditures for the three months ended March 31, 2024.

(3) The Company's equity method investments in the Life Sciences segment totaled $0.9 million as of December 31, 2024.

	Three Months Ended March 31,
	2025		2024
Reconciliation of the consolidated segment income from operations to consolidated loss from operations before income taxes:
Income from operations	$	3.4	$	2.8
Interest expense	(20.2)		(17.2)
Loss from equity investees	(5.9)		(1.2)
Other income (expense), net	4.0		(1.2)
Loss from operations before income taxes	$	(18.7)	$	(16.8)

XML

Basic and Diluted Loss Per Common Share (Tables)

3 Months Ended

Mar. 31, 2025

Earnings Per Share [Abstract]

Schedule of Reconciliation of Net Loss to Net Loss used in the Basic and Diluted EPS Calculations

The following table presents a reconciliation of net loss to net loss used in the basic and diluted EPS calculations (in millions, except shares and per share amounts):

	Three Months Ended March 31,
	2025			2024
Net loss	$	(25.8)		$	(20.1)
Net loss attributable to non-controlling interest and redeemable non-controlling interest	1.3			2.7
Net loss attributable to INNOVATE Corp.	(24.5)			(17.4)
Less: Preferred dividends	0.3			0.3
Net loss attributable to common stockholders and participating preferred stockholders	$	(24.8)		$	(17.7)
Participating shares
Weighted-average common shares outstanding (1)	13,114,804			7,865,361
Series C Preferred stock (1)	—			156,986
Total	13,114,804			8,022,347
Percentage of loss allocated to:
Common stock	100.0		%	98.0		%
Series C Preferred stock	—		%	2.0		%
Numerator for loss per share:
Net loss attributable to common stock holders, basic and diluted	$	(24.8)		$	(17.3)
Net loss attributable to Series C holder, basic and diluted	—			(0.4)
Denominator for loss per share:
Weighted-average common shares outstanding - basic and diluted (1)	13,114,804			7,865,361
Weighted-average Series C shares outstanding - basic and diluted (1)	—			156,986
Loss per share
Loss per common share - basic and diluted (1)	$	(1.89)		$	(2.21)
Loss per Series C share - basic and diluted (1)	$	(1.89)		$	(2.21)

(1) Basic and diluted loss per common share and weighted-average common shares outstanding for the three months ended March 31, 2024, in the table above have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on August 8, 2024.

XML

Fair Value of Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2025

Fair Value Disclosures [Abstract]

Schedule of Financial Instruments Measured at Fair Value on Nonrecurring Basis

The following tables presents the carrying amounts and estimated fair values of the Company’s financial instruments, which were not measured at fair value on a recurring basis and not measured using the equity method of accounting, with fair values shown according to the fair value hierarchy. The tables exclude carrying amounts for cash and cash equivalents and restricted cash (Level 1 measurements), accounts receivable and contract assets, accounts payable, contract liabilities and other current liabilities, and other assets and liabilities (Level 2 measurements) that approximate fair value due to the relatively short periods to maturity (in millions):

March 31, 2025					Fair Value Measurement Using:
	Carrying Value		Estimated Fair Value		Quoted Prices (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets
Measurement alternative investment (1)	$	0.9	$	0.9	$	—	$	—	$	0.9
Total assets not accounted for at fair value	$	0.9	$	0.9	$	—	$	—	$	0.9
Liabilities
Debt obligations (2)	$	663.2	$	618.4	$	—	$	618.4	$	—
Total liabilities not accounted for at fair value	$	663.2	$	618.4	$	—	$	618.4	$	—

(1) Refer to Note 6. Investments for additional information.

(2) Excludes lease obligations accounted for under ASC 842, Leases.

December 31, 2024					Fair Value Measurement Using:
	Carrying Value		Estimated Fair Value		Quoted Prices (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets
Measurement alternative investment (1)	$	0.9	$	0.9	$	—	$	—	$	0.9
Total assets not accounted for at fair value	$	0.9	$	0.9	$	—	$	—	$	0.9
Liabilities
Debt obligations (2)	$	662.2	$	577.1	$	—	$	577.1	$	—
Total liabilities not accounted for at fair value	$	662.2	$	577.1	$	—	$	577.1	$	—

(1) Refer to Note 6. Investments for additional information.

(2) Excludes lease obligations accounted for under ASC 842, Leases.

XML

Supplementary Financial Information (Tables)

3 Months Ended

Mar. 31, 2025

Offsetting [Abstract]

Schedule of Other (Loss) Income, Net

The following table provides information relating to Other income (expense), net (in millions):

	Three Months Ended March 31,
	2025		2024
Gain on step-up of equity method investment	4.4		—
Net loss on extinguishment of debt	—		(2.2)
Interest income	0.4		0.5
Foreign currency translation (loss) gain	(0.4)		0.5
Other	(0.4)		—
Total other income (expense), net	$	4.0	$	(1.2)

Schedule of Restricted Cash and Cash Equivalents

The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts reported within the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Cash Flows (in millions):

	Three Months Ended March 31,
	2025		2024
Cash and cash equivalents, beginning of the period	$	48.8	$	80.8
Restricted cash included in other current assets	—		0.9
Restricted cash included in other assets (non-current)	0.5		0.6
Total cash, cash equivalents and restricted cash, beginning of the period	$	49.3	$	82.3
Cash and cash equivalents, end of the period	$	33.3	$	38.4
Restricted cash included in other current assets	—		0.9
Restricted cash included in other assets (non-current)	0.6		0.6
Total cash and cash equivalents and restricted cash, end of the period	$	33.9	$	39.9
Supplemental cash flow information:
Cash paid for interest	$	19.5	$	19.6
Cash paid for income taxes (proceeds from tax refunds), net	$	0.8	$	(0.8)
Non-cash investing and financing activities:
Accrued interest capitalized into principal debt	$	1.2	$	3.3
Property, plant and equipment included in accounts payable or accrued expenses	$	1.1	$	0.9

Schedule of Cash and Cash Equivalents

The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts reported within the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Cash Flows (in millions):

	Three Months Ended March 31,
	2025		2024
Cash and cash equivalents, beginning of the period	$	48.8	$	80.8
Restricted cash included in other current assets	—		0.9
Restricted cash included in other assets (non-current)	0.5		0.6
Total cash, cash equivalents and restricted cash, beginning of the period	$	49.3	$	82.3
Cash and cash equivalents, end of the period	$	33.3	$	38.4
Restricted cash included in other current assets	—		0.9
Restricted cash included in other assets (non-current)	0.6		0.6
Total cash and cash equivalents and restricted cash, end of the period	$	33.9	$	39.9
Supplemental cash flow information:
Cash paid for interest	$	19.5	$	19.6
Cash paid for income taxes (proceeds from tax refunds), net	$	0.8	$	(0.8)
Non-cash investing and financing activities:
Accrued interest capitalized into principal debt	$	1.2	$	3.3
Property, plant and equipment included in accounts payable or accrued expenses	$	1.1	$	0.9

XML

Organization and Business (Details) - segment	3 Months Ended
	Mar. 31, 2025	Dec. 31, 2024
Business And Organization [Line Items]
Number of reportable segments	3
MediBeacon Inc.
Business And Organization [Line Items]
Percentage of ownership (approximately)	44.70%	45.90%
Triple Ring
Business And Organization [Line Items]
Ownership percentage, fully diluted basis	1.60%
Scaled Cell
Business And Organization [Line Items]
Percentage of ownership (approximately)	20.10%
DBMG
Business And Organization [Line Items]
Controlling interest (approximately)	91.20%
Genoval Orthopedics inc.
Business And Organization [Line Items]
Controlling interest (approximately)	80.00%
R2 Technologies
Business And Organization [Line Items]
Controlling interest (approximately)		81.40%
R2 Technologies | R2 Technologies
Business And Organization [Line Items]
Controlling interest (approximately)	81.00%
HC2 Broadcasting Holdings, Inc
Business And Organization [Line Items]
Controlling interest (approximately)	98.00%
Noncontrolling interest, ownership percentage by parent, fully diluted basis	85.80%
DTV America
Business And Organization [Line Items]
Controlling interest (approximately)	69.20%
Minority Holders
Business And Organization [Line Items]
Percentage of proxy and voting rights from minority holders	2.80%
GMSL
Business And Organization [Line Items]
Controlling interest (approximately)	72.80%

XML

Revenue and Contracts in Process - Schedule of Reconciliation of Revenue from Segments to Consolidated (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Segment Reporting Information [Line Items]
Total revenue	$ 274.2	$ 315.2
Infrastructure
Segment Reporting Information [Line Items]
Total revenue	264.9	307.9
Life Sciences
Segment Reporting Information [Line Items]
Total revenue	3.1	1.0
Spectrum
Segment Reporting Information [Line Items]
Total revenue	$ 6.2	$ 6.3

XML

Revenue and Contracts in Process - Schedule of Accounts Receivable (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Segment Reporting Information [Line Items]
Total accounts receivables with customers	$ 160.4	$ 188.2
Infrastructure
Segment Reporting Information [Line Items]
Total accounts receivables with customers	156.3	184.8
Life Sciences
Segment Reporting Information [Line Items]
Total accounts receivables with customers	2.1	1.5
Spectrum
Segment Reporting Information [Line Items]
Total accounts receivables with customers	$ 2.0	$ 1.9

XML

Revenue and Contracts in Process - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024	Jan. 01, 2024
Revenue from External Customer [Line Items]
Accounts receivable, net, contracts with customers				$ 273.2
Contract assets	$ 135.3		$ 106.3
Contract liabilities	95.3		$ 109.1
Infrastructure
Revenue from External Customer [Line Items]
Contract assets				118.6
Contract liabilities				$ 153.5
Contract assets, increase due to new projects	74.6	$ 15.7
Contract assets, reclassified to receivables	45.6	52.1
Contract liabilities, increase due to new projects	54.0	62.9
Contract liabilities, revenue recognized	67.8	$ 91.0
Remaining performance obligation amount	$ 1,357.8
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01 | Infrastructure | Within One Year
Revenue from External Customer [Line Items]
Remaining performance obligation period	1 year
Remaining performance obligation amount	$ 1,058.6
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01 | Infrastructure | Within Three Years
Revenue from External Customer [Line Items]
Remaining performance obligation period	5 years
Remaining performance obligation amount	$ 299.2
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01 | Spectrum | Broadcast station
Revenue from External Customer [Line Items]
Remaining performance obligation amount	$ 14.6
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01 | Spectrum | Broadcast station | Within One Year
Revenue from External Customer [Line Items]
Remaining performance obligation period	1 year
Remaining performance obligation amount	$ 8.8
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01 | Spectrum | Broadcast station | Within Three Years
Revenue from External Customer [Line Items]
Remaining performance obligation period	3 years
Remaining performance obligation amount	$ 5.8
DBMG | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01 | Infrastructure
Revenue from External Customer [Line Items]
Remaining performance obligation period	2 years

XML

Revenue and Contracts in Process - Schedule of Infrastructure Segment Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Disaggregation of Revenue [Line Items]
Total Infrastructure segment revenue	$ 274.2	$ 315.2
Infrastructure
Disaggregation of Revenue [Line Items]
Revenue	264.3	307.5
Other revenue	0.6	0.4
Total Infrastructure segment revenue	264.9	307.9
Infrastructure | Industrial
Disaggregation of Revenue [Line Items]
Revenue	74.6	84.1
Infrastructure | Commercial
Disaggregation of Revenue [Line Items]
Revenue	53.8	77.3
Infrastructure | Healthcare
Disaggregation of Revenue [Line Items]
Revenue	52.0	34.3
Infrastructure | Transportation
Disaggregation of Revenue [Line Items]
Revenue	44.7	100.4
Infrastructure | Government
Disaggregation of Revenue [Line Items]
Revenue	24.8	2.7
Infrastructure | Leisure
Disaggregation of Revenue [Line Items]
Revenue	6.6	1.0
Infrastructure | Convention
Disaggregation of Revenue [Line Items]
Revenue	5.9	5.5
Infrastructure | Energy
Disaggregation of Revenue [Line Items]
Revenue	$ 1.9	$ 2.2

XML

Revenue and Contracts in Process - Schedule of Contract Assets and Contract Liabilities and Recognized Earnings (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Revenue from Contract with Customer [Abstract]
Costs incurred on contracts in progress	$ 1,245.9	$ 1,435.2
Estimated earnings	97.5	75.8
Contract revenue earned on uncompleted contracts	1,343.4	1,511.0
Less: progress billings	1,303.4	1,513.8
Net of cost earned on uncompleted contracts	40.0	(2.8)
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract]
Contract assets	135.3	106.3
Contract liabilities	(95.3)	(109.1)
Net contract assets (liabilities)	$ 40.0	$ (2.8)

XML

Revenue and Contracts in Process - Schedule of Infrastructure Segment Contract with Customer, Asset and Liability (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Segment Reporting Information [Line Items]
Contract assets	$ 135.3	$ 106.3
Contract liabilities	(95.3)	(109.1)
Infrastructure
Segment Reporting Information [Line Items]
Cost in excess of billings and estimated earnings	71.2	50.8
Conditional retainage	64.1	55.5
Contract assets	135.3	106.3
Billings in excess of costs and estimated earnings	(127.4)	(147.7)
Conditional retainage	32.1	38.6
Contract liabilities	$ (95.3)	$ (109.1)

XML

Revenue and Contracts in Process - Schedule of Infrastructure Segment Revenue (Details) - Infrastructure $ in Millions	Mar. 31, 2025 USD ($)
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 1,357.8
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01 | Within One Year
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 1,058.6
Remaining performance obligation period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01 | Within Five Years
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 299.2
Remaining performance obligation period	5 years
Healthcare
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 247.1
Healthcare | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01 | Within One Year
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 176.2
Remaining performance obligation period	1 year
Healthcare | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01 | Within Five Years
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 70.9
Remaining performance obligation period	5 years
Transportation
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 193.4
Transportation | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01 | Within One Year
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 114.6
Remaining performance obligation period	1 year
Transportation | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01 | Within Five Years
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 78.8
Remaining performance obligation period	5 years
Commercial
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 441.4
Commercial | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01 | Within One Year
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 333.8
Remaining performance obligation period	1 year
Commercial | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01 | Within Five Years
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 107.6
Remaining performance obligation period	5 years
Industrial
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 285.5
Industrial | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01 | Within One Year
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 250.8
Remaining performance obligation period	1 year
Industrial | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01 | Within Five Years
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 34.7
Remaining performance obligation period	5 years
Government
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 167.3
Government | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01 | Within One Year
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 162.0
Remaining performance obligation period	1 year
Government | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01 | Within Five Years
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 5.3
Remaining performance obligation period	5 years
Leisure
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 18.9
Leisure | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01 | Within One Year
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 17.0
Remaining performance obligation period	1 year
Leisure | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01 | Within Five Years
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 1.9
Remaining performance obligation period	5 years
Convention
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 2.6
Convention | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01 | Within One Year
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 2.6
Remaining performance obligation period	1 year
Convention | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01 | Within Five Years
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 0.0
Remaining performance obligation period	5 years
Energy
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 1.6
Energy | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01 | Within One Year
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 1.6
Remaining performance obligation period	1 year
Energy | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01 | Within Five Years
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 0.0
Remaining performance obligation period	5 years

XML

Revenue and Contracts in Process - Schedule of Life Sciences Segment Disaggregation of Revenue (Details) - Life Sciences - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Segment Reporting Information [Line Items]
Revenue	$ 3.1	$ 1.0
Systems and consumables revenue
Segment Reporting Information [Line Items]
Revenue	$ 3.1	$ 1.0

XML

Revenue and Contracts in Process - Schedule of Spectrum Segment Disaggregation of Revenue (Details) - Spectrum - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Segment Reporting Information [Line Items]
Revenue	$ 6.2	$ 6.3
Broadcast station
Segment Reporting Information [Line Items]
Revenue	$ 6.2	$ 6.3

XML

Accounts Receivable, Net - Schedule of Accounts Receivable, net (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024	Jan. 01, 2024
Receivables [Abstract]
Contracts in progress	$ 156.3	$ 184.9
Unbilled retentions	0.1	0.1
Trade receivables	4.1	3.3
Other receivables	4.1	5.8
Allowance for expected credit losses	(0.1)	(0.1)
Total	$ 164.5	$ 194.0	$ 278.4

XML

Accounts Receivable, Net - Narrative (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024	Jan. 01, 2024
Receivables [Abstract]
Accounts receivable, net	$ 164.5	$ 194.0	$ 278.4

XML

Inventory (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Inventory Disclosure [Abstract]
Raw materials and consumables	$ 18.5	$ 19.6
Work in process	0.4	0.4
Finished goods	0.8	0.8
Total inventory	$ 19.7	$ 20.8

XML

Investments - Schedule of Company Investments (Details) $ in Millions	3 Months Ended
	Mar. 31, 2025 USD ($) company	Mar. 31, 2024 USD ($)	Dec. 31, 2024 USD ($)
Schedule of Investments [Line Items]
Total	$ 4.1		$ 3.6
Loss from equity investees	$ 5.9	$ 1.2
Number of publicly traded companies | company	2
Common Stock
Schedule of Investments [Line Items]
Equity method	$ 0.9		0.9
Fair value	2.3		1.8
Measurement alternative	0.9		0.9
Total	$ 4.1		$ 3.6

XML

Investments - MedicBeacon Narrative (Details) - USD ($)		3 Months Ended
	Jan. 17, 2025	Mar. 31, 2025	Mar. 31, 2024	Jan. 18, 2025	Dec. 31, 2024
Schedule of Investments [Line Items]
Conversion of the convertible notes		$ 1,500,000
MediBeacon Inc.
Schedule of Investments [Line Items]
Beneficial ownership percentage		44.70%			45.90%
MediBeacon Inc. | Life Sciences
Schedule of Investments [Line Items]
Gain on sale of investments		$ 4,400,000
Realized loss, equity issuance		5,900,000
Equity method investments		0			$ 0
Cumulative unrecognized loss on equity method investments		15,400,000
MediBeacon Inc. | Life Sciences | Huadong
Schedule of Investments [Line Items]
Convertible notes and accrued interest converted to stock, in process	$ 7,500,000
Beneficial ownership percentage	45.90%			44.70%
Ownership percentage, fully diluted basis	40.10%			39.70%
MediBeacon Inc. | Life Sciences | Convertible Debt
Schedule of Investments [Line Items]
Notes receivable, face amount	$ 11,400,000
Accrued interest receivable	1,500,000
Convertible notes and accrued interest converted to stock	$ 12,900,000
MediBeacon Inc. | Notes Receivable | Life Sciences
Schedule of Investments [Line Items]
Accrued interest receivable		300,000			1,700,000
Notes receivable		500,000			$ 12,000,000
Interest income		$ 100,000	$ 300,000

XML

Investments - Marketable Securities Narrative (Details) - USD ($) $ in Millions	1 Months Ended		3 Months Ended
	Mar. 31, 2025	Oct. 31, 2024	Mar. 31, 2025
Investments, Debt and Equity Securities [Abstract]
Payments to acquire marketable securities	$ 0.3	$ 2.0
Payments to acquire marketable securities, percentage of issuer's outstanding common stock (less than)	1.00%	1.00%	1.00%
Marketable securities unrealized gain			$ 0.2

XML

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, net (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Property, Plant and Equipment [Line Items]
Property, plant, and equipment and finance lease right-of-use asset, gross	$ 286.4	$ 281.8
Less: Accumulated depreciation	153.8	148.2
Property, plant, and equipment and finance lease right-of-use asset, net	132.6	133.6
Equipment, furniture and fixtures, and software
Property, Plant and Equipment [Line Items]
Property, plant, and equipment and finance lease right-of-use asset, gross	212.6	211.0
Building and leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant, and equipment and finance lease right-of-use asset, gross	36.9	36.8
Land
Property, Plant and Equipment [Line Items]
Property, plant, and equipment and finance lease right-of-use asset, gross	18.6	18.6
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant, and equipment and finance lease right-of-use asset, gross	10.9	8.0
Plant and transportation equipment
Property, Plant and Equipment [Line Items]
Property, plant, and equipment and finance lease right-of-use asset, gross	$ 7.4	$ 7.4

XML

Property, Plant and Equipment, Net - Narrative (Details) $ in Millions	3 Months Ended
	Mar. 31, 2025 USD ($) building	Mar. 31, 2024 USD ($)	Dec. 31, 2024 USD ($) building
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 5.9	$ 6.5
Depreciation expense within cost of revenue	3.5	$ 4.0
Finance lease	0.1		$ 0.5
Property, plant, and equipment and finance lease right-of-use asset, gross	286.4		281.8
Property, plant and equipment, net	132.6		133.6
Assets held for sale	$ 6.0		$ 7.0
Number of buildings held-for-sale | building	1		1
Internal-Use Software
Property, Plant and Equipment [Line Items]
Property, plant, and equipment and finance lease right-of-use asset, gross	$ 20.7		$ 20.7
Property, plant and equipment, net	$ 9.0		$ 9.8

XML

Goodwill and Intangibles, Net - Schedule of Changes in the Carrying Amount of Goodwill (Details) $ in Millions	Mar. 31, 2025 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 126.7
Ending balance	126.7
Infrastructure
Goodwill [Roll Forward]
Beginning balance	105.3
Ending balance	105.3
Spectrum
Goodwill [Roll Forward]
Beginning balance	21.4
Ending balance	$ 21.4

XML

Goodwill and Intangibles, Net - Schedule of Indefinite-lived Intangible Assets (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Acquired Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	$ 107.7	$ 107.7
FCC licenses
Acquired Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	$ 107.7	$ 107.7

XML

Goodwill and Intangibles, Net - Schedule of Definite Lived Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2025	Dec. 31, 2024
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 128.8	$ 129.0
Accumulated Amortization	(66.1)	(64.3)
Net/Total	$ 62.7	$ 64.7
Trade names
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Original Useful Life	15 years	15 years
Gross Carrying Amount	$ 25.1	$ 25.1
Accumulated Amortization	(11.4)	(11.0)
Net/Total	$ 13.7	$ 14.1
Customer relationships and contracts
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Original Useful Life	11 years	11 years
Gross Carrying Amount	$ 87.4	$ 87.4
Accumulated Amortization	(50.4)	(49.1)
Net/Total	$ 37.0	$ 38.3
Channel sharing arrangements
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Original Useful Life	35 years	35 years
Gross Carrying Amount	$ 12.6	$ 12.6
Accumulated Amortization	(2.3)	(2.2)
Net/Total	$ 10.3	$ 10.4
Other
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Original Useful Life	10 years	10 years
Gross Carrying Amount	$ 3.7	$ 3.9
Accumulated Amortization	(2.0)	(2.0)
Net/Total	$ 1.7	$ 1.9

XML

Goodwill and Intangibles, Net - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 2.0	$ 1.9

XML

Leases - Schedule of Right-of-use Assets and Liabilities (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Right-of-use assets:
Operating lease	$ 53.0	$ 53.7
Finance lease	0.1	0.5
Total right-of-use assets	53.1	54.2
Lease liabilities:
Current portion of operating lease	12.9	12.9
Non-current portion of operating lease	41.9	43.5
Finance lease	0.2	0.6
Total lease liabilities	$ 55.0	$ 57.0
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other assets	Other assets
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, plant and equipment, net	Property, plant and equipment, net
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other current liabilities	Other current liabilities
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other liabilities	Other liabilities
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Debt obligations	Debt obligations

XML

Leases - Schedule of Components of Lease Expense (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Finance lease cost:
Amortization of right-of-use assets	$ 0.1	$ 0.1
Net finance lease cost	0.1	0.1
Operating lease cost	4.2	4.5
Variable lease cost	0.2	0.1
Sublease income	0.0	(0.2)
Total non-current lease cost	4.5	4.5
Short-term lease costs	8.0	7.2
Total lease cost	$ 12.5	$ 11.7

XML

Leases - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$ 5.2	$ 5.0
Financing cash flows for finance leases	0.1	0.1
Right-of-use assets obtained in exchange for new lease liabilities:
Operating leases	$ 2.5	$ 2.6

XML

Leases - Schedule of Weighted Average Remaining Lease Term and Discount Rate (Details)	Mar. 31, 2025	Dec. 31, 2024
Leases [Abstract]
Weighted-average remaining lease term (years) - operating leases	7 years 3 months 18 days	7 years 4 months 24 days
Weighted-average remaining lease term (years) - finance leases	2 years 7 months 6 days	2 years 8 months 12 days
Weighted-average discount rate - operating leases	6.20%	6.10%
Weighted-average discount rate - finance leases	5.00%	5.30%

XML

Leases - Schedule of Future Payments of Lease Liabilities (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Operating Leases
2025 (remaining period)	$ 11.4
2026	12.7
2027	10.0
2028	7.4
2029	4.7
Thereafter	21.4
Total future minimum lease payments	67.6
Less: amounts representing interest	(12.8)
Total lease liability	54.8
Finance Leases
2025 (remaining period)	0.1
2026	0.1
2027	0.0
2028	0.0
2029	0.0
Thereafter	0.0
Total future minimum lease payments	0.2
Less: amounts representing interest	0.0
Total lease liability	$ 0.2	$ 0.6

XML

Leases - Narrative (Details) - DBMGi $ in Millions	Mar. 31, 2025 USD ($) installment	Dec. 31, 2024 USD ($)	May 01, 2024 USD ($) lease installment
Lessee, Lease, Description [Line Items]
Number of property leases with amended termination dates | lease			3
Early lease termination payment receivable | $	$ 4.0		$ 12.0
Surrender fees, number of equal installments to be received | installment			3
Surrender fees payments received for lease termination | $		$ 4.0
Surrender fees, number of equal installments to be received remaining | installment	2

XML

Other Assets, Accrued Liabilities and Other Liabilities - Schedule of Other Current Assets (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid assets	$ 9.8	$ 10.9
Assets held-for-sale	6.0	7.0
Income tax receivable	0.5	0.6
Other	2.4	2.5
Total other current assets	$ 18.7	$ 21.0

XML

Other Assets, Accrued Liabilities and Other Liabilities - Schedule of Other Assets (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024	Mar. 31, 2024	Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Right-of-use assets	$ 53.0	$ 53.7
Restricted cash - non-current	0.6	0.5	$ 0.6	$ 0.6
Other	7.5	8.1
Total other assets	$ 61.1	$ 62.3

XML

Other Assets, Accrued Liabilities and Other Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Accrued expenses	$ 12.3	$ 13.4
Accrued payroll and employee benefits	22.9	34.1
Accrued interest and exit fees (current portion)	64.3	61.0
Accrued sales and use taxes	0.3	0.4
Accrued income taxes	7.0	0.8
Total accrued liabilities	$ 106.8	$ 109.7

XML

Other Assets, Accrued Liabilities and Other Liabilities - Schedule of Other Current Liabilities (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Operating lease liability, current portion	$ 12.9	$ 12.9
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Total other current liabilities	Total other current liabilities
Other	$ 4.4	$ 4.3
Total other current liabilities	$ 17.3	$ 17.2

XML

Other Assets, Accrued Liabilities and Other Liabilities - Schedule of Other Liabilities (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Operating lease liability, net of current portion	$ 41.9	$ 43.5
Accrued interest (non-current portion)	0.0	0.7
Other	3.0	2.6
Total other liabilities	$ 44.9	$ 46.8

XML

Debt Obligations - Schedule of Debt (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Dec. 31, 2024	Dec. 31, 2021	Feb. 01, 2021
Debt Instrument [Line Items]
Obligations under finance leases	$ 0.2	$ 0.6
Total aggregate finance lease and debt payments	672.0	668.3
Unamortized issuance discount, issuance premium, and deferred financing costs	(8.6)	(5.5)
Less: current portion of debt obligations	(523.5)	(162.2)
Debt obligations, net of current portion	139.9	500.6
Infrastructure
Debt Instrument [Line Items]
Obligations under finance leases	0.2	0.6
Total aggregate finance lease and debt payments	147.2	144.7
Spectrum
Debt Instrument [Line Items]
Total aggregate finance lease and debt payments	69.7	69.7
Life Sciences
Debt Instrument [Line Items]
Total aggregate finance lease and debt payments		24.0
Non-Operating Corporate
Debt Instrument [Line Items]
Total aggregate finance lease and debt payments	429.9	429.9
8.50% Note due 2025 | Spectrum
Debt Instrument [Line Items]
Outstanding debt	19.3	19.3
11.45% Notes due 2025 | Spectrum
Debt Instrument [Line Items]
Outstanding debt	$ 50.4	50.4
20.00% Notes due 2025 | Life Sciences
Debt Instrument [Line Items]
Interest rate	20.00%
8.50% Senior Secured Notes due 2026 | Secured Debt | Non-Operating Corporate
Debt Instrument [Line Items]
Interest rate	8.50%		8.50%	8.50%
Outstanding debt	$ 330.0	330.0
7.50% Convertible Senior Notes due 2026 | Non-Operating Corporate
Debt Instrument [Line Items]
Interest rate	7.50%
Outstanding debt	$ 48.9	48.9
SOFR plus 5.75% Line of Credit due 2025 | Non-Operating Corporate
Debt Instrument [Line Items]
Basis spread on variable rate	5.75%
Outstanding debt	$ 20.0	20.0
CGIC Unsecured Note due 2026 | Non-Operating Corporate
Debt Instrument [Line Items]
Outstanding debt	$ 31.0	31.0
Revolving Credit Facility | PRIME minus 1.00% Line of Credit due 2025 | Line of Credit | Infrastructure | DBM Global Credit Facilities
Debt Instrument [Line Items]
Basis spread on variable rate	1.00%
Revolving Credit Facility | 3.25% Term Loan due 2026 | Term Loan | Infrastructure | DBM Global Credit Facilities
Debt Instrument [Line Items]
Interest rate	3.25%
Outstanding debt		74.6
Revolving Credit Facility | PRIME minus 1.00% Term Loan due 2026 | Line of Credit | Infrastructure | DBM Global Credit Facilities
Debt Instrument [Line Items]
Basis spread on variable rate	1.00%
Outstanding debt	$ 24.2	$ 24.5

XML

Debt Obligations - Schedule of Aggregate Debt and Finance Lease Maturities (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Finance Leases
2025 (remaining period)	$ 0.1
2026	0.1
Total future minimum lease payments	0.2
Less: Amount representing interest	0.0
Total lease liability	0.2	$ 0.6
Debt
2025 (remaining period)	234.5
2026	507.6
Total minimum principal and interest payments	742.1
Less: Amount representing interest	(70.3)
Total aggregate finance lease and debt payments	671.8
Total
2025 (remaining period)	234.6
2026	507.7
Total minimum principal and interest payments	742.3
Less: Amount representing interest	(70.3)
Total aggregate finance lease and debt payments	$ 672.0	$ 668.3

XML

Debt Obligations - Infrastructure Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Dec. 31, 2024	Jun. 28, 2024
Revolving Credit Facility | PRIME minus 1.00% Line of Credit due 2025 | Infrastructure | UMB Bank
Debt Instrument [Line Items]
Line of credit, maximum amount	$ 135.0
Interest rate, effective percentage	6.72%	6.98%
Commitment fee percentage	0.25%
Revolving Credit Facility | PRIME minus 1.00% Line of Credit due 2025 | Line of Credit | Infrastructure | DBM Global Credit Facilities
Debt Instrument [Line Items]
Basis spread on variable rate	1.00%
Revolving Credit Facility | PRIME minus 1.00% Line of Credit due 2025 | Line of Credit | Infrastructure | DBM Global Credit Facilities | UMB Bank
Debt Instrument [Line Items]
Outstanding debt	$ 50.0	$ 45.0
Availability for revolving loans	$ 84.9	89.9
Revolving Credit Facility | 3.25% Term Loan due 2026 | Infrastructure | UMB Bank
Debt Instrument [Line Items]
Interest rate	3.25%
Interest rate, effective percentage	3.30%
Revolving Credit Facility | 3.25% Term Loan due 2026 | Term Loan | Infrastructure | UMB Bank
Debt Instrument [Line Items]
Interest rate	3.25%
Revolving Credit Facility | 3.25% Term Loan due 2026 | Term Loan | Infrastructure | DBM Global Credit Facilities
Debt Instrument [Line Items]
Interest rate	3.25%
Outstanding debt		74.6
Revolving Credit Facility | 3.25% Term Loan due 2026 | Term Loan | Infrastructure | DBM Global Credit Facilities | UMB Bank
Debt Instrument [Line Items]
Interest rate	3.25%
Outstanding debt	$ 72.8
Revolving Credit Facility | PRIME minus 1.00% Term Loan due 2026 | Line of Credit | Infrastructure | DBM Global Credit Facilities
Debt Instrument [Line Items]
Outstanding debt	$ 24.2	$ 24.5
Basis spread on variable rate	1.00%
Revolving Credit Facility | PRIME minus 1.00% Term Loan due 2026 | Term Loan | Infrastructure | UMB Bank
Debt Instrument [Line Items]
Outstanding debt			$ 25.0
Minimum
Debt Instrument [Line Items]
Finance lease, interest rate	3.00%
Minimum | Revolving Credit Facility | PRIME minus 1.00% Line of Credit due 2025 | Infrastructure | UMB Bank
Debt Instrument [Line Items]
Interest rate	4.25%
Maximum
Debt Instrument [Line Items]
Finance lease, interest rate	6.80%

XML

Debt Obligations - Spectrum Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Nov. 09, 2024	Mar. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Nov. 30, 2023
Debt Instrument [Line Items]
Accrued interest and exit fees (current portion)		$ 64.3	$ 61.0
Spectrum | Senior Notes
Debt Instrument [Line Items]
Additional exit fee payable				$ 8.3
Exit fees (non-current portion)		15.9	15.9
Accrued interest and exit fees (current portion)		$ 22.4	$ 20.5
Exit fees	$ 2.0
Spectrum | Senior Notes | HC2 Broadcasting Holdings, Inc
Debt Instrument [Line Items]
Number of warrants outstanding (in shares)					145,825
Exercise price of warrants (in usd per share)					$ 0.01
Spectrum | Senior Notes | Weighted Average
Debt Instrument [Line Items]
Interest rate, effective percentage		22.90%	22.80%
8.50% Note due 2025 | Spectrum | Senior Notes
Debt Instrument [Line Items]
Interest rate		8.50%
11.45% Notes due 2025 | Spectrum | Senior Notes
Debt Instrument [Line Items]
Interest rate		11.45%

XML

Debt Obligations - Life Sciences Narrative (Details) - USD ($) $ in Millions		3 Months Ended
	Jan. 31, 2024	Mar. 31, 2025	Mar. 31, 2024	Aug. 01, 2025	Dec. 31, 2024	Jan. 30, 2024
Debt Instrument [Line Items]
Accrued interest and exit fees (current portion)		$ 64.3			$ 61.0
Total aggregate finance lease and debt payments		$ 672.0			668.3
Life Sciences
Debt Instrument [Line Items]
Total aggregate finance lease and debt payments					24.0
Life Sciences | 20.00% Notes due 2025
Debt Instrument [Line Items]
Interest rate		20.00%
R2 Technologies | Related Party | Life Sciences
Debt Instrument [Line Items]
Interest rate	20.00%
Interest cost relating to contractual interest coupon		$ 4.5	$ 0.9
Interest costs capitalized		$ 1.2	$ 0.7
R2 Technologies | Related Party | Life Sciences | 20.00% Notes due 2025
Debt Instrument [Line Items]
Interest rate	20.00%	20.00%
Face amount	$ 20.0
Short-term debt		$ 25.2			24.0
Accrued interest and exit fees (current portion)	$ 2.6
Exit fee percentage	10.50%	12.41%
Exit fees	$ 2.2	$ 8.7
Debt covenant, maturity, number of days after event	5 days
Debt covenant, proceeds received amount to cause debt maturity	$ 20.0
Optional prepayment, number of days written notice	5 days
Additional exit fee payable		1.0
Increase in exit fee per month		$ 1.0
Increase in exit fee percentage		0.17%
Exit fees (non-current portion)		$ 16.5			7.9
Outstanding debt		36.4			$ 31.9
Total aggregate finance lease and debt payments		25.2
Unamortized discount		$ 5.3
Interest rate, effective percentage		51.30%			57.80%
R2 Technologies | Related Party | Life Sciences | 20.00% Notes due 2025 | Forecast
Debt Instrument [Line Items]
Additional exit fee payable				$ 5.0
R2 Technologies | Related Party | Life Sciences | 20.00% Senior Notes Due 2024
Debt Instrument [Line Items]
Interest rate						20.00%
Short-term debt						$ 17.4

XML

Debt Obligations - Non-Operating Corporate 2026 Senior Secured Notes Narrative (Details) - 8.50% Senior Secured Notes due 2026 - Secured Debt - Non-Operating Corporate - USD ($)	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024	Dec. 31, 2021	Feb. 01, 2021
Debt Instrument [Line Items]
Face amount				$ 330,000,000
Interest rate	8.50%			8.50%	8.50%
Debt issued, percentage of par value				100.00%
Interest rate, effective percentage				9.30%
Debt issuance costs				$ 10,800,000
Amortization of discount on investments, net	$ 7,600,000	$ 7,600,000
Debt issuance costs, net	$ 2,200,000		$ 2,800,000

XML

Debt Obligations - Non-Operating Corporate 2026 Convertible Notes Narrative (Details)	3 Months Ended
	Mar. 31, 2025 USD ($) $ / shares	Mar. 31, 2024 USD ($)	Dec. 31, 2024 USD ($)	Jul. 31, 2024 USD ($)	Feb. 01, 2021 USD ($) $ / shares
Debt Instrument [Line Items]
Accrued interest and exit fees (current portion)	$ 64,300,000		$ 61,000,000.0
7.50% Convertible Senior Notes due 2026 | Non-Operating Corporate
Debt Instrument [Line Items]
Interest rate	7.50%
Outstanding debt	$ 48,900,000		48,900,000
7.50% Convertible Senior Notes due 2026 | Convertible Debt | Non-Operating Corporate
Debt Instrument [Line Items]
Face amount					$ 51,800,000
Interest rate					7.50%
Debt issued, percentage of par value					100.00%
Embedded conversion feature, fair value					$ 12,300,000
Interest rate, effective percentage					3.21%
Unamortized premium	3,200,000		3,800,000		$ 12,300,000
Debt issuance costs					$ 1,100,000
Debt instrument, repurchase principal amount				$ 2,900,000
Debt Instrument repurchase amount				1,100,000
Accrued interest and exit fees (current portion)				$ 100,000
Outstanding debt	51,800,000		52,300,000
Debt issuance costs, net	300,000		$ 400,000
Interest cost relating to contractual interest coupon	400,000	$ 500,000
Amortization of discount on investments, net	$ 400,000	$ 500,000
Convertible notes, conversion ratio	0.0236327
Conversion price (in usd per share) | $ / shares					$ 42.31
Share price (in usd per share) | $ / shares	$ 7.83

XML

Debt Obligations - Non-Operating Corporate Revolving Line of Credit Narrative (Details) - Revolving Credit Facility - Revolving Credit Agreement - Line of Credit - Non-Operating Corporate - USD ($)	3 Months Ended
	Mar. 31, 2025	Dec. 31, 2024
Debt Instrument [Line Items]
Face amount	$ 20,000,000
Line of credit outstanding	$ 20,000,000	$ 20,000,000
Basis spread on variable rate	5.75%
Interest rate, effective percentage	10.30%	10.60%
Commitment fee percentage	1.00%
Asset sale prepayment requirement threshold	$ 10,000,000

XML

Debt Obligations - Non-Operating Corporate CGIC Unsecured Notes Due 2026 Narrative (Details) - USD ($)		3 Months Ended
	Apr. 26, 2024	Mar. 31, 2025	Mar. 31, 2024	May 08, 2025	Dec. 31, 2024	May 09, 2024	May 08, 2024	May 09, 2023	Dec. 31, 2021	Feb. 01, 2021
Debt Instrument [Line Items]
Cash paid for interest		$ 19,500,000	$ 19,600,000
Accrued interest and exit fees (current portion)		$ 64,300,000			$ 61,000,000.0
Non-Operating Corporate | Secured Debt | 8.50% Senior Secured Notes due 2026
Debt Instrument [Line Items]
Face amount									$ 330,000,000
Interest rate		8.50%							8.50%	8.50%
Interest rate, effective percentage									9.30%
CGIC | Non-Operating Corporate | Secured Debt
Debt Instrument [Line Items]
Face amount								$ 35,100,000
Repayments of long-term debt	$ 4,100,000
CGIC | Non-Operating Corporate | Secured Debt | 8.50% Senior Secured Notes due 2026
Debt Instrument [Line Items]
Interest cost relating to contractual interest coupon		$ 1,400,000	1,600,000
Cash paid for interest		1,200,000	$ 800,000
Accrued interest and exit fees (current portion)		$ 3,600,000			$ 3,400,000
DBMGi | Non-Operating Corporate
Debt Instrument [Line Items]
Interest rate						16.00%	9.00%
Interest rate, effective percentage		17.50%			17.50%
Debt covenant, mandatory prepayment, proceeds from certain asset sales, amount threshold		$ 3,000,000
Debt covenant, mandatory prepayment, proceeds from equity sales percentage		12.50%
DBMGi | Non-Operating Corporate | Forecast
Debt Instrument [Line Items]
Interest rate				32.00%

XML

Income Taxes (Details) - USD ($)	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024
Operating Loss Carryforwards [Line Items]
Income tax expense	$ 7,100,000	$ 3,300,000
Unrecognized tax benefits that would impact effective tax rate	0	$ 0
Operating loss carryforwards, decrease for uncertain tax positions	$ 58,700,000
Domestic Tax Authority
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards			$ 174,300,000
Operating loss carryforwards, US			117,700,000
Domestic Tax Authority | Various Nonconsolidated Subsidiaries
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards			149,400,000
Net operating loss, not subject to expiration			113,300,000
Net operating losses subject to expiration			36,100,000
Domestic Tax Authority | R2 Technologies
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards			102,800,000
Domestic Tax Authority | DTV America
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards			44,100,000
Domestic Tax Authority | Other Entities
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards			$ 2,500,000

XML

Commitments and Contingencies - Narrative (Details) - DBMG - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Credit And Security Agreements
Loss Contingencies [Line Items]
Letters of credit outstanding	$ 0.1	$ 0.1
Performance Bonds
Loss Contingencies [Line Items]
Letters of credit outstanding	$ 259.1	$ 183.9

XML

Commitments and Contingencies - Schedule of Concentration of Risk, by Risk Factor (Details)	3 Months Ended
	Mar. 31, 2024
Customer A | Revenue | Customer Concentration Risk | Infrastructure
Concentration Risk [Line Items]
Concentration risk percentage	27.60%

XML

Share-based Compensation - Narrative (Details) - USD ($) shares in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 800,000	$ 400,000
Unrecognized compensation expense, period for recognition (in years)	6 months
Intrinsic value of options outstanding	$ 0
Average remaining life of option outstanding	7 years 8 months 12 days
Maximum contractual term of company's exercisable options	10 years
Unvested stock options (in shares)	100
Compensation expense unrecognized	$ 200,000
Restricted Stock and Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate fair value of restricted common stock vested	300,000	$ 200,000
Unrecognized compensation expense	$ 1,200,000
Unrecognized compensation expense, period for recognition (in years)	1 year 4 months 24 days
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service period (in years)	1 year
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service period (in years)	3 years

XML

Share-based Compensation - Schedule of Company's Restricted Stock Activity (Details) - Restricted Stock and Restricted Stock Units	3 Months Ended
	Mar. 31, 2025 $ / shares shares
Number of Shares
Unvested at beginning of period (in shares) | shares	294,663
Granted (in shares) | shares	36,881
Vested (in shares) | shares	(38,835)
Unvested at ending of period (in shares) | shares	292,709
Weighted-Average Grant Date Fair Value
Unvested at beginning of period (in usd per share) | $ / shares	$ 8.12
Granted (in usd per share) | $ / shares	7.66
Vested (in usd per share) | $ / shares	18.46
Unvested at ending of period (in usd per share) | $ / shares	$ 6.70

XML

Share-based Compensation - Schedule of Company's Stock Option Activity (Details) - $ / shares	Mar. 31, 2025	Dec. 31, 2024
Number of Stock Options
Exercisable (in shares)	117,733	117,733
Weighted-Average Exercise Price
Exercisable (in usd per share)	$ 27.74	$ 27.74

XML

Equity and Temporary Equity - 2024 Rights Offering and Concurrent Private Placement Narrative (Details) - USD ($)					3 Months Ended
	Jun. 18, 2024	Apr. 24, 2024	Mar. 28, 2024	Mar. 08, 2024	Mar. 31, 2024	Mar. 31, 2025	Dec. 31, 2024
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares issued (in shares)						13,447,060	13,410,179
Series C Preferred Stock
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock value outstanding	$ 0
Private Placement | Series C Preferred Stock
Accumulated Other Comprehensive Income (Loss) [Line Items]
Consideration to be received on sale of stock			$ 25,000,000
Private Placement | Series C Preferred Stock | Lancer Capital
Accumulated Other Comprehensive Income (Loss) [Line Items]
Consideration to be received on sale of stock		$ 6,300,000
Issuance of common stock (in shares)		6,286
Rights Offering
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares issued (in shares)		530,611
Cash proceeds from the sale of common stock		$ 3,700,000
Rights Offering | Previously Reported
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares issued (in shares)		5,306,105
Rights Offering and Concurrent Private Placement
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cash proceeds from the sale of common stock		$ 35,000,000
Stock issuance cost other offering expenses		$ 1,800,000
Rights Offering and Concurrent Private Placement | Series C Preferred Stock
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock (in shares)	31,286
Number of shares to be issued upon conversion of preferred stock (in shares)	4,469,390
Rights Offering and Concurrent Private Placement | Series C Preferred Stock | Previously Reported
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares to be issued upon conversion of preferred stock (in shares)	44,693,895
Lancer Capital | Rights Offering For Existing Shareholders
Accumulated Other Comprehensive Income (Loss) [Line Items]
Backstop commitment amount				$ 19,000,000	$ 19,000,000
Consideration to be received on sale of stock			$ 25,000,000
Issuance of common stock (in shares)			25,000
Lancer Capital | Private Placement | Preferred stock and fixed maturities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of preferred stock in private placement				$ 16,000,000	$ 16,000,000
Lancer Capital | Rights Offering and Concurrent Private Placement | Series C Preferred Stock
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock (in shares)		6,286

XML

Equity and Temporary Equity - Reverse Stock Split Narrative (Details)	Aug. 08, 2024 shares	Mar. 31, 2025 $ / shares shares	Dec. 31, 2024 $ / shares shares	Aug. 07, 2024 shares
Equity [Abstract]
Reverse stock split, conversion ratio	0.1
Common stock, par value (in usd per share) | $ / shares		$ 0.001	$ 0.001
Common stock, shares outstanding (in shares)	13,166,057	13,283,218	13,261,379	130,529,931
Incremental shares issued for fractional shares (in shares)	113,064

XML

Equity and Temporary Equity - Schedule of Stock by Class (Details) - $ / shares	Mar. 31, 2025	Dec. 31, 2024
Class of Stock [Line Items]
Preferred stock, par value (in usd per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Series A-3 Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares issued (in shares)	6,125	6,125
Preferred stock, shares outstanding (in shares)	6,125	6,125
Series A-4 Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares issued (in shares)	10,000	10,000
Preferred stock, shares outstanding (in shares)	10,000	10,000

XML

Equity and Temporary Equity - Series A-3 and Series A-4 Shares Narrative (Details) - USD ($) $ / shares in Units, $ in Millions			3 Months Ended
	Aug. 08, 2024	Jul. 01, 2021	Mar. 31, 2025	Dec. 31, 2024
Series A-3 and A-4 Preferred Stock
Class of Stock [Line Items]
Preferred stock cumulative cash dividend rate			7.50%
Preferred stock dividend rate			4.00%
Accreting dividend threshold rate			7.25%
Volume weighted average price threshold percentage			150.00%
Preferred stock force conversion, trading days to calculate volume weighted average price			30 days
Preferred stock trading days to calculate volume weighted average price (at least)			20 days
Preferred stock trading days to calculate volume weighted average price, trading day period			30 days
Consent rights percentage (at least)			75.00%
Number of shares to be issued upon conversion of preferred stock (in shares)			259,212	290,672
Series A-3 and A-4 Preferred Stock | Maximum
Class of Stock [Line Items]
Preferred stock dividend rate			2.00%
Series A-3 and A-4 Preferred Stock | Minimum
Class of Stock [Line Items]
Preferred stock dividend rate			0.00%
Series A-3 Preferred Stock
Class of Stock [Line Items]
Accrued value per share (in usd per share)			$ 1,000
Series A-3 Preferred Stock | Private Placement
Class of Stock [Line Items]
Preferred stock conversion price (in usd per share)	$ 23.63
Series A-4 Preferred Stock
Class of Stock [Line Items]
Accrued value per share (in usd per share)			$ 1,000
Series A-4 Preferred Stock | Private Placement
Class of Stock [Line Items]
Preferred stock conversion price (in usd per share)	$ 34.40
CGIC | Series A shares issued and outstanding
Class of Stock [Line Items]
Issuance of common stock (in shares)		6,125
CGIC | Series A-2 shares issued and outstanding
Class of Stock [Line Items]
Issuance of common stock (in shares)		10,000
CGIC | Series A-3 and A-4 Preferred Stock
Class of Stock [Line Items]
Redemption value		$ 16.1
Preferred stock value outstanding			$ 16.4
Accrued dividend payable			$ 0.3

XML

Equity and Temporary Equity - Schedule of Cash, PIK and Special Cash Dividends (Details) - USD ($) $ in Millions			3 Months Ended
	Apr. 15, 2025	Apr. 15, 2024	Mar. 31, 2025	Mar. 31, 2024
Class of Stock [Line Items]
Dividend payments			$ 0.3	$ 0.3
Series A-3 and A-4 Preferred Stock
Class of Stock [Line Items]
Total Dividend			$ 0.3	$ 0.3
Dividend payments		$ 0.3
Series A-3 and A-4 Preferred Stock | Subsequent Event
Class of Stock [Line Items]
Dividend payments	$ 0.3

XML

Equity and Temporary Equity - R2 Technologies Non-Controlling Interests Narrative (Details) - USD ($) $ in Millions	Mar. 31, 2025	Feb. 20, 2025	Dec. 31, 2024
Class of Stock [Line Items]
Redeemable non-controlling interest	$ (0.7)		$ (0.5)
R2 Technologies
Class of Stock [Line Items]
Redeemable non-controlling interest	(0.7)		(0.5)
Liquidation preference	146.3		143.5
Liquidation preference attributable to redeemable non-controlling interests	52.8		51.8
R2 Technologies | Non-Controlling Interests
Class of Stock [Line Items]
Redeemable non-controlling interest	$ 6.2		$ (4.9)
R2 Technologies
Class of Stock [Line Items]
Investment in subsidiary, convertible note		$ 3.5
R2 Technologies | R2 Technologies
Class of Stock [Line Items]
Investment in subsidiary, convertible note		$ 3.5
Interest rate		13.00%

XML

Related Parties - Non-Operating Corporate Narrative (Details) - USD ($)						3 Months Ended
	Jun. 18, 2024	Apr. 26, 2024	Apr. 24, 2024	Mar. 28, 2024	Mar. 08, 2024	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024	Mar. 05, 2024	May 09, 2023	Feb. 01, 2021
Related Party Transaction [Line Items]
Interest expense						$ 20,200,000	$ 17,200,000
7.50% Convertible Senior Notes due 2026 | Non-Operating Corporate
Related Party Transaction [Line Items]
Interest rate						7.50%
7.50% Convertible Senior Notes due 2026 | Convertible Debt | Non-Operating Corporate
Related Party Transaction [Line Items]
Face amount											$ 51,800,000
Interest rate											7.50%
CGIC | Secured Debt | Non-Operating Corporate
Related Party Transaction [Line Items]
Face amount										$ 35,100,000
Repayments of long-term debt		$ 4,100,000
Series C Preferred Stock
Related Party Transaction [Line Items]
Preferred stock value outstanding	$ 0
Private Placement | Series C Preferred Stock
Related Party Transaction [Line Items]
Consideration to be received on sale of stock				$ 25,000,000
Private Placement | Series C Preferred Stock | Lancer Capital
Related Party Transaction [Line Items]
Consideration to be received on sale of stock			$ 6,300,000
Issuance of common stock (in shares)			6,286
Rights Offering and Concurrent Private Placement | Series C Preferred Stock
Related Party Transaction [Line Items]
Issuance of common stock (in shares)	31,286
Number of shares to be issued upon conversion of preferred stock (in shares)	4,469,390
Rights Offering and Concurrent Private Placement | Series C Preferred Stock | Previously Reported
Related Party Transaction [Line Items]
Number of shares to be issued upon conversion of preferred stock (in shares)	44,693,895
Lancer Capital | 7.50% Convertible Senior Notes due 2026 | Convertible Debt | Non-Operating Corporate
Related Party Transaction [Line Items]
Number of shares to be issued upon conversion of preferred stock (in shares)						47,265		47,265
Face amount						$ 2,000,000		$ 2,000,000
Interest rate											7.50%
Interest expense						$ 37,500	37,500
Lancer Capital | Rights Offering For Existing Shareholders
Related Party Transaction [Line Items]
Backstop commitment amount					$ 19,000,000		19,000,000
Consideration to be received on sale of stock				$ 25,000,000
Issuance of common stock (in shares)				25,000
Lancer Capital | Private Placement | Preferred stock and fixed maturities
Related Party Transaction [Line Items]
Issuance of preferred stock in private placement					$ 16,000,000		$ 16,000,000
Lancer Capital | Rights Offering and Concurrent Private Placement | Series C Preferred Stock
Related Party Transaction [Line Items]
Issuance of common stock (in shares)			6,286
Avram A. Glazer | Innovate Corp
Related Party Transaction [Line Items]
Percentage of proxy and voting rights from minority holders			52.10%			51.10%	48.80%		29.10%

XML

Related Parties - Infrastructure Narrative (Details) - Related Party - Infrastructure - Banker Steel Acquisition - Subordinated Debt - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
DMBG and Donald Banker
Related Party Transaction [Line Items]
Subordinated borrowing, interest rate	4.00%
Donald Banker
Related Party Transaction [Line Items]
Scheduled payment amount	$ 2.5
Donald Banker | Donald Banker's Family Trust
Related Party Transaction [Line Items]
Controlling interest (approximately)		25.00%

XML

Related Parties - Life Sciences Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024	Jan. 31, 2024
Related Party Transaction [Line Items]
Share-based compensation expense	$ 0.8	$ 0.4
R2 Technologies | Related Party
Related Party Transaction [Line Items]
Related receivables from this subsidiary	0.2		$ 0.1
Life Sciences
Related Party Transaction [Line Items]
Revenue	3.1	1.0
Life Sciences | R2 Technologies | Related Party
Related Party Transaction [Line Items]
Interest rate				20.00%
Revenue	0.4	0.2
Share-based compensation expense	$ 0.3	$ 0.1
20.00% Notes due 2025 | Life Sciences
Related Party Transaction [Line Items]
Interest rate	20.00%
20.00% Notes due 2025 | Life Sciences | R2 Technologies | Related Party
Related Party Transaction [Line Items]
Short-term debt	$ 25.2		$ 24.0
Interest rate	20.00%			20.00%

XML

Operating Segments and Related Information - Narrative (Details)	3 Months Ended
	Mar. 31, 2025 segment
Segment Reporting [Abstract]
Number of reportable geographic segments	1
Number of reportable operating segments	3
Number of reportable segments	3

XML

Operating Segments and Related Information - Schedule of Company's Operating Segments (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 274.2	$ 315.2
Cost of revenue	228.7	266.6
Selling, general and administrative	37.8	39.5
Depreciation and amortization	4.4	4.4
Other operating income (loss)	(0.1)	1.9
Income (loss) from operations	3.4	2.8
Other data:
Capital expenditures	4.7	5.6
Investments	4.1		$ 3.6
Total assets	868.0		891.1
Infrastructure
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	264.9	307.9
Life Sciences
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	3.1	1.0
Spectrum
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	6.2	6.3
Operating Segments | Infrastructure
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	264.9	307.9
Cost of revenue	223.5	263.1
Selling, general and administrative	29.3	30.9
Depreciation and amortization	3.1	3.0
Other operating income (loss)	(0.1)	1.6
Income (loss) from operations	9.1	9.3
Other data:
Capital expenditures	4.1	5.2
Investments	0.0		0.0
Total assets	671.9		683.6
Operating Segments | Life Sciences
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	3.1	1.0
Cost of revenue	2.3	0.6
Selling, general and administrative	3.7	3.5
Depreciation and amortization	0.1	0.1
Other operating income (loss)	0.0	0.0
Income (loss) from operations	(3.0)	(3.2)
Other data:
Capital expenditures	0.1	0.1
Investments	1.8		1.8
Total assets	11.7		11.9
Equity method investments	0.9		0.9
Operating Segments | Spectrum
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	6.2	6.3
Cost of revenue	2.9	2.9
Selling, general and administrative	1.9	1.9
Depreciation and amortization	1.2	1.3
Other operating income (loss)	0.0	0.0
Income (loss) from operations	0.2	0.2
Other data:
Capital expenditures	0.5	0.3
Investments	0.0		0.0
Total assets	178.3		178.9
Non-Operating Corporate
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	0.0	0.0
Cost of revenue	0.0	0.0
Selling, general and administrative	2.9	3.2
Depreciation and amortization	0.0	0.0
Other operating income (loss)	0.0	0.3
Income (loss) from operations	(2.9)	(3.5)
Other data:
Capital expenditures	0.0	0.0
Investments	2.3		1.8
Total assets	6.1		16.7
Other and Eliminations
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue		0.0
Cost of revenue	0.0	0.0
Selling, general and administrative	0.0	0.0
Depreciation and amortization	0.0	0.0
Other operating income (loss)	0.0	0.0
Income (loss) from operations	0.0	0.0
Other data:
Capital expenditures	0.0	$ 0.0
Investments	0.0		0.0
Total assets	$ 0.0		$ 0.0

XML

Operating Segments and Related Information - Schedule of Reconciliation of the Consolidated Segment (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Reconciliation of the consolidated segment income from operations to consolidated loss from operations before income taxes:
Income from operations	$ 3.4	$ 2.8
Interest expense	(20.2)	(17.2)
Loss from equity investees	(5.9)	(1.2)
Other income (expense), net	4.0	(1.2)
Loss from operations before income taxes	$ (18.7)	$ (16.8)

XML

Basic and Diluted Loss Per Common Share - Narrative (Details) - shares	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive common stock equivalents (in shares)	0	0
Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	294,329	70,299

XML

Basic and Diluted Loss Per Common Share - Schedule of Calculation of Basic Loss Per Common Share to Diluted Loss Per Common Share (Details) $ / shares in Units, $ in Millions			3 Months Ended
		Aug. 08, 2024	Mar. 31, 2025 USD ($) $ / shares shares	Mar. 31, 2024 USD ($) $ / shares shares
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Net loss			$ (25.8)	$ (20.1)
Net loss attributable to non-controlling interest and redeemable non-controlling interest			1.3	2.7
Net loss attributable to INNOVATE Corp.			(24.5)	(17.4)
Less: Preferred dividends			0.3	0.3
Net loss attributable to common stockholders and participating preferred stockholders, basic			(24.8)	(17.7)
Net loss attributable to common stockholders and participating preferred stockholders, diluted			$ (24.8)	$ (17.7)
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted-average common shares outstanding (in shares) | shares	[1]		13,114,804	7,865,361
Series C Preferred stock (in shares) | shares	[1]		0	156,986
Total (in shares) | shares			13,114,804	8,022,347
Percentage of loss allocated to:
Common stock (as percent)			100.00%	98.00%
Series C Preferred stock (as percent)			0.00%	2.00%
Numerator and denominator for (loss) per share
Net loss attributable to common stock holders, basic			$ (24.8)	$ (17.3)
Net loss attributable to common stock holders, diluted			(24.8)	(17.3)
Net loss attributable to Series C holder, basic			0.0	(0.4)
Net loss attributable to Series C holder, diluted			$ 0.0	$ (0.4)
Weighted average common shares/ Series C shares outstanding - basic (in shares) | shares	[1]		13,114,804	7,865,361
Weighted average common shares/ Series C shares outstanding - diluted (in shares) | shares	[1]		13,114,804	7,865,361
Loss per common share/ series C share - basic (in usd per share) | $ / shares	[1]		$ (1.89)	$ (2.21)
Loss per common share/ series C share - diluted (in usd per share) | $ / shares	[1]		$ (1.89)	$ (2.21)
Reverse stock split, conversion ratio		0.1
Series C Preferred Stock
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted-average common shares outstanding (in shares) | shares	[1]		0	156,986
Numerator and denominator for (loss) per share
Weighted average common shares/ Series C shares outstanding - basic (in shares) | shares	[1]		0	156,986
Weighted average common shares/ Series C shares outstanding - diluted (in shares) | shares	[1]		0	156,986
Loss per common share/ series C share - basic (in usd per share) | $ / shares	[1]		$ (1.89)	$ (2.21)
Loss per common share/ series C share - diluted (in usd per share) | $ / shares	[1]		$ (1.89)	$ (2.21)

[1] Basic and diluted loss per common share and weighted-average common shares outstanding for the three months ended March 31, 2024, have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on August 8, 2024.

XML

Fair Value of Financial Instruments - Schedule of Financial Instruments Measured on Not Measured at Fair Value (Details) - Nonrecurring - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Carrying Value
Assets
Measurement alternative investment	$ 0.9	$ 0.9
Total assets not accounted for at fair value	0.9	0.9
Liabilities
Debt obligations	663.2	662.2
Total liabilities not accounted for at fair value	663.2	662.2
Estimated Fair Value
Assets
Measurement alternative investment	0.9	0.9
Total assets not accounted for at fair value	0.9	0.9
Liabilities
Debt obligations	618.4	577.1
Total liabilities not accounted for at fair value	618.4	577.1
Estimated Fair Value | Quoted Prices (Level 1)
Assets
Measurement alternative investment	0.0	0.0
Total assets not accounted for at fair value	0.0	0.0
Liabilities
Debt obligations	0.0	0.0
Total liabilities not accounted for at fair value	0.0	0.0
Estimated Fair Value | Significant Other Observable Inputs (Level 2)
Assets
Measurement alternative investment	0.0	0.0
Total assets not accounted for at fair value	0.0	0.0
Liabilities
Debt obligations	618.4	577.1
Total liabilities not accounted for at fair value	618.4	577.1
Estimated Fair Value | Significant Unobservable Inputs (Level 3)
Assets
Measurement alternative investment	0.9	0.9
Total assets not accounted for at fair value	0.9	0.9
Liabilities
Debt obligations	0.0	0.0
Total liabilities not accounted for at fair value	$ 0.0	$ 0.0

XML

Fair Value of Financial Instruments - Narrative (Details) - Non-Operating Corporate	Mar. 31, 2025	Dec. 31, 2021	Feb. 01, 2021
8.50% Senior Secured Notes due 2026 | Secured Debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate	8.50%	8.50%	8.50%
7.50% Convertible Senior Notes due 2026
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate	7.50%

XML

Supplementary Financial Information- Schedule of Other (Loss) Income, Net (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Offsetting [Abstract]
Gain on step-up of equity method investment	$ 4.4	$ 0.0
Net loss on extinguishment of debt	0.0	(2.2)
Interest income	0.4	0.5
Foreign currency translation (loss) gain	(0.4)	0.5
Other	(0.4)	0.0
Total other income (expense), net	$ 4.0	$ (1.2)

XML

Supplementary Financial Information - Schedule of Cash and Cash Equivalents (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Cash, Cash Equivalents, Restricted Cash, And Restricted Cash Equivalents [Roll Forward]
Cash and cash equivalents, beginning of the period	$ 48.8	$ 80.8
Restricted cash included in other current assets, beginning of period	0.0	0.9
Restricted cash included in other assets (non-current), beginning of period	0.5	0.6
Cash, cash equivalents and restricted cash, beginning of period	49.3	82.3
Cash and cash equivalents, end of the period	33.3	38.4
Restricted cash included in other current assets, end of period	0.0	0.9
Restricted cash included in other assets (non-current), end of period	0.6	0.6
Cash, cash equivalents and restricted cash, end of period	33.9	39.9
Total cash, cash equivalents and restricted cash	33.9	39.9
Supplemental cash flow information:
Cash paid for interest	19.5	19.6
Cash paid for income taxes (proceeds from tax refunds), net	0.8	(0.8)
Non-cash investing and financing activities:
Accrued interest capitalized into principal debt	1.2	3.3
Property, plant and equipment included in accounts payable or accrued expenses	$ 1.1	$ 0.9

XML

Label	Element	Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	217,733
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	217,733
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	$ 16.94
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	$ 16.94